Investigating retinal pathology in patients carrying m.3243A>G mutation using human induced pluripotent stem cells by Chichagova, Valeria
  
 
 
Investigating retinal pathology in patients carrying 
m.3243A>G mutation using human induced 
pluripotent stem cells 
 
 
 
 
Valeria Chichagova 
Doctor of Philosophy 
 
 
 
 
Institute of Genetic Medicine 
Faculty of Medical Sciences 
Newcastle University 
February 2017
ii 
 
  
iii 
 
Abstract 
The heteroplasmic mutation in the mitochondrial gene MT-TL1 encoding 
tRNALeucine (UUR) at nucleotide position 3243 resulting in the arginine to guanine 
transition (m.3243A>G) is the most common pathogenic mutation in the 
mitochondrial genome. Originally associated with mitochondrial encephalomyopathy, 
lactic acidosis, and stroke-like episodes syndrome, it has also been linked to a 
number of other clinical phenotypes. It is common for patients harbouring the 
mutation to develop a range of ocular abnormalities, including those affecting retinal 
pigment epithelium (RPE) cells. The underlying mechanisms of RPE degeneration 
remain unclear. Using fibroblasts derived from patients with retinal changes with the 
m.3243A>G, I generated heteroplasmic human induced pluripotent stem cell (hiPSC) 
clones harbouring the m.3243A>G mutation. RPE cells differentiated from patient 
hiPSCs displayed typical cobblestone morphology and expressed mature RPE-
associated markers. The RPE cells retained their ability to form blood-retinal barrier 
as assessed by measuring transepithelial resistance. However, cells with high levels 
of the m.3243A>G showed reduced propensity for pigment formation. Additionally, 
the RPE cells contained abnormal mitochondria and melanosomes, which is likely to 
manifest as a reduced ability to absorb stray light. These findings have remarkable 
similarities to the ones seen in RPE cells described in post mortem tissues of patients 
with the m.3243A>G mutation. In addition, patient cells showed defects in 
phagocytosis of photoreceptor outer segments, a functional defect associated with 
other retinal diseases. Overall, the results provide an indication that RPE cells with 
the m.3243A>G have reduced ability to perform at least two of their main functions: 
absorption of stray light and phagocytosis, suggesting possible pathological 
processes associated with ocular symptoms seen in patients. The ability to mimic 
these manifestations in vitro would allow investigating pathological mechanisms 
further and allow testing novel therapeutic agents aimed at alleviating or treating the 
symptoms.  
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Chapter 1. Introduction 
The heteroplasmic mutation in the mitochondrial gene MT-TL1 at nucleotide position 
3243 resulting in the arginine to guanine transition is the most common pathogenic 
mutation in the mitochondrial genome. Visual impairment with atrophic maculopathy 
akin to dry age-related macular degeneration (AMD) is observed in a high proportion 
of patients with the mutation. To date, the pathological mechanism of retinal 
abnormalities seen in this patient group remains unclear. 
1.1 Overview of mitochondrial biology 
1.1.1 Origin and features 
The mitochondrion is a unique organelle that carries numerous essential cellular 
functions. It is involved in a number of critical processes, including its role in 
adenosine triphosphate (ATP) production through oxidative phosphorylation 
(OXPHOS), iron metabolism, the citric acid cycle, apoptosis, fatty acid oxidation, and 
amino acid biosynthesis (Sproule and Kaufmann, 2008). Research has shown that 
mitochondria originated from a proteobacterial ancestor. One of the earliest articles 
to suggest the endosymbiotic origin of mitochondria came out almost 100 years ago 
(Wallin, 1926). It took over 70 years to experimentally illustrate protein sequence 
similarities of mitochondria and the closest living relative of the original 
proteobacterial species, confirming its origins (Andersson et al., 1998). Although, still 
retaining certain features of its ancestors, such as a double membrane, a circular 
genome and the ability to form dynamic networks, mitochondria have adapted to their 
eukaryotic cellular host by transferring most of their genes to the nuclear genome 
(Vafai and Mootha, 2012). 
Mitochondria are highly heterogeneous organelles and they form dynamic 
networks by undergoing fusion and fission which results in the exchange of matrix 
proteins and mitochondrial DNA (mtDNA) (Nunnari et al., 1997; Legros et al., 2002). 
One of the fascinating features of mitochondria is the plasticity of the morphology and 
content. They can appear in different shapes from elongated tubules to spheres or 
rods depending on the cell type and the environmental cues (Figure 1.1). 
Additionally, mitochondria have defined subcellular distribution as they are 
continuously transported along the cytoskeletal tracks depending on the cells 
bioenergetic requirements (Hollenbeck and Saxton, 2005).  
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Figure 1.1. Heterogeneity of mitochondrial morphology in different tissues [adapted 
from Vafai and Mootha (2012)]. 
Structurally mitochondria are unusual since they have a double membrane. The inner 
membrane contains numerous invaginations that form the cristae protruding into the 
matrix, and the outer membrane separates the mitochondrion from the cytosol. The 
inner membrane contains the enzyme complexes of the OXPHOS system (McBride 
et al., 2006).  
1.1.2 Oxidative phosphorylation 
The respiratory chain complexes are composed of 92 protein components that are 
encoded by both nuclear DNA and mtDNA (Figure 1.2). 
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Figure 1.2. Schematic representation of the mitochondrial respiratory chain and the 
main components of OXPHOS, including the number of proteins in different 
complexes of the respiratory chain encoded by nuclear and mtDNA. Complexes I, II and 
III are involved in proton (H+) transport from the matrix to the inter-membrane space 
generating electrochemical gradient resulting in driving H+ back into the matrix by Complex V 
producing ATP [adapted from Sproule and Kaufmann (2008)]. NAD - nicotinamide adenine 
dinucleotide; FAD - flavin adenine dinucleotide; SDH - succinate dehydrogenase; CoQ – 
coenzyme Q, ubiquinone; Cyt - cytochrome; COX - cytochrome c oxidase. 
The respiratory chain drives OXPHOS through a number of redox reactions.  
Donation of electrons to the respiratory chain drives protons through Complex I, 
Complex III and Complex IV, generating a proton motive force. Complex I and 
Complex II are involved in transferring electrons from NADH and FADH2 to a mobile 
electron carrier coenzyme Q. Complex III passes on the electrons to cytochrome c. 
Complex IV accepts the electrons and reduces oxygen to water. The resulting pH 
gradient facilitates the production of ATP by Complex V (F1F0-ATPase) through the 
movement of protons back to the mitochondrial matrix. Almost all of the redox 
reactions within the cell are linked to the respiratory chain including the tricarboxylic 
acid (TCA) cycle. One of the by-products of the metabolic reactions in the respiratory 
chain, especially at Complex I and Complex III, are reactive oxygen species (ROS) 
which are potentially toxic to the cell. There is a dedicated control system which 
involves superoxide dismutase and catalase, which regulate ROS levels (Vafai and 
Mootha, 2012). 
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1.1.3 Mitochondrial genetics 
Mitochondria are regulated by both the nuclear and mitochondrial genomes. mtDNA 
in humans is a circular, double-stranded molecule approximately 16 569 base pairs 
long (Anderson et al., 1981). Each strand is different in nucleotide composition. H-
strand (heavy strand) is guanine rich and L-strand (light strand) is cytosine-rich 
(Chinnery and Hudson, 2013). mtDNA is different from nuclear DNA in a number of 
respects. Firstly, it is exceptional in its economic organisation. Its genes do not 
contain intronic regions and the coding region represents ~93% of the genome with 
the only non-coding region located in the D-loop (displacement loop) which contains 
the site of mtDNA replication initiation and transcription (Chinnery and Hudson, 
2013). Additionally, the mitochondrial genetic code deviates from the standard code. 
It contains only two stop codons comparing to three stop codons in the nuclear DNA 
(Temperley et al., 2010). Despite the differences, mtDNA and nuclear DNA exist in 
synergy. 
mtDNA contains 37 genes, 13 of which encode for polypeptide components of 
the OXPHOS system (components of Complex I, Complex III, Complex IV and 
Complex V) and 24 encoding for RNA products, including 22 mitochondrial transfer 
RNAs (tRNAs), a 16s ribosomal RNA (rRNA) and a 12s rRNA (Anderson et al., 
1981). A schematic of the human mtDNA is shown in Figure 1.3. 
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Figure 1.3. Schematic representation of the human mtDNA [adapted from Ding et al. 
(2013)]. 
One of the key features of mitochondrial genetics is the mode of inheritance of 
mtDNA. It has been widely accepted that mtDNA nucleoids are inherited exclusively 
through maternal lineage (Giles et al., 1980). One of the proposed theories suggests 
that this is due to the ubiquitination of sperm mitochondria inside the male 
reproductive tract or upon entering the oocyte. This leads to targeted proteolysis 
resulting in the expression of only maternal mtDNA in the zygote (Sutovsky et al., 
1999). Thus far, only one case of paternal inheritance has been recorded (Schwartz 
and Vissing, 2002). mtDNA in mature mammalian oocytes is estimated to have 
approximately 100 000 copies containing between 1 and 2 copies per organelle. 
During early embryogenesis, various combinations of mitochondria are segregated 
between individual primordial cells and their number is reduced drastically to around 
0.1% of the original population. This process characterises developmental 
bottleneck, when only a small proportion of the original population of mitochondria 
contributes to the offspring (Shoubridge and Wai, 2007).  
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1.1.4 mtDNA mutations 
mtDNA does not have an efficient repair system and lacks protective histones. 
Furthermore, it has a high rate of replication independent of the cell cycle and it 
exists in the environment enriched with ROS. This therefore results in a high rate of 
mutations in mtDNA, especially when compared to nuclear DNA. Due to the polyploid 
nature of the mitochondrial genome, this leads to co-existence of mutant and wild-
type mtDNA within a single organelle resulting in heterogeneous mutation levels in 
different cells and tissues. The mixture of different mtDNA genotypes in the same cell 
is referred to as heteroplasmy. When all of the copies of mtDNA are identical it is 
referred to as homoplasmy (McFarland et al., 2002; Chinnery and Hudson, 2013). 
Heteroplasmy is one the most clinically important features of segregation of 
mitochondrial genome, as it is believed that pathogenic phenotypes arise as a result 
of the heteroplasmy reaching a pathogenic threshold level (Prigione et al., 2011). 
Due to the fact that the developmental bottleneck is a stochastic process, it is difficult 
to predict how much mutant mtDNA will be passed on to the next generation. It 
should be noted that mtDNA haplogroups arose from the accumulation of benign 
mutations which became homoplasmic polymorphisms (McFarland et al., 2002). 
More than 200 mtDNA disease-causing mutations have been reported since 
the initial description of the first mtDNA mutations (Holt et al., 1988; Wallace et al., 
1988; Hamalainen et al., 2013). For the vast majority of cases, the diseases have 
variable penetrance depending on the proportion of mutated mtDNA and their 
stochastic segregation during development (Shoubridge and Wai, 2007). 
Epidemiological studies estimate that ~1:8000 of general population has clinically 
manifesting mtDNA disease and ~1:200 of healthy individuals harbours a potentially 
pathogenic mtDNA mutation (Chinnery et al., 2000; Darin et al., 2001; Elliott et al., 
2008; Schaefer et al., 2008). The conditions resulting from the mutations manifest in 
various forms including myopathies, neurodegeneration, multi-organ failure, 
cardiomyopathies and retinopathies, with the age of onset varying between infancy 
and adulthood and presenting with high clinical variability (Ylikallio and Suomalainen, 
2012) (Figure 1.4).  
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Figure 1.4. Schematic representation of the clinical spectrum of mitochondrial 
disorders [adapted from Khondrion (2014)]. 
Most pathogenic mtDNA mutations are heteroplasmic and mitochondrial respiratory 
chain activity becomes compromised when the level of the mutant species exceeds a 
critical threshold, which is both mutation and tissue specific. A recent study found 
that heteroplasmy level of 50% in any tissue was associated with the development of 
various clinical abnormalities (Dvorakova et al., 2016). 
1.1.5 Mitochondrial pathogenesis associated with m.3243A>G mutation 
The heteroplasmic mutation in the mitochondrial gene MT-TL1 encoding 
tRNALeucine (UUR) (tRNALeu(UUR)) at nucleotide position 3243 resulting in the 
arginine (A) to guanine (G) transition (m.3243A>G) has been identified as the most 
common pathogenic mutation in the mitochondrial genome (Moraes et al., 1993; 
Majamaa et al., 1998). Originally associated with mitochondrial encephalomyopathy, 
lactic acidosis, and stroke-like episodes (MELAS), it has also been linked to a 
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number of other clinical phenotypes including diabetes mellitus and chronic 
progressive external ophthalmoplegia (CPEO) (Moraes et al., 1993; Kadowaki et al., 
1994; van den Ouweland et al., 1994). Although, over 30 mitochondrial mutations 
have been found to be associated with MELAS, in over 80% of cases, it is caused by 
the m.3243A>G point mutation (Hirano et al., 1992). 
The molecular mechanisms underlying the pathogenesis of the m.3243A>G 
are complex and not completely understood, although the prevailing theory suggests 
that translation defects are a possible explanation. There are 22 species of 
mitochondrial tRNA which are able to recognise 60 codons. The reduced number of 
tRNAs required to decipher all the codons is achieved by post-transcriptional 
modification of the anticodons (Suzuki, 2014). tRNAs are able to recognise codons 
by having a modified first letter of the anticodon in the uridine position which leads to 
recognition of all four bases and reduction in the total number of tRNAs that are 
required (Barrell et al., 1980; Bonitz et al., 1980). Healthy mitochondrial tRNALeu(UUR) 
has a 5-taurinomethyluridine (τm5U) post-transcriptional modification which is found 
at the anticodon wobble position and results in stabilisation of wobble pairing, 
specifically for decoding UUG (Suzuki and Nagao, 2011). Studies using cybrid cell 
lines containing mutant mtDNA derived from patients harbouring the m.3243A>G 
showed defects in mitochondrial protein synthesis attributed to wobble modification 
deficiency leading to reduced translational ability of tRNALeu(UUR) (Kirino et al., 2004). 
Wobble modification deficiency is thought to be due to the inability of a tRNA-
modifying enzyme responsible for taurine modification to recognise the tRNA due to 
tertiary structure changes resulting from the mutation (Kirino and Suzuki, 2005). The 
effect of the m.3243A>G on tRNALeu(UUR) is outlined in Figure 1.5. It has also been 
suggested that there are possible additional mechanisms that also attribute to the 
negative effect of the mutation, including defects in transcription termination and 
decreased aminoacylation (Suzuki and Nagao, 2011). 
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Figure 1.5. Deficiency in tRNALeu(UUR) wobble modification in m.3243A>G resulting from 
defects in taurine modification which in turn leads to altered UUG-rich gene 
translation. 
Autopsy studies in MELAS patients have shown that patients most commonly have 
Complex I deficiency, however some studies show that combined deficiencies of 
respiratory chain complexes are observed (Hamalainen et al., 2013). Complex I 
deficiency could be linked to the deficiency in mitochondrial translation and wobble 
modification deficiency in tRNALeu. Complex I contains 42.1% of the total leucine 
codons encoded by ND6 genes, which are rich in UUG, and defects in tRNALeu could 
potentially lead to a reduction in Complex I activity (Kirino et al., 2004). 
1.2 Clinical features of MELAS 
Early clinical reports isolated a number of key features of MELAS. They included 
normal early development with later presentation of encephalopathy with seizures, 
stroke-like episodes, and evidence of mitochondrial dysfunction in the form of lactic 
acidosis and / or ragged red fibres. Patients can also present with additional features 
such as motor deficits, cortical blindness, dementia, exercise intolerance, migraine-
like headaches, hearing loss and a short statue (Pavlakis et al., 1984; Hirano et al., 
1992). According to one of the early case reports, patients can develop prominent 
neurological features before 40 years of age and although the signs and symptoms 
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may appear at various ages, most commonly patients present with the early 
symptoms between the ages of 2 and 20 years (Hirano et al., 1992; Lin et al., 2014). 
According to a recent study of 50 patients, 58% have four or more symptoms 
associated with MELAS and 12% are monosymptomatic (Dvorakova et al., 2016). 
Sensorineural hearing loss and myopathy were the most common findings followed 
by CPEO.  
One of the most debilitating features of MELAS is the clinical manifestation of 
stroke-like episodes. They are associated with transient neurological deficits and 
progress over a longer period of time unlike an ischaemic stroke (Fryer et al., 2016). 
They are believed to be caused by an impaired binding of cytochrome c to 
mitochondrial respiratory chain proteins. In addition, excess extracellular potassium 
and glutamate within the synaptic cleft may lead to neuronal cytotoxicity causing 
epileptic seizures (Bhuvaneswar et al., 2008). One study suggested that being a 
male was a risk factor for developing stroke-like episodes in patients with the 
m.3243A>G (64.7% or 33 out of 51 patients) (Mancuso et al., 2014). 
It is presumed that pathogenesis of MELAS is largely driven by a chronic state 
of energy failure where the cell is unable to generate sufficient amount of ATP due to 
the presence of dysfunctional mitochondria (Sproule and Kaufmann, 2008). 
Histopathological studies of patient muscle biopsies show appearance of ragged red 
fibres. This indicates that there is increased mitochondrial proliferation; a 
compensatory mechanism in response to deficient protein synthesis resulting in the 
increased overall cytochrome c oxidase activity. This could potentially be the driving 
force of the pathogenesis of MELAS. Picard et al. (2014) recently investigated the 
connection between the heteroplasmy levels of the m.3243A>G and the effect it has 
on nuclear gene expression, with the view of providing explanation for variable 
clinical phenotypes seen in patients that harbour the mutation. They created a series 
of cell cybrids with various levels of mutated mtDNA. There were a number of 
important findings that were described in this study. It was shown that there was a 
direct correlation between the levels of the m.3243A>G and the amount of mtDNA 
encoded proteins of the electron transport chain. In addition, presence of mutated 
mtDNA resulted in alterations in the mitochondrial morphology resulting in their 
elongated shape and ultra-structural changes affecting cristae. Interestingly, even 
when the mutation level was as low as 20-30%, the ability of the cells to generate 
enough energy was markedly reduced. The most important finding was that cells with 
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50-90% m.3243A>G had similar transcriptional profile comparable to that seen in 
some neurodegenerative diseases and was a result of altered retrograde signalling 
between the mitochondria and the nucleus. 
To date all the treatment for MELAS is symptomatic with no curative options. 
Patients are often offered treatment in the form of coenzyme Q, vitamins C and E, 
riboflavin and creatine (Sproule and Kaufmann, 2008).  
1.2.1 Ophthalmological findings in mitochondrial diseases 
There are several primary mtDNA mutations and nuclear mutations that affect 
mitochondria that lead to ocular diseases, some of which are described below. 
Optic neuropathies are a common manifestation in mitochondrial diseases. Leber’s 
Hereditary Optic Neuropathy (LHON) is characterised by the degeneration of retinal 
ganglion cells (RGC) which leads to central vision loss by the age of 50 in the 
majority of patients. Prevalence of LHON has been estimated to be ~1:31,000 and 
over 90% of patients harbour one of the three mutations in mtDNA affecting Complex 
I: m.11778G>A, m.14484T>C, and m.3460G>A (Wallace et al., 1988; Huoponen et 
al., 1991; Johns et al., 1992; Yu-Wai-Man et al., 2003). Most of the affected 
individuals are males. The gender bias of LHON has been suggested to arise as a 
result of nuclear genetic factors, such as visual loss susceptibility gene located on 
the X-chromosome, which renders males to be more exposed to the mtDNA mutation 
acting in synergy with the nuclear gene (Bu and Rotter, 1991). More studies are 
required in order to identify the nuclear modifier genes that are specific to LHON (Yu-
Wai-Man et al., 2011a). Hormonal factors have also been shown to be associated 
with male prevalence in LHON. One study used cell cybrids harbouring the three 
mtDNA point mutations m.11778G>A, m.14484T>C, and m.3460G>A to investigate 
metabolic basis for gender bias in LHON (Giordano et al., 2011). The authors 
showed that the addition of 17β-oestradiol to the cells reduced overproduction of 
ROS, thereby increasing cell viability and mitochondrial function in the cells, which 
supported the hypothesis of the protective effect of hormones in females. 
Autosomal-dominant optic atrophy is another disorder that results in the loss of 
RGCs and their axons. It has a prevalence of 1:35,000 in the North of England and 
has a mean age of onset between 6 and 10 years of age (Yu-Wai-Man et al., 2010). 
It has a less severe phenotype comparing to LHON, however most of patients have 
worsening symptoms with age (Cohn et al., 2008; Yu-Wai-Man et al., 2011b). The 
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majority of cases are caused by the mutation in the OPA1 gene, which results in the 
reduced levels of OPA1 protein (Yu-Wai-Man et al., 2011b). OPA1 is located in the 
inner domain of the mitochondrial membrane and is involved in mitochondrial fusion. 
The mutation in the gene leads to the impairment in mitochondrial fusion and a 
coupling defect of OXPHOS (Chevrollier et al., 2008; Zanna et al., 2008). 
CPEO is a mitochondrial myopathy which manifests as bilateral ptosis and reduced 
eye movement (Richardson et al., 2005). Patients harbour large-scale mtDNA 
deletions or multiple mtDNA point mutations secondary to nuclear DNA defect 
resulting in cytochrome c oxidase (COX) deficiency in extraocular muscles (Greaves 
et al., 2010). Kearns-Sayre syndrome is a systemic disorder associated with single 
large-scale heteroplasmic deletions in mtDNA (Zeviani et al., 1988). Patients are 
normally young at diagnosis and develop CPEO within a few years. In addition, this 
disorder is characterised by other symptoms, including retinopathy, central nervous 
system (CNS) deficits, ataxia and cardiac conduction abnormalities (Yamashita et al., 
2008). 
Maternally inherited diabetes and deafness (MIDD) results from the m.3243A>G 
mutation and patients present with diabetes and sensorineural hearing loss with a 
maternal family history of the condition (van den Ouweland et al., 1992). Macular 
pattern dystrophy has been shown to be present in 86% of MIDD patients with 8% of 
patients presenting with diabetic retinopathy (Guillausseau et al., 2001). Both retinal 
pigment epithelium (RPE) and choroid atrophy have been reported, with RPE atrophy 
localising to the posterior pole (Murphy et al., 2008). 
Examples of retinal changes in a patient with m.3243A>G, and a patient with the 
same mutation and diagnosed with MELAS are shown in Figure 1.6 and Figure 1.7. 
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Figure 1.6. Images of the eyes of the patient with m.3243A>G. (A, B) Colour fundus 
photograph shows hyper-pigmented lesions in the area surrounding the macula and the optic 
disc, suggesting depigmentation of the RPE; (C, D) Fundus autofluorescence shows 
speckled appearance of the macula. [Adapted from Daruich et al. (2014)]. 
 
Figure 1.7. Images of the eyes of the patient with m.3243A>G diagnosed with MELAS. 
(A, B) Fundus photographs show perifoveal atrophy and pale deposits; (C, D) Atrophic areas 
show decreased autofluorescence, areas with deposits have increased autofluorescence. 
There is speckled autofluorescence around atrophic areas. [Adapted from Daruich et al. 
(2014)]. 
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AMD is a neurodegenerative disease of the elderly which affects the macula of the 
eye. Its characteristic features include early presence of drusen with areas of 
depigmentation and hyperpigmentation, followed by geographic atrophy or choroidal 
neovascularisation as disease progresses (Barot et al., 2011). There is a theory that 
suggests that AMD disease progression is related to oxidative stress which has 
damaging effects on lipids, proteins, and DNA. One study investigated oxidative 
stress response using donor eyes from AMD patients (Decanini et al., 2007). Relative 
content of some antioxidant enzymes (cytosolic copper-zinc superoxide dismutase, 
mitochondrial manganese superoxide dismutase, and catalase) and total proteasome 
content were increased with disease progression, suggesting a compensatory 
mechanism against oxidative damage. Another study used donor eyes from AMD 
patients to show that compared to controls, patients diagnosed with AMD had 
significantly decreased number of mitochondria, with loss of cristae and matrix 
density (Feher et al., 2006b). Together with changes in the mitochondrial membrane 
and mtDNA damage, reduced mitochondrial redox function has been reported in 
RPE cells exposed to H2O2, further suggesting potential mitochondrial involvement 
and oxidative damage in aetiology of AMD (Ballinger et al., 1999; Liang and Godley, 
2003). Increased mtDNA damage was also seen in aged rodent RPE and choroid 
(Wang et al., 2008a). DNA polymerase gamma is involved in mtDNA replication and 
is a possible target of ROS and H2O2, potentially leading to reduced mtDNA 
replication (Graziewicz et al., 2002). In order to evaluate the effect of antioxidants on 
AMD progression, a large 11-centre clinical trial was undertaken (AREDS, Age-
Related Eye Disease Study), where patients were given an antioxidant cocktail with 
vitamins C and E, β-carotene, and zinc (Age-Related Eye Disease Study Research, 
2001). It was found that in those over 55 years of age with non-central geographic 
atrophy, and intermediate and at least one large druse, there was a reduction in the 
risk of developing advanced AMD with antioxidants and zinc supplementation. A 
recent study suggested that there was a positive correlation between the effect of 
antioxidant and zinc supplementation and genotype, specifically amongst age-related 
maculopathy susceptibility 2 (ARMS2) gene carriers, highlighting the importance of 
further research on genetic variants, supplementation, and AMD progression 
(Seddon et al., 2016). Lifestyle factors, such as cigarette smoking are also 
associated with an increased risk of developing AMD (Christen et al., 1996; Khan et 
al., 2006). 
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Ocular abnormalities are a common finding in mitochondrial diseases, however there 
is no consensus as to what the prevalence of these findings is. According to 
Gronlund et al. (2010), 80.7% (study based on 59 patients) of mitochondrial patients 
have one or more findings that affect ocular health, including reduced eye motility, 
optic atrophy, pigmentary retinopathy, retinal dystrophy, external ophthalmoplegia, 
ptosis and low visual acuity. Zhu et al. (2016) found that 35% of patients (from a 
cohort of 74 patients) had at least one ophthalmological abnormality, with 16% 
presenting with retinal pigmentary changes making it the most common finding. 
Retinal pigmentary abnormalities similar to those found in AMD are one of the 
most common ophthalmological findings in MELAS patients with the m.3243A>G 
(Phillips and Newman, 1997; Sue et al., 1997). Other histopathological changes that 
appear as a result of the mutation include degeneration of the choroid and 
photoreceptors (Rummelt et al., 1993). RPE abnormalities are normally present in 
conjunction with other features associated with the mutation. A study of two patients 
reported observations of depigmentation of RPE surrounding the macula and 
formation of pigmented or pale deposits (Daruich et al., 2014). Another study looked 
at twelve patients and common findings included perifoveal atrophy and RPE 
deposits (Rath et al., 2008). de Laat et al. (2013) reported that 86% of the mutation 
carriers (out of 29 patients) had retinal abnormalities and visual acuity deterioration. 
Pigmentary abnormalities ranged from very mild changes seen in central fundus to 
the formation of sub-retinal deposits, changes in the macula and around the optic 
disc. More severe observations were made in some patients that presented with 
geographic atrophy often sparing central fovea, although in 7% of patients with the 
advanced stage of the disease it was not the case. This and the study by Sue et al. 
(1997) did not observe formation of sub-retinal deposits associated with typical 
drusen. Daruich et al. (2014) suggested that the drusen seen in m.3243A>G are 
different to the ones seen in AMD patients with the ones in AMD located more 
centrally. de Laat et al. (2013) reported observing accumulations of lipofuscin in 
atrophic areas of RPE. Latkany et al. (1999) reported a patient with progressive 
bilateral RPE atrophy. Another study investigated a group of patients with the 
m.3243A>G (diagnosed with MIDD) (Smith et al., 1999). 77% of their cohort (10 out 
of 13 patients) had evidence of retinal pigment disease, including RPE and choroidal 
atrophy, areas of pigmentation and depigmentation, photophobia and reduced night 
vision pointing to photoreceptor involvement. One patient had appearance of drusen. 
The study suggested that the RPE cell layer was predominantly affected leading to 
 16 
defects in photoreceptors. Dvorakova et al. (2016) reported that 67% of their patients 
(50 patient cohort) had ocular abnormalities, including optic nerve atrophy, 
pigmentary retinal degeneration and reduced visual acuity.  
It has been suggested that there is a correlation between the degree of mutant 
heteroplasmy in the muscle and the risk of developing RPE abnormalities. Patients 
harbouring >68% of mutant load have a 2-3 fold higher risk (Latvala et al., 2002). de 
Laat et al. (2013) found that in their patient cohort the mean level of the m.3243A>G 
in urinary epithelial cells was 55% ± 22 and 21% ± 13 in leukocytes; however, there 
was no correlation between heteroplasmy levels and disease severity. 
Both RPE and photoreceptors are vulnerable even at low levels of 
heteroplasmy due to their localisation in a highly oxidative environment, however 
there is no evidence to clearly suggest whether it is RPE or photoreceptors that are 
affected first in MELAS (de Laat et al., 2013). MELAS patients have striking 
overlapping features with the geographic retinal atrophy observed in AMD, the 
commonest cause of blindness in the United Kingdom (Sue et al., 1997; Owen et al., 
2003; Bunce et al., 2010). It is thought that AMD is a disease of the RPE which leads 
to secondary photoreceptor degeneration (Bhutto and Lutty, 2012). There is 
mounting evidence pointing towards oxidative stress and mitochondrial dysfunction 
as central pathological factors in the aetiology of AMD (Liang and Godley, 2003; 
Feher et al., 2006a). Even though, m.3243A>G is a very rare cause of AMD, this 
suggests that there is a common pathogenic pathway in MELAS and AMD (Jones et 
al., 2004). Investigating the pathophysiology of the outer retinal changes and 
specifically RPE in patients with the m.3243A>G mtDNA mutations may thus provide 
insight into the nature and role of the mitochondrial abnormalities seen in patients 
with AMD. 
To date, there are no in vivo models for human mitochondrial tRNA mutations 
and the mechanism of retinal pathogenesis remains unknown. Generation of human 
induced pluripotent stem cells (hiPSCs) from patient-derived cells with the 
m.3243A>G mutation provides a potential tool to study the impact of mitochondrial 
dysfunction on RPE and photoreceptors. A recent publication demonstrated the 
ability to create hiPSCs from MELAS patients harbouring m.3243A>G mutation 
(Fujikura et al., 2012). Another study investigating a different MELAS causing mtDNA 
mutation (m.13513G>A) has furthermore shown that the hiPSC clones produced can 
have varying levels of mtDNA heteroplasmy as in the donor cells (Folmes et al., 
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2013). Significantly this means that the effect of varying degrees of heteroplasmy on 
the production and function of retinal cells can potentially be assessed.  
1.3 Human pluripotent stem cells 
The discovery of human pluripotent stem cells (hPSCs) has opened up extraordinary 
opportunities in various areas of biomedical research, including disease modelling, 
drug discovery and basic science. Animal models have contributed tremendously to 
our understanding of disease mechanisms; however, they do not always provide a 
solid platform for accurate recapitulation of human system. A number of key 
differences exist between animal models and humans including life span and 
physiology. In addition, for some developmental and pathological processes no 
animal models currently exist. It is especially significant for the disorders affecting the 
retina. Rodent models have been used extensively in eye research and they offer 
several advantages, such as quick disease progression and the possibility of genetic 
manipulation. However, the most important limitation of mouse and rat models is the 
absence of a macula. Non-human primates provide a close recapitulation of the 
anatomy of the human eye and bypass the limitations of rodent models. However, 
there are some ethical concerns related to their use, the disease progression is slow, 
their maintenance is costly, and there are difficulties in genetic manipulation (Pennesi 
et al., 2012). In human studies, post mortem tissues are limited and represent the 
end stage of the disease without offering insight into disease pathogenesis. hPSCs 
provide an opportunity for establishment of model systems that would enhance our 
understanding of the disease mechanisms. 
Embryonic and induced pluripotent cells are the two main types of stem cells 
that are used in disease modelling research. Pre-implantation blastocysts are used 
for the derivation of mammalian embryonic stem cells (ESCs) (Evans and Kaufman, 
1981; Martin, 1981; Thomson et al., 1998) [Figure 1.8 (A)]. They are characterised by 
their capability of indefinite in vitro undifferentiated proliferation and the potential to 
be differentiated into cell types representative of three embryonic germ layers and 
extraembryonic tissues that support development (Thomson and Marshall, 1998). 
There are thousands of research manuscripts that have been published exploring 
human ESCs (hESCs) as a tool for disease modelling, studying development, drug 
screening and therapeutics. However, there are numerous ethical issues and 
controversies that are associated with their derivation and use. It has also been 
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suggested that they might generate immunological and oncological barriers if used 
therapeutically (Preynat-Seauve et al., 2009). 
 
Figure 1.8. Derivation of hESCs. (A) Schematic representation of hESC derivation [adapted 
from Yu and Thomson (2006)]. (B) Example of hPSC colonies (white arrows). In culture, 
hPSCs form tightly packed colonies with clearly defined borders, and contain small round 
cells with large nuclei and notable nucleoli. 
In 2007, a major breakthrough resulted in the discovery of an alternative to 
hESCs in the form of hiPSCs. Yu et al. (2007) and Takahashi et al. (2007) reported 
generation of hiPSCs by reprogramming terminally differentiated somatic cells by 
ectopically expressing four transcription factors required for resetting them to 
pluripotent state. These cells were similar to hESCs in pluripotency potential, 
morphology [Figure 1.8 (B)], proliferation and epigenetic status. The discovery of 
hiPSCs lead to their extensive use as a tool for disease modelling and investigating 
patient-specific mutations, studying human development and drug screening. They 
have also started being investigated as a potential therapeutic tool and are currently 
part of a clinical trial for wet AMD undertaken in Rikagaku Kenkyūsho Institute in 
Japan, albeit the trial is currently on hold (Kimbrel and Lanza, 2015). 
Initial studies using hiPSCs identified a number of issues which have now 
been resolved, including development of chemically defined cell culture conditions in 
the absence of serum, reprogramming of human somatic cells with non-integrating 
vector systems and recent advances in site-specific genome editing in hPSCs 
(Hockemeyer et al., 2009; Yu et al., 2009; Chen et al., 2011a; Hockemeyer et al., 
2011; Okita et al., 2011; Okita et al., 2013). However, there are still issues including 
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clonal and cell line variations in the propensity of hiPSCs to differentiate into specific 
lineages due to stochastic processes during reprogramming (Ghosh et al., 2010; 
Kajiwara et al., 2012). 
Recently, an area of research emerged focussing on studying PSCs in 
alternative pluripotent states ranging between naïve and primed states which exist in 
murine PSCs. Epiblast cells constitute an extraembryonic set of cells which is 
uncommitted and provides cues to the blastocyst for embryonic development. Mouse 
ESCs derived from the pre-implantation epiblast have been suggested to be the only 
true totipotent (able to differentiate into any cell type) type of cells which constitutes 
naïve ground state (Nichols and Smith, 2009). Mouse post-implantation epiblast stem 
cells constitute a primed state. The main difference between the naïve and primed 
pluripotent states is that cells in the ground state are able to effectively form 
blastocyst chimeras, have no differentiation bias and have a high clonogenicity. 
Primate ESCs, including hESCs, have been associated with primed state and a lot of 
efforts have been invested in order to recapitulate mouse naïve state in human cells. 
Xiao et al. (2016) reviewed a number of publications that aimed at reprogramming 
human somatic and embryonic stem cells into naïve stem cells. Many of the studies 
only partially recapitulate ground state and the cells they describe vary in their 
morphology and chromosome status. Efficient generation of human naïve PSCs 
would allow better directed differentiation outcome. 
1.3.1 Reprogramming human somatic cells 
The process of cellular reprogramming is inefficient and Yamanaka (2009) proposed 
an explanation in the form of two mechanistic models. Firstly, the elite model of 
reprogramming suggests a deterministic approach where some but not all cells are 
capable of reprogramming. This has later been confirmed experimentally by Smith et 
al. (2010). The second model describes the idea that most somatic cells have 
potential to be reprogrammed due to the stochastic nature of the process. There has 
been a report which showed that reprogramming combines both of these models and 
consists of initial stochastic alterations in gene expression followed by a more 
deterministic phase (Buganim et al., 2012). Polo et al. (2012) used genome-wide 
analyses to show that there are early and late deterministic phases with a 
probabilistic phase in-between. 
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1.3.2 Factors affecting reprogramming efficiency 
Chromatin organisation and stochastic epigenetic events are some of the factors that 
could have an effect on reactivation of pluripotency circuitry. It has been shown that 
DNA hypermethylation at pluripotency-related genes may lead to the failure to 
achieve a stable reprogrammed state (Polo et al., 2012). Treating partially 
reprogrammed cells with DNA methyltransferase inhibitor 5-aza-cytidine has been 
shown to induce full reprogramming (Mikkelsen et al., 2008). 
Similar to DNA methylation state, remodelling of histone modification is also 
implicated in the success of somatic cell reprogramming. Histone methylation was 
shown to be one of the epigenetic changes during the acquisition of the pluripotent 
state (Polo et al., 2012). Addition of ascorbic acid improves reprogramming efficiency 
(0.1% to >10%) by reducing histone H3 lysine 36 methylation, reducing p53 levels 
and alleviating cell senescence by having an opposing effect on bone morphogenetic 
protein (BMP) (Esteban et al., 2010; Chen et al., 2013). Furthermore, ascorbic acid 
was shown to induce the activity of H3K36 demethylases Jhdm1a/1b (Wang et al., 
2011). Additionally, it was further shown that chromatin remodelling is a rate-limiting 
step in reprogramming and histone deacetylase inhibitor valproic acid induces 81% 
reprogramming efficiency (Huangfu et al., 2008a; Huangfu et al., 2008b). 
A number of studies reported the existence of microRNAs (miRNAs) that are 
specific to ESCs and play a role in their phenotype by interfering with the different 
phases of the cell cycle (Wang et al., 2007; Wang et al., 2008b). miRNAs are non-
coding RNA molecules that are involved in post-transcriptional gene regulation by 
binding to target messenger RNA (Bartel, 2004). A recent report has shown that 
miRNAs specific to ESCs can promote the shift to pluripotency and mimic 
reprogramming kinetics when combined with Oct4, Sox2 and Klf4 reprogramming 
factors thereby substituting c-Myc (Judson et al., 2009). miRNA302 cluster has been 
shown to be abundantly expressed in hESCs and embryonal carcinoma cells and to 
be under transcriptional control of Oct4 and Sox2 which in turn might be involved in 
the regulation of the cell cycle by increasing the S-phase in pluripotent cells (Card et 
al., 2008). hiPSC generation can also be affected by epigenetic signature of donor 
cells including miRNA expression and histone modification pattern (Li et al., 2013). 
Recently our group demonstrated that overexpression of miR-1305 resulted in hPSC 
differentiation by having an effect on cell cycle and survival (Jin et al., 2016). 
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During development, cell differentiation is accompanied by epithelial-to-
mesenchymal transition (EMT) which is crucial for body plan formation (Thiery et al., 
2009). A study that used mouse embryonic fibroblasts demonstrated that 
mesenchymal-to-epithelial (MET) transition is required for cell reprogramming 
through upregulation of E-cadherin, a protein involved in cell adhesion by forming 
adherens junctions (Li et al., 2010). Additionally, it has been shown that 
reprogramming is associated with three transitional phases including initiation, 
maturation and stabilisation and MET marks the initiation stage of the process 
accompanied by downregulation of EMT mediators including BMP and transforming 
growth factor beta (TGFβ) (Samavarchi-Tehrani et al., 2010).  H3K79 
methyltransferase has been shown to be implicated in MET signalling indicating the 
importance of chromatin modification on MET completion (Onder et al., 2012). 
Recently, our group showed that stress-activated kinases c-Jun N-terminal kinase 
(JNK) / stress-activated protein kinase (SAPK) are important for the induction of MET 
(Neganova et al., 2016). 
1.3.3 Reprogramming methods 
In 1938, a first attempt of a nuclear transfer experiment was performed by Hans 
Spemann who suggested that a differentiated nucleus can express pluripotency. It 
took almost 15 years to confirm it experimentally by transplanting nuclei from frog 
blastula into enucleated eggs showing the possibility of subsequent normal 
embryonic development (Briggs and King, 1952). 10 years later, Sir John Gurdon 
used Xenopus cells to extend the previous studies to show that it was possible to 
transfer nuclei from fully differentiated epithelial cells into enucleated eggs which lead 
to development of normal tadpoles (Gurdon, 1962). This work was the basis of his 
award of a Nobel Prize. Later studies focused on the attempts to derive cloned 
mammals. Robl et al. (1986) and Tsunoda et al. (1987) showed that transferring 
nuclei of eight-cell mouse embryos to two-cell embryo resulted in some of them 
developing to 12 days of gestation and in some cases to full term. Subsequent 
studies showed successful transfer of adult nuclei to enucleated oocytes of a sheep 
producing viable offspring (Campbell et al., 1996; Wilmut et al., 1997). First attempts 
to generate ESC lines were performed using mouse and primate cells. Although 
those studies showed potential benefit in clinical applications, the induction efficiency 
of the technique was low (Hochedlinger and Jaenisch, 2002; Rideout et al., 2002; 
Byrne et al., 2007). Another study obtained hESCs by somatic cell nuclear transfer 
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with high efficiency, however the complexity of the process makes its wide 
application challenging (Tachibana et al., 2013). Somatic cell nuclear transfer 
technique has been recently shown to be promising in studying mutations in mtDNA 
using patient cells (Ma et al., 2015). 
First reports of generating hiPSCs came in 2006, when two groups 
independently reprogrammed human somatic cells into hiPSCs by inducing 
pluripotent genes and chromatin modification with a set of transcription factors 
(Takahashi et al., 2007; Yu et al., 2007). Both of the groups used retroviral vectors to 
deliver the transcription factors. They identified SOX2 (SRY (sex determining region 
Y)-box 2) and OCT4 (octamer binding factor 4, also known as POU5F1) as 
transcription factors required for successful reprogramming. In addition, KLF4 
(Kruppel-like factor 4) and c-MYC (v-myc avian myelocytomatosis viral oncogene 
homolog) were introduced by Takahashi et al. (2007) and NANOG and LIN28 by Yu 
et al. (2007).  
Since these two reports came out, a number of novel delivery methods for 
target genes have been developed, including the use of integrating and non-
integrating methods. Despite their efficiency, using integrating viral vectors, including 
retroviruses and lentiviruses, has its own disadvantages. They carry a risk of 
insertional mutagenesis potentially promoting tumorigenicity (Park et al., 2013). A 
number of alternatives have been developed to avoid the issues described above, 
including using non-integrating viruses and non-viral delivery of the required factors. 
1.3.4 Non-viral delivery 
A number of groups used episomal vectors in order to avoid viral delivery, however 
the efficiency of the process remains low. Reprogramming human fibroblasts with 
OCT4, SOX2, NANOG, LIN28, c-MYC, KLF4, and SV40LT resulted in 0.0003–
0.0006 % efficiency; using new-born cord blood and introducing OCT4, SOX2, KLF4, 
c-MYC, and LIN28 resulted in 0.0007% efficiency; another study used human dermal 
skin fibroblasts and dental pulp with OCT4, SOX2, KLF4, LIN28, MYCL1, and TP53 
resulting in ~0.003% reprogramming efficiency (Yu et al., 2009; Chou et al., 2011; 
Okita et al., 2011).  
Minicircle DNA, free of bacterial DNA, results in low reprogramming efficiency 
(~0.005%) and is labour-intensive requiring multiple transfections (Jia et al., 2010; 
Narsinh et al., 2011). 
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DNA-free reprogramming methods use recombinant cell-penetrating proteins. 
Studies using murine fibroblast cells showed successful reprogramming using Oct4, 
Sox2, Klf4 and c-Myc (Zhou et al., 2009; Cho et al., 2010). This technique may also 
require multiple transfections with the addition of valproic acid. In addition, it has 
been shown to be stochastic and inefficient (~0.001%). Similar experiments with 
human somatic cells showed similar results (0.001% efficiency) and required 
repeated protein treatment cycles (Kim et al., 2009). 
A more efficient way of delivering reprogramming factors is by using mRNA. 
This results in intracellular post-translational modification of the proteins. This 
technique is relatively efficient (2-4.4%) however it also requires numerous daily 
transfections (Warren et al., 2010; Yakubov et al., 2010). 
1.3.5 Non-integrating viral vectors 
In order to eliminate the risks of the insertion of foreign DNA into a host genome, a 
number of non-integrating viral vectors have been proposed as an alternative. 
Adenovirus transiently expresses reprogramming factors and allows transfecting of 
non-dividing cells (i.e. hepatocytes) without integrating into the genome. However the 
efficiency of this method is low (0.0002%) and it requires repeated transfections 
(Zhou and Freed, 2009).  
A more efficient and less labour-intensive alternative exists that avoids the use 
of integrating viral vectors which is the Sendai virus. It was first isolated in Japan in 
1950s from a mouse and was identified as a parainfluenza virus from the 
Paramyxoviridae family (Kuroya and Ishida, 1953; Li et al., 2000). The viral particle is 
150-200 nm in diameter and consists of 15 384 nucleotides. It replicates as a 
negative-strand RNA and was shown to be able to self-replicate in its inactive form 
(Li et al., 2000). The virus replicates in the cytoplasm and does not enter the nucleus 
thereby avoiding the possibility of integrating into the host genome. It is cleared by 
clonal propagation of primary colonies resulting in the generation of Sendai-free sub-
clones. An alternative way of clearing the virus involves using temperature-sensitive 
vectors which enables clearing of the virus with passaging (Ban et al., 2011). A 
number of studies successfully used Sendai virus for the reprogramming of different 
types of somatic cells including T cells and fibroblasts with 0.1-0.2% efficiencies 
(Fusaki et al., 2009; Seki et al., 2010). Another group also successfully 
reprogrammed CD34+ cord blood cells (Nishishita et al., 2012). Life Technologies 
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(now Thermo Fisher Scientific Inc.) developed the CytoTune® Sendai-based 
reprogramming kit, which contains either four individual vectors with hKLF4, hc-MYC, 
hOCT3/4 and hSOX2 or a polycistronic vector hKLF4-hOCT3/4-hSOX2 (KOS) with 
two additional vectors with hKLF4 and hc-MYC. This reprogramming system was 
chosen for the PhD project because it is relatively efficient, the vectors do not 
integrate into the host genome and it does not require multiple transfections.  
Reprogramming methods and their efficiencies are summarised in Table 1.1. 
Reprogramming 
method 
Efficiency (%) Source 
Episomal vectors 0.003–0.0007 
(Yu et al., 2009; Chou et al., 2011; Okita et 
al., 2011) 
Minicircle DNA ~0.005 (Jia et al., 2010; Narsinh et al., 2011) 
Recombinant cell-
penetrating proteins 
0.001 
(Kim et al., 2009; Zhou et al., 2009; Cho et 
al., 2010) 
mRNA 2-4.4 (Warren et al., 2010; Yakubov et al., 2010) 
Adenovirus 0.0002 (Zhou and Freed, 2009) 
Sendai virus 0.1-0.2 (Fusaki et al., 2009; Seki et al., 2010) 
Table 1.1. Somatic cell reprogramming methods and their efficiencies. 
1.4 Using hiPSCs for modelling mitochondrial diseases 
Mitochondria play an important role in somatic cell reprogramming and differentiation 
and their dynamics and biogenesis change according to the state of the cell. 
Although this phenomenon is still poorly understood, it is believed that similar to 
hESCs, hiPSCs contain mitochondria that are spherical, underdeveloped and with 
perinuclear distribution as opposed to elongated and cristae-rich organelles found in 
somatic cells (Bukowiecki et al., 2014). Additionally, the cells undergo a metabolic 
switch from OXPHOS to mainly glycolysis during reprogramming (Folmes et al., 
2011). Upon hiPSCs differentiation, the properties of mitochondria start to resemble 
those of somatic cells. 
Since 2012, a number of studies have demonstrated the derivation of hiPSCs 
carrying various mtDNA mutations (Fujikura et al., 2012; Cherry et al., 2013; Folmes 
et al., 2013; Hamalainen et al., 2013; Kodaira et al., 2015; Ma et al., 2015; Yokota et 
al., 2015). Most of these reports described derivation of cells with the m.3243A>G. 
The details of these papers are to be discussed in further chapters; however, the 
possibility of having fully established hiPSCs with mtDNA mutations seen in patients, 
able to give rise to cells of various lineages, provides a great platform for the 
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investigation carried out as part of this PhD project. In addition, they hold great 
promise in providing wild-type isogenic hiPSC clones that can be studied along with 
the cells harbouring various heteroplasmy levels without the requirement for gene 
editing. 
1.5 Retinal development and in vitro differentiation  
1.5.1 Structure of the eye and retinal development 
The eye is a complex specialised organ, as shown in Figure 1.9. Sclera and cornea 
form part of the external layer of the eye. Iris, ciliary body, and choroid form the 
intermediate layer of the eye, and retina is located at the posterior layer. Cornea and 
iris are separated by the anterior chamber, iris and the lens are separated by the 
posterior chamber, and vitreous gel is located between the lens and the retina. 
Macula can be found in central retina 3 mm lateral to the optic disc; fovea can be 
found in its centre, where there is a high concentration of cone photoreceptors. 
Retina is positioned as an innermost layer of the eye and is involved in 
phototransduction by converting biochemical information into neural impulses to the 
brain. The two main components of the retina are neural retina and RPE (Kolb, 
2012). 
 
Figure 1.9. Gross anatomy of the eye [adapted from Vera-Díaz and Doble (2012)]. 
Neural retina is responsible for converting light energy to neural impulses that are 
passed on through the ganglion cells to the optic nerve and to the brain. The main 
Sclera
Choroid
 26 
neural cell types in the retina are photoreceptors, bipolar cells and RGCs; the activity 
of these cells is regulated by horizontal and amacrine cells. The main types of 
photoreceptors are rods and cones, which are involved in dim light vision and fine 
resolution colour vision, respectively. Cones are mostly found in the macula and 
fovea, whereas rods are found predominantly in the peripheral retina. Bipolar cells 
form synapses primarily with photoreceptors, RGCs, and amacrine cells. Axons of 
RGCs form an optic nerve and eventually form synapses in the lateral geniculate 
nucleus of the thalamus connecting retinal impulses to the brain (Forrester et al., 
2008). 
The RPE forms one of the blood-brain barriers of the eye. It faces Bruch’s membrane 
with its basolateral membrane and photoreceptor outer segments with the apical 
membrane (Strauss, 2005). It is involved in light absorption and is essential for 
supporting a number of physiological processes including growth factor secretion in 
the form of pigment epithelium-derived growth factor (PEDF) and vascular 
endothelial growth factor (VEGF), phagocytosis of photoreceptor outer segments, 
retinol cycling and production of pigment (Ramsden et al., 2013) (RPE functions are 
pictured in Figure 1.10). 
 
Figure 1.10. Summary of RPE functions [adapted from Toops et al. (2014)]. Basal layer 
of RPE cells lies adjacent to Bruch’s membrane and apical layer is next to photoreceptors, 
where it forms a protective barrier. 
In vivo, embryonic eye development commences in the fourth week as a result of 
complex interactions between embryological tissues. Prior to neural tube folding, 
optic sulci appear in the inner region of the neural plate which eventually will give rise 
to rostral diencephalon. Protrusion of the optic sulci leads to the formation of the optic 
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vesicles. Each optic vesicle extends until it contacts the surface ectoderm and as a 
consequence, it undergoes invagination to form the optic cup. The end of week eight 
is identified by the formation of the thin outer layer which will form RPE and a thick 
inner layer marking neural retina. First appearance of melanin within the embryonic 
RPE could be observed from day 28 of gestation. RPE cells show distinct hexagonal 
morphology and are homogenous in size. Mitotic activity is observed in early 
development and terminates at birth which leads to RPE growth by either 
enlargement or hypertrophy of the existing cells. At the optic cup stage, basal lamina 
of the RPE is recognisable and by 10 weeks, collagen fibrils are laid down beneath it 
(Forrester et al., 2008) (Summarised in Figure 1.11). 
 
Figure 1.11. Schematic illustration of human retinal development in vivo. (1) Start of 
week 4 (day 22); (2) End of week 4 (day 27); (3) Start of week 5 (day 29); (4) Start of week 6 
(day 37). [Adapted from Forrester et al. (2008)]. 
A number of molecular studies have shown that there are complex interactions 
between different retinal tissues and their formation could be interdependent. For 
example, formation of an optic vesicle and well-defined layers of neuroretina and 
RPE is dependent on fibroblast growth factors (FGFs) signalling from surface 
ectoderm, which drives the progenitor cells towards neural retina formation (Hyer et 
al., 1998). Additionally, exposing RPE to bFGF has been shown to induce it to 
transdifferentiate into neural retina (Pittack et al., 1991; Zhao et al., 1995). Other 
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studies have shown that ablation of the surface ectoderm leads to optic vesicle 
formation with inverted localisations of retinal areas which could be a result of a lack 
of local signalling coming from the neuroepithelium of the brain, the mesenchyme or 
the RPE itself (Nguyen and Arnheiter, 2000). 
 Numerous studies have focused on identifying critical genes and transcription 
factors in ocular development. Retinal progenitor cell proliferation and optic vesicle 
formation is dependent on retinal homeobox protein (RX) (Mathers et al., 1997). 
PAX6 is expressed in anterior neural plate and together with LIM homeobox 2 
(LHX2) is required for optic cup formation (Hill et al., 1991; Porter et al., 1997). 
Microphthalmia-associated transcription factor (MITF) has been shown to be critical 
in separation of an optic vesicle into RPE and neural retina (under the regulation of 
FGFs) becoming specifically restricted to RPE, whereas CHX10 [same as visual 
system homeobox 2 (VSX2)] is characteristic of neural retina (Burmeister et al., 1996; 
Nguyen and Arnheiter, 2000). Markers of different stages of retinal development are 
summarised in Figure 1.12. 
 
Figure 1.12. Markers identifying different stages of retinogenesis [adapted from Meyer 
et al. (2009)].  
Borrowing the basic principles gained from developmental neurobiology, the field has 
identified a number of ways in which to direct pluripotent stem cells towards retinal 
fate. In vitro differentiation protocols have been developed for differentiation of 
hESCs and hiPSCs using two main principles: default differentiation in the absence 
of extrinsic factors, and differentiation with the addition of transcription factors, 
proteins and small molecules (Borooah et al., 2013). 
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1.5.2 Default differentiation 
In vivo, vertebrate neural development is a conserved process that generates distinct 
classes of progenitors that will make up the forebrain, midbrain, hindbrain and spinal 
cord (Stern et al., 2006). Forebrain morphogenesis is more complex than in other 
parts of the CNS and results in the formation of ventrally positioned hypothalamus 
and caudally positioned diencephalon, dorsal telencephalon and ocular structures 
(Wilson and Houart, 2004). The default model of cell differentiation suggests that 
neural induction occurs in the absence of extrinsic factors, resulting in the 
differentiation to neural and retinal cell lineages (Munoz-Sanjuan and Brivanlou, 
2002). hESCs and hiPSCs have been shown to recapitulate key events and follow 
the same principles of developent by differentiating into rostral telencephalic 
neuroectoderm in the absence of exogenous signalling molecules and  presence of 
minimal media (Pankratz et al., 2007; Hu et al., 2010; Ozair et al., 2013).  
 Differentiation to neuroectoderm occurs as a result of suppression of other cell 
lineages including mesoderm and endoderm. In the default model of differentiation it 
is believed to be a result of the inhibitory mechanisms on the BMP pathway (Tropepe 
et al., 2001; Munoz-Sanjuan and Brivanlou, 2002).  Extracellular antagonists such as 
Chordin and Noggin inhibit the BMP pathway which leads to induction of 
neuroectoderm with anterior positional identity (Wilson and Houart, 2004).  
 Early work on retinal differentiation showed that ESCs follow embryologic 
differentiation pathways and “spontaneously” differentiate. A pioneering study 
published by Yoshiki Sasai’s group first showed that mouse ESCs are capable of 
spontaneously differentiating into retinal progenitors and form optic cup-like 
structures (Eiraku et al., 2011). This study was followed by a study using hESCs 
demonstrating optic cup self-organisation (Nakano et al., 2012). Studies using both 
hESCs and hiPSCs showed that differentiating cells go through different stages 
showing attributes of retinal progenitors and subsequently express more mature RPE 
and neuroretina markers (Klimanskaya et al., 2004; Vugler et al., 2008; Buchholz et 
al., 2009). RPE cells are identified by the appearance of melanin pigment within four 
weeks and the display of typical cobblestone morphology similar to what is seen in 
primary cell cultures (Carr et al., 2009). Spontaneous differentiation allows derivation 
of layers of RPE however the process is time consuming, relatively inefficient and 
could result in heterogeneous cell populations (Borooah et al., 2013; Buchholz et al., 
2013). It has been suggested that hESCs display innate heterogeneity of the original 
stem cell populations and present differential propensity for differentiation based on 
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their histone modifications (Stewart et al., 2006; Hong et al., 2011). Additionally, 
some cells show bias toward certain retinal cell fates due to intrinsic difference in 
endogenous signalling molecules (Meyer et al., 2009; Meyer et al., 2011; Mellough et 
al., 2012). 
1.5.3 Directed differentiation 
Retinal differentiation is controlled by a diverse set of signalling pathways which 
affect the regional identity of the resulting cell population. A number of studies used 
exogenous factors in order to direct differentiation towards the desirable retinal cell 
type more efficiently. 
 TGFβ and BMP pathways are involved in stem cell self-renewal and 
differentiation (Schmierer and Hill, 2007; Moustakas and Heldin, 2009). It has been 
shown that full neural conversion can be achieved using SB431542 and Noggin 
respectively as inhibitors generating neuroepithelium with rostral telencephalic 
identity (Chambers et al., 2009; Chambers et al., 2012). Mimicking development in a 
stepwise differentiation process using small molecules has been shown to produce 
retinal progenitors, RPE and photoreceptors with recombinant proteins Dickkopf-
related protein 1 (DKK1) and left-right determination factor A (LEFTY-A), a Wnt and 
Nodal antagonists (Osakada et al., 2008). A later study showed that similar efficiency 
could be achieved with small molecule CKI-7 which is known to act on casein kinase 
I and block Wnt, and an Activin receptor-like kinase-4 inhibitor SB431542 (Osakada 
et al., 2009). Thus, these studies highlighted the importance of TGFβ, BMP, Wnt and 
Nodal signalling pathways in retinal fate commitment. Recently, it has been shown 
that VSX2, a transcription factor involved in proliferation of neural retinal progenitors, 
directly targets Wnt pathway thereby creating a fine balance between neural retina 
and RPE development (Capowski et al., 2016). IGF1 signalling pathway has also 
been shown to be implicated in efficient differentiation of hESCs towards retinal 
progenitors, RPE, photoreceptors as well as 3D laminated retina (Lamba et al., 2006; 
Mellough et al., 2015). A recent study suggested that RPE differentiation is also 
regulated by non-coding regulatory RNA molecules, miRNAs, and in particular miR-
184 (Jiang et al., 2016). It was found that it targets and suppresses RAC-beta 
serine/threonine-protein kinase (AKT2) / mammalian target of rapamycin (mTOR) 
pathway thereby inhibiting cell proliferation and migration. Interestingly, patients with 
AMD show downregulation of miR-184 and upregulation of AKT2 leading to reduction 
in lysosomal-associated membrane protein 1 (LAMP1) and as a result defects in 
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phagocytosis, suggesting one possible pathophysiological pathways of the disease. 
Miyagishima et al. (2016) showed that miRNA expression is unrelated to starting 
donor tissue or epigenetic status. 
 Some groups have tested variations in media composition by adding extra 
supplementation (Borooah et al., 2013). B27 and N2 are known to promote retinal 
differentiation and are used widely in the field (Lu et al., 2009; Meyer et al., 2009; 
Meyer et al., 2011; Mellough et al., 2012; Buchholz et al., 2013; Rowland et al., 2013; 
Zhang et al., 2013; Zhu et al., 2013). Other conditions such as oxygen levels have 
been investigated as a possible modulator in cell differentiation. It has been 
previously suggested that in adult CNS oxygen levels are approximately 3% as 
opposed to the atmospheric 20% (Stacpoole et al., 2011). There is growing evidence 
that oxygen levels during stem cell culture could have an implication on cell survival 
and differentiation at neuroectodermal stage (Stacpoole et al., 2011). hESC and 
hiPSC studies showed that hypoxia was beneficial for derivation of retinal progenitor 
cells, whereas mESCs have been shown to have an improved efficiency in 
differentiating towards photoreceptors (Bae et al., 2012; Garita-Hernandez et al., 
2013). 
1.5.4 Differentiation to RPE 
Molecular signature of differentiating RPE cells 
A number of markers exist to identify different retinal cells types. The homeobox 
gene OTX2 is expressed at pluripotent stem cell stage and is also required for the 
formation of the anterior neuroectoderm (Frantz et al., 1994; Acampora et al., 2013). 
PAX6 and RX are expressed at the early eye field stage. At optic vesicle stage, 
neuroepithelial cells are able to become both RPE and neural retina. Expression of 
PAX6 pre-determines RPE fate by targeting MITF promoter (Baumer et al., 2003). 
Therefore, PAX6 and MITF are upregulated and when the cells differentiate into 
RPE, MITF expression is increased whereas cells that are destined to differentiate 
towards neural retina suppress MITF and upregulate CHX10 expression (Meyer et 
al., 2009; Borooah et al., 2013) (Figure 1.13). 
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Figure 1.13. Retinal markers at different stages of hESCs differentiation [adapted from 
Meyer et al. (2009)]. 
Existing protocols for RPE differentiation from hPSCs 
Differentiation protocols have been developed for derivation of RPE cells from both 
hESCs and hiPSCs (Klimanskaya et al., 2004; Meyer et al., 2009). Initial studies 
showed that RPE derived from hESCs express a similar genetic profile to primary 
human RPE cells and the resulting cell population initially goes through neuronal 
specification before attaining RPE features (Klimanskaya et al., 2004). Further 
studies showed that it was possible to derive functional RPE cells capable of 
surviving sub-retinal transportation in rats with a functional defect of RPE (Lu et al., 
2009). Another study showed that hiPSCs-derived RPE cells were similar in function 
to foetal RPE and hESCs-derived RPE (Buchholz et al., 2009). In this study, RPE 
were obtained by first removing bFGF from culture and later adding it for propagation 
of the resulting RPE sheets. However, the efficiency of differentiation was low and 
the first appearance of well-defined pigmented clusters ready for isolation was not 
observed until 40-90 days of differentiation. This issue was first addressed in 2009, 
when Idelson et al. (2009) showed that the addition of nicotinamide (Vitamin B3) 
together with Activin A substantially improved production of functional RPE cells with 
pigmented foci appearing after 4 weeks of differentiation. It was later suggested that 
at the early stages of neutralisation there is an increased mitochondrial respiration 
leading to oxidative stress and ROS leakage leading to apoptosis and the addition of 
nicotinamide has protective properties in the developing neuroectoderm 
(Cimadamore et al., 2009). Subsequent studies showed that the addition of Activin A 
 33 
augments generation of RPE and MITF expression from optic vesicle-like structures 
and results in the majority of cells in culture acquiring RPE morphology (Meyer et al., 
2011; Zhu et al., 2013). Addition of sonic hedgehog (SHH) and retinoic acid (RA) 
together with Activin A did not show an improved yield or maturation of RPE (Zhang 
et al., 2013). However, serial addition of SHH, RA, Noggin and bFGF generated 60% 
of MITF positive cells after 60 days of differentiation (Zahabi et al., 2012). Other 
factors, such as NOGGIN, DKK1 and IGF1 were shown to be favourable for 
generation of retinal progenitor cells with over 80% expressing Pax6 and Chx10 
(Lamba et al., 2006). Based on the studies described above, Buchholz et al. (2013) 
showed efficient production of pigmented RPE sheets as early as 14 days after the 
start of differentiation with an efficiency of 80% by combined use of IGF1, NOGGIN, 
DKK1, bFGF, nicotinamide and Activin A resulting in expandable population of cells. 
Another group aimed at replacing growth factors and complex differentiation 
protocols with the use of small molecules. They screened a library of 300 compounds 
and identified chetomin as a potent promoter of RPE identity when used in 
combination with nicotinamide (Maruotti et al., 2015). 
 Together with the addition of various factors, different groups have also looked 
at the effect of culture conditions on differentiation. Some groups have tested the 
initial differentiation steps in adherent cultures by allowing cells to overgrow and 
subsequently removing mitogens from culture and allowing the cells to differentiate 
(Klimanskaya et al., 2004; Vugler et al., 2008; Buchholz et al., 2009; Liao et al., 2010; 
Zhang et al., 2012; Buchholz et al., 2013; Rowland et al., 2013). Patches of 
pigmented cells are normally seen from 14 to 90 days and when they reach the size 
of ~1mm, they are mechanically dissected, re-plated and propagated. Some groups 
expand cells in the same media as differentiation media, whereas others add bFGF 
or FBS (Buchholz et al., 2009; Liao et al., 2010; Zhang et al., 2012). Groups also 
vary substrate that they use for cell culture including mouse embryonic fibroblasts, 
human embryonic fibroblasts and feeder-free matrices. 
Substrates and culture conditions used for differentiation and growth of RPE 
cells 
The use of animal-derived feeder layers could potentially introduce the risk of 
transmitting animal pathogens to human cells (Martin et al., 2005). Human feeder 
cells have also been successfully utilised in RPE differentiation protocols with hESCs 
however they have not been extensively studied in their applications to hiPSCs 
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differentiation (Zhang et al., 2012; Sorkio et al., 2014). Some studies have reported 
that feeder-free cultures produced pigment faster (Klimanskaya et al., 2004).  Some 
studies have also looked at the effect of different extracellular matrix (ECM) proteins 
on hPSCs differentiation. In vivo, the RPE cell layer is supported by Bruch’s 
membrane which contains several ECM proteins important to RPE including laminin-
111, -332, -511 and -521, collagen I and IV, fibronectin and vitronectin (Rowland et 
al., 2013). Rowland et al. (2013) showed that laminin-111 and matrigel are ideal 
substrates for generating high yields of RPE. This study provided a useful insight into 
the importance of the choice of ECM however the cells were cultured for a relatively 
short period of time (4-5 weeks until pigmentation and further 80 days to allow for 
enrichment) with a limited number of functional assays. A more recent study used 
laminin-521 and showed that hESC-RPE cells were similar to native RPE and 
showed integration and survival after sub-retinal transplantation into rabbits (Plaza 
Reyes et al., 2016). A study by a different group did a more extensive analysis using 
several human ECM proteins including collagen I and IV, laminin, fibronectin, 
vitronectin and commercial substrates CELLstart and matrigel (Sorkio et al., 2014). 
The cells were cultured for an extended period of time for a total of 140 days and 
specific RPE proteins were investigated as well as epithelial polarisation, phagocytic 
activity and transepithelial resistance as a measure of the integrity of the RPE layer. 
Although, different ECMs have shown to be heterogeneous in their performance in 
different tests, it was concluded that overall collagen IV was the most favourable for 
enrichment and maturation of functional RPE cells (personal communication; Dr 
Tanja Ilmarinen, University of Tampere). It is possible to propagate hPSC-derived 
RPE cells for several passages however after they reach senescence they lose some 
of the key features (Singh et al., 2013). Additionally, cells express DNA damage and 
telomere shortening (Kokkinaki et al., 2011). 
 Another popular method for inducing RPE fate is through neurosphere 
formation at the initial stages of neuroectoderm induction and subsequently plating 
the aggregates into adherent culture (Klimanskaya et al., 2004; Meyer et al., 2009; 
Meyer et al., 2011; Gong et al., 2015). A classical way of generating pigment is 
through gradual reduction of knock-out serum replacement in culture, however xeno-
free defined culture conditions have also been shown to be able to produce 
functional RPE cells (Vaajasaari et al., 2011; Plaza Reyes et al., 2016). 
 Although few studies have compared two of the culture methods directly, 
some of the groups reported that differentiation in adherent cultures is more 
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favourable when compared to differentiation in suspension (Vugler et al., 2008; 
Rowland et al., 2013). Combining two of the culture conditions is possible by first 
culturing cells as neurospheres in matrigel and subsequently plating them down for 
further expansion (Zhu et al., 2013). 
A summary of previously published RPE differentiation protocols has been 
provided in Table 1.2.
  
hPSCs to 
retinal cells 
Differentiation method Substrate 
Length of 
differentiation / 
first appearance 
of pigment 
References 
hESCs / 
hiPSCs to 
RPE 
Monolayer spontaneous differentiation by removal of 
bFGF. 
 
ECMs identified as 
the most favourable: 
mouse laminin-111, 
matrigel 
21-33 days (Rowland et 
al., 2013) 
hESCs / 
hiPSCs to 
RPE 
Monolayer differentiation with the addition of Noggin, 
IGF1 and DKK1. 
Matrigel 14 days (Buchholz et 
al., 2013) 
hESCs / 
hiPSCs to 
RPE 
3D culture in the presence of matrigel, KOSR, Activin A, 
N2 and B27. 
hESC-qualified 
matrigel  
18-30 days (Zhu et al., 
2013)  
hESCs to RPE Monolayer differentiation in the presence of KOSR with 
RA and SHH, or Activin A. With the additional 
supplementation with N2 and B27. 
hESC-qualified 
matrigel  
3 weeks after 
Activin A 
treatment; 35 days 
with RA and SHH 
(Zhang et al., 
2013) 
3
6
 
  
hESCs / 
hiPSCs to 
RPE 
Monolayer spontaneous differentiation by removal of 
bFGF in the presence of KOSR and FBS. 
Gelatin 20-35 days (Buchholz et 
al., 2009) 
hESCs to RPE Monolayer spontaneous differentiation without bFGF. Matrigel 3-4 weeks (Zhang et al., 
2012) 
hESCs / 
hiPSCs to 
retinal cells 
Spontaneous differentiation in 3D culture with N2 and 
heparin or B27. In some experiments cells were then 
plated as monolayer. 
Laminin for 
monolayer 
differentiation 
30-50 days (Meyer et al., 
2009) 
hESCs to RPE Spontaneous differentiation in the presence of KOSR 
and FBS. 
Gelatin 6-8 weeks (Klimanskaya 
et al., 2004) 
hESCs / 
hiPSCs to 
RPE 
3D culture with subsequent plating in the presence of 
KOSR, Wnt and Nodal inhibitors CKI-7 and SB431542. 
Poly-D-lysine-laminin 
fibronectin 
35-140 days (Osakada et 
al., 2009) 
hESCs to RPE Spontaneous differentiation in floating cultures in the 
presence of N2 and heparin. Then B27 (-RA). 
Laminin 40 days (Capowski et 
al., 2014) 
hESCs to RPE Monolayer spontaneous differentiation. Growth factor 
reduced matrigel 
4-5 weeks (Lane et al., 
2014) 
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hiPSCs to 
RPE 
Cells were allowed to overgrow for 8-14 days, until 
changing the medium to X-VIVO 10. 
Matrigel 4-6 weeks (Croze et al., 
2014) 
hESCs / 
hiPSCs to 
RPE and 
neural retina 
On day 4, differentiation was initiated with: DMEM/F12, 
0.1 mM NEAA, 2 mM L-glutamine, 1% N2. By day 7, 
aggregates were transferred to adherent culture. On day 
14 medium changed to: Neurobasal, 14% KOSR, 0.1 
mM NEAA, 2 mM L-glutamine, 10 mM Nicotinamide. 
Days 18–22, Activin A (20 ng/ml). 
Mouse embryonic 
fibroblasts 
44 days (Wang et al., 
2015) 
hESCs to RPE Adapted from (Buchholz et al., 2013). Included 3 μM 
CHIR99021 from day 8 to 14. On day 14, RPE cells 
were manually enriched to passage 0 and maintained in 
X-VIVO 10 supplemented with 10 μM Y-27632 for 4 to 7 
days. 
Matrigel 97.77% PMEL17 
positive cells at 
day 14 
(Leach et al., 
2015) 
hiPSCs to 
RPE 
EB differentiation with GMEM, 0.1 mM NEAA, 1 mM 
pyruvate, 0.1 mM 2-mercaptoethanol. 20% KOSR for 
three days, then 15% KOSR for 9 days, and finally 10% 
KOSR. 5 μM CKI-7 and 5 μM SB431542 were added for 
21 days during suspension culture, then plated down. 
Matrigel 10 weeks (Li et al., 
2016) 
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hiPSCs to 
RPE 
hiPSC colonies were lifted and grown as uniform EBs in 
AggreWell™ plates (STEMCELL Technologies) for 4 
days in EB formation medium (STEMCELL 
Technologies). At day 5, medium changed to 
DMEM/F12, 1% N2, MEM NEAA and 2 μg/mL heparin. 
At day 7, aggregates were plated onto laminin-coated 
culture plates for an additional 10 days. At day 16, 
medium replaced with: DMEM/F12 (3:1), 2% B27 (- RA), 
MEM NEAA and penicillin/streptomycin. After re-plating 
pigmented patches, cells cultured with 10% FBS, then 
2% FBS until confluent. Thereafter, FBS was removed. 
Laminin 60-90 days (Gong et al., 
2015) 
hiPSCs to 
RPE 
Monolayer differentiation. Day 1: DMEM/F12, 15% 
KOSR, 2mM Glutamine, 0.1 mM NEAA, 1% Anti-Anti, 
0.1 mM β-Mercaptoethanol. Day 2 – Day 16: addition of 
10 mM nicotinamide, 25-100 nM chetomin. Day 17: 
DMEM (70% vol/vol), F12 (30% vol/vol), B27, Anti-Anti. 
Synthetic vitronectin 
peptide-acrylate 
surfaces 
1 month (Maruotti et 
al., 2015) 
hESCs to RPE 3D method with xeno-free NutriStem hESC XF medium 
without bFGF and TGFβ. 
Recombinant human 
laminin-521 
3 weeks (Plaza Reyes 
et al., 2016) 
Table 1.2. Summary of some published RPE differentiation protocols.
3
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The field has identified a number of ways by which to characterise hPSC-derived 
RPE cells. These are summarised in Table 1.3. 
Characteristic Verification method / Marker 
Morphology Polygonal monolayer of pigmented 
cells (“cobblestone” morphology) 
verified with light microscopy 
Electron micrograph to show ultra-
structural compartments 
Early eye field transcription factor 
network 
OTX2, LHX2, RX, SIX, SIX6, Tll 
Optic vesicle markers PAX6, MITF 
RPE-specific markers  Terminally differentiated RPE  
MITF, CRALBP, RPE65, BEST1, 
MERTK, COLLAGEN IV 
Tight junction proteins 
Claudin, ZO1 
Pigment synthesis 
Tyrosinase, Silver (Pmel17) 
Polarity / growth factor secretion 
PEDF (secreted apically) 
VEGF (secreted basally)  
Na+/K+ATPase staining (apical) 
BEST1 (basal) 
Vectorial fluid flow 
Aquaporin expression 
Functional characterisation Rod outer segment phagocytosis 
assay 
Sub-retinal injection of cells in animal 
models of RPE deficiency 
RPE layer integrity Transepithelial resistance 
Electrical impedance spectrum 
Table 1.3. Examples of assays for verification of RPE cells derived from hPSCs 
(Rowland et al., 2012; Borooah et al., 2013; Juuti-Uusitalo et al., 2013; Wright et al., 
2014; Miyagishima et al., 2016). 
There is no minimum requirement for the specific tests needed to be performed for 
classifying cells as RPE cells. However, some of the methods described in Table 1.3 
are used more often than others, for example, confirming the morphology of the cells 
to appear “cobblestone”, looking for the expression of RPE markers, such as MITF, 
RPE65, and CRALBP, and most importantly, confirming their functional maturity by 
performing the phagocytosis of photoreceptor outer segments assay. Therefore, 
these tests should comprise the minimum for confirming RPE status of the cells. 
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1.6 Aims and objectives 
The aim of this research project was to investigate the pathological links between 
retinal degeneration, specifically RPE cells, and mitochondrial dysfunction seen in 
patients with the m.3243A>G mutation using hiPSCs as a tractable disease model. 
Specifically, during this project, it was aimed to: 
 Create an hiPSC disease model for the m.3243A>G mutation 
 Optimise RPE differentiation protocol using hESCs 
 Assess the impact of the m.3243A>G mutation on RPE cells derived from 
hiPSCs with this mutation 
1.7 Hypothesis 
The main hypothesis was that reprogramming of fibroblasts from patients with the 
m.3243A>G mutation would result in the generation of hiPSC clones with varying 
heteroplasmy levels. It was expected for hiPSC-derived RPE cells to show 
deficiencies similar to those found in patient tissues and provide a novel model for 
retinal pathogenesis in patients with the m.3243A>G. 
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Chapter 2. Methods 
2.1 Patients and healthy controls information 
Adult human dermal fibroblasts (HDFs) used for the generation of control hiPSC lines 
were either obtained from Lonza (Control 1 (SB-Ad5), 57 year-old female), or 
obtained from a healthy control patient (Control 2 (SUN007), 74 year-old male) by Mr 
David Steel, Consultant Ophthalmologist, Sunderland Eye Infirmary. hiPSCs Ad2 
(referred to as Control hiPSCs) were reprogrammed and characterised by Mrs 
Adriana Buskin using adult HDFs (Lonza) obtained from a 51 year-old male with no 
known clinical abnormalities. Skin biopsies from patients harbouring the m.3243A>G 
mutation were taken by Mr Patrick Yu Wai Man, Consultant Ophthalmologist, Royal 
Victoria Infirmary (Newcastle-upon-Tyne). 
Patient 1 cells (F216) came from a 73 year-old female presenting with bilateral 
pigmentary macular degeneration (sparing left fovea), and significant visual acuity 
deterioration over the past ten years (visual acuities: right eye 6/60, left eye 6/9), 
insulin-treated type 2 diabetes mellitus and bilateral sensorineural hearing loss. The 
patient does not have any significant neurological deficits. Patient 2 cells (F350) 
came from a 62 year-old male with insulin-treated type 2 diabetes mellitus, bilateral 
sensorineural hearing loss and extensive macular geographic atrophy (visual 
acuities: right eye 6/36, left eye 6/36). Patient 3 cells (F217) came from a 61 year-old 
male who is the brother of Patient 1. Patient 3 has no pigmentary retinopathy or 
maculopathy and has normal vision in both eyes (visual acuities: right eye 6/6, left 
eye 6/6). He has insulin-treated type 2 diabetes mellitus and significant neurological 
deficits including bilateral sensorineural hearing loss, ataxia, peripheral neuropathy 
and epilepsy. Patients’ ocular phenotype and proportion of m.3243A>G in different 
tissues is summarised in Table 2.1. All samples were obtained as part of a NHS 
research ethics committee approved biobank for fibroblasts from patients with retinal 
disease and based at the Institute of Genetic Medicine (ethics number 11/NE/0294), 
Newcastle University.
  
Patient, 
Age / 
Gender 
Fundus images Ocular phenotype 
% m.3243A>G 
Blood Urine 
Skeletal 
muscle 
Patient 1, 
73/F 
  
 bilateral pigmentary macular 
degeneration (sparing left fovea) 
 significant visual acuity 
deterioration over the past ten 
years  
 visual acuities: right eye 6/60, 
left eye 6/9 
10% 49% No data 
Patient 2, 
62/M 
  
 extensive macular geographic 
atrophy  
 visual acuities: right eye 6/36, 
left eye 6/36 
No data No data No data 
Patient 3, 
61/M 
  
 no pigmentary retinopathy or 
maculopathy 
 normal vision in both eyes  
 visual acuities: right eye 6/6, left 
eye 6/6 
No data 66% 67% 
Table 2.1. Patient information.  
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2.2 Cell culture 
2.2.1 Human fibroblast culture 
Cells were maintained in fibroblast medium containing Advanced DMEM (Dulbecco's 
Modified Eagle Medium), high glucose (Life Technologies), supplemented with 10% 
Fetal Bovine Serum (FBS) (Life Technologies), 1% 100X GlutaMAX (Life 
Technologies), 1% Penicillin-Streptomycin (Life Technologies). When confluent, 
fibroblast cells were passaged with 0.05% Trypsin-EDTA (1X) solution (Life 
Technologies). For all cell culture experiments, cells were maintained in a humidified 
tissue culture incubator (37°C, 5% CO2, 20% O2). Additionally, for all cell culture 
experiments with MELAS cells 0.05 mg/ml uridine (Sigma) was added to the medium.  
2.2.2 Preparation of mouse embryonic fibroblasts feeder layer 
Mouse embryonic fibroblasts (MEFs) were derived and prepared by Dr Georgios 
Anyfantis from 12.5 – 13.5 day old embryos from Swiss MF1 mice. Fibroblasts were 
isolated via dissection and cultured in T75 flasks at a density of 13 – 15  104 cells 
per flask in fibroblast medium. Once confluent, the MEFs were mitotically inactivated 
by being subjected to irradiation using a Faxitron CP-160 radiation machine at a dose 
of 120 kV, 4.0 mA for 7 minutes and let to recover in an incubator for 1 hour. The 
irradiated MEFs were then harvested with 0.05% Trypsin-EDTA (1X) solution and 
plated on tissue culture plates pre-coated with 0.2% gelatin at a density of 1.5  104 
cells/cm2 and incubated for 24 hours prior to use. 
2.2.3 Preparation of MEF conditioned medium 
Proliferating MEFs were let to achieve 80 – 90% confluence and were subsequently 
irradiated using a Faxitron CP-160 radiation machine at a dose of 120 kV, 4.0 mA for 
7 minutes and let to recover in an incubator for 1 hour. The cells were then harvested 
using 0.05% Trypsin-EDTA (1X) solution and plated in tissue culture flasks at a 
density of 5.6  104 cells/cm2 in fibroblast medium. On the following day, the medium 
was changed to Knock-Out DMEM (Life Technologies) with 20% Knock-Out Serum 
Replacement (Life Technologies) (KOSR), 1% 100X MEM Non-Essential Amino 
Acids Solution (Life Technologies), 1% GlutaMAX (Life Technologies) and 1% 
Penicillin-Streptomycin Solution (Life Technologies). For the next 9 days, the medium 
was collected each day replacing it with fresh medium. Prior to use the medium was 
supplemented with 1% Insulin–Transferrin–Selenium (Life Technologies), 8 ng/ml 
 45 
basic fibroblast growth factor (bFGF) (Life Technologies) and filtered through a 2 µm 
filter. 
2.2.4 Induced pluripotent stem cell generation 
Control and patient fibroblasts were seeded onto a 12-well plate at a density of 1  
105 cells per well and cultured in fibroblast medium. 24 hours later the cells were 
transfected with the CytoTune-iPS Sendai Reprogramming Kit (CytoTune 1) 
containing four reprogramming vectors expressing Yamanka factors: hOCT3/4, 
hSOX2, hKLF4, hc-MYC at multiplicity of infection (MOI) = 3 or CytoTune®-iPS 2.0 
Sendai Reprogramming Kit (CytoTune 2) containing three reprogramming vector 
preparations: polycistronic KOS, hKLF4, and hc-MYC at MOI = 5-5-3 (Thermo 
Scientific). The medium was changed every other day for the next 7 days. On day 7 
post transduction, cells were passaged on a 6-well plate either on irradiated MEF 
feeder layer or in feeder-free experiments on plates pre-coated with 0.08 mg/ml 
Matrigel Basement Membrane Matrix (matrigel) (Corning). Cells on MEFs were 
plated at a density of 8  103 cells per well initially in hPSC medium with Knock-Out 
DMEM (Life Technologies), 20% KOSR (Life Technologies), 1% 100X MEM Non-
Essential Amino Acids Solution (Life Technologies), 1% GlutaMAX (Life 
Technologies), 1% Penicillin-Streptomycin Solution (Life Technologies), and 8 ng/ml 
bFGF (Life Technologies). The medium was changed to conditioned medium seven 
days later. Cells cultured on matrigel were plated at a density of 50  103 cells per 
well and maintained in mTeSR™1 medium (STEMCELL Technologies) 
supplemented with 1% Penicillin-Streptomycin Solution (Life Technologies). The 
medium was changed every day thereafter. When visible hiPSC colonies with hESC-
like morphology had developed and established (4 – 5 weeks), they were manually 
dissected out with a 10 µl pipette tip and re-plated on a 4-well plate either on MEFs 
or pre-coated with matrigel one colony per well and further expanded first on a 12-
well and then on a 6-well plate. 
2.2.5 Human pluripotent stem cell culture 
hESC line H9 obtained from WiCell (Madison, WI) and the derived MELAS and 
control hiPSCs were maintained on either irradiated MEF feeder layer or on matrigel 
in hPSC medium or mTeSR™1 medium (STEMCELL technologies) respectively. The 
medium was changed daily. The areas of differentiation were mechanically removed 
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daily under a stereomicroscope using a 10 μl micropipette tip. The cells cultured on 
MEFs were passaged 1:3 either mechanically or by treating them with 1 μg/ml 
Collagenase type IV in hPSC medium solution (Life Technologies) for 5 – 10 
minutes. The cells that were cultured on matrigel were passaged 1:6 with Versene® 
(EDTA) 0.02% solution (Lonza). Cells derived on MEFs were adapted to feeder-free 
culture conditions by re-plating them on plates pre-coated with matrigel in mTeSR1 
medium prior to using in downstream analyses and experiments. 
2.2.6 Retinal pigment epithelium differentiation and expansion 
For the RPE differentiation experiments, hPSCs on matrigel were grown to different 
densities: normal density and overgrown density, where the cells were let to grow 
until no distinct borders between the colonies could be observed. On day 1 of 
differentiation, the medium was changed to RPE differentiation medium (different 
medium combinations are summarised in Table 2.2) and replaced every day for the 
first 3 weeks and twice a week thereafter. Differentiation continued for 3 – 4 months. 
When pigmented areas reached 3 – 5 mm in size, they were mechanically dissected 
out under a stereomicroscope using a 10 µl pipette tip, dissociated with TrypLE™ 
Select Enzyme (1X) or (10X) (Life Technologies), filtered through a 40 µm cell 
strainer (Fisher Scientific) and re-plated for enrichment and maturation at a density of 
4.5  105 cells per cm2 on plates or 0.33 cm2 PET hanging cell culture inserts (Merck 
Millipore) pre-coated with laminin from human placenta (5 mg/ml), collagen IV or 
fibronectin (both 5 µg/cm2) (all Sigma-Aldrich), or growth factor reduced matrigel. 
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Base medium 
Additional supplementation for 
differentiation optimisation 
experiments 
mTeSR™1 with 1% Penicillin-
Streptomycin 
None 
Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12, GlutaMAX™ 
(DMEM/F12) (Life Technologies) with 1% 
100X MEM Non-Essential Amino Acids 
Solution and 1% Penicillin-Streptomycin 
Solution 
None 
B-27® Supplement (50X) (B27) (Life 
Technologies) 
B27 and N-2 Supplement (100X) (N2) 
(Life Technologies) 
B27 and 5 ng/ml human Insulin-like 
Growth Factor-I (IGF1) (Sigma-Aldrich) 
B27, N2 and IGF1 
RPMI 1640 Medium (RPMI) (Life 
Technologies) with 1% 100X MEM Non-
Essential Amino Acids Solution and 1% 
Penicillin-Streptomycin Solution 
None 
B27 
B27 and N2 
B27 and IGF1  
B27, N2 and IGF1 
Advanced RPMI 1640 Medium (AdRPMI) 
(Life Technologies) with 1% 100X 
GlutaMAX, 1% Penicillin-Streptomycin 
None 
B27 
B27 and N2 
B27 and IGF1  
B27, N2 and IGF1 
Table 2.2. RPE differentiation medium composition. 
2.2.7 In vitro differentiation into three germ layers 
In order to assess the ability of hiPSCs to spontaneously differentiate into cell types 
representative of the three embryonic germ layers, two different experiments were 
performed: spontaneous differentiation in suspension culture with embryoid body 
(EB) formation, or differentiation of cells as a monolayer. For the EB formation 
experiment, cells from two 6-well plates were incubated with 1 ml of 1:1 solution of 
Collagenase type IV (Life Technologies) powder dissolved in hPSC medium to a 
concentration of 1 mg/ml and Dispase II (Life Technologies) powder dissolved in 
Knock-Out DMEM (Life Technologies) to a concentration of 0.5 mg/ml. The solution 
was then filtered through a 0.2 μm filter. Cells were incubated for 40 minutes at 37 C 
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checking for colony detachment. Cells were then collected into a 50 ml conical tube, 
let to settle and re-suspended in EB formation medium containing DMEM/F-12 (Life 
Technologies), 20% FBS (Life Technologies), 1% Penicillin-Streptomycin Solution 
(Life Technologies) and 1% MEM Non-essential Amino Acids Solution (Life 
Technologies). Cells were then transferred to a 10 cm Petri dish and cultured for 7 
days replacing medium every day. On day 8, the EBs were transferred to a 24-well 
plate pre-coated with 0.1% gelatin replacing the medium daily. For spontaneous 
monolayer differentiation experiments, cells were let to grow to a normal density and 
the medium was changed to EB formation medium and replaced daily for 14 days. 
Cells were then collected with the cell scraper, washed and stored as pellets at -80C 
until further use. 
2.3 Teratoma formation 
Teratoma induction from the hiPSCs was undertaken by Prof L. Armstrong & Prof M. 
Lako, Newcastle University. Cells were injected subcutaneously into 8 weeks old 
male ICRF-Foxn1nu mice (Harlan Laboratories) at a concentration of 5  105 cells per 
100 µl of PBS + 2% FBS pre-mixed with 100 µl of matrigel. Two mice were used per 
cell line. From three weeks after the injection onwards, mice were monitored weekly 
for the appearance of tumours for up to 12 weeks. 
2.4 DNA extraction 
DNA was isolated using the QIAamp DNA Mini Kit (Qiagen), following the instructions 
of the manufacturer. The purity of the DNA was checked with NanoDrop 2000 
spectrophotometer expecting the A260/A280 ratio to be ~1.8. Isolated DNA was stored 
at -20C. 
2.5 RNA extraction 
Cells were harvested using a cell scraper (Sarstedt) or normal passaging treatment, 
washed with phosphate-buffered saline (PBS) (Life Technologies), pelleted and 
stored at -80C until further analysis. RNA was isolated using ReliaPrep™ RNA Cell 
Miniprep System (Promega) following the instructions of the manufacturer. The purity 
of RNA was confirmed using NanoDrop 2000 spectrophotometer expecting the 
A260/A280 ratio to be ~2.0. 
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2.6 cDNA synthesis 
Complementary DNA (cDNA) was synthesised subsequently to RNA extraction from 
1 mg of total RNA in 40 µl volume using GoScript™ Reverse Transcription System 
(Promega) according to the manufacturer’s instructions. The resulting product was 
stored at -20C. 
2.7 Polymerase chain reaction 
2.7.1 Sendai clearance experiments 
The primary polymerase chain reaction (PCR) was a 20 µl GoTaq DNA polymerase 
(Promega) reaction with 5X GoTaq® Reaction Buffer (1.5 mM MgCl2, 0.2 mM dNTP), 
1 µM forward and reverse primers, 0.025 U/µl GoTaq® DNA Polymerase and dH2O. 
PCR program: denaturation 95C 30 seconds, annealing 30 seconds, elongation 
72C 30 seconds for 35 cycles (primer sequences and specific annealing 
temperatures are shown in Table 2.3). The products were analysed by standard 2% 
agarose gel (Lonza) electrophoresis using GelRed (Biotium) at a concentration of 
1:10 000 as a nucleic acid dye. The appearance of bands was visualised with a UV 
transilluminator (Gel Doc-II Imaging system). 
Target Primer sequence 
Product 
size 
(bp) 
Annealing 
temperature 
(C) 
SeV Forward: GGATCACTAGGTGATATCGAGC 
Reverse: 
ACCAGACAAGAGTTTAAGAGATATGTATC 
181 61 
KOS Forward: ATGCACCGCTACGACGTGAGCGC 
Reverse: ACCTTGACAATCCTGATGTGG 
528 64 
hKLF4 Forward: TTCCTGCATGCCAGAGGAGCCC 
Reverse: AATGTATCGAAGGTGCTCAA 
410 63 
hc-
MYC 
Forward: TAACTGACTAGCAGGCTTGTCG 
Reverse: 
TCCACATACAGTCCTGGATGATGATG 
532 58 
GAPDH Forward: TGCACCACCAACTGCTTAGC 
Reverse: GGCATGGACTGTGGTCATGAG 
87 60 
Table 2.3. Primer sequences and annealing temperatures for Sendai clearance 
experiments. 
2.7.2 Pyrosequencing experiments 
Primers for PCR and pyrosequencing were designed using PyroMark® Assay Design 
SW 2.0 (QIAGEN) prior to the start of the PhD project. 
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PCR was set up with 50 ng DNA template. The primary PCR was a 25 μl 
MyTaq™ HS DNA Polymerase reaction (Bioline) with 5x MyTaq Reaction Buffer (3 
mM MgCl2, 1 mM dNTP), 0.4 µM forward and reverse primers, 5 U/µl MyTaq HS 
DNA Polymerase and dH2O. PCR program: denaturation 95C 15 seconds, 
annealing 65C 30 seconds, elongation 72C 10 seconds for 30 cycles (primer 
sequences are shown in Table 2.4). The products were analysed by standard 2.5% 
agarose gel electrophoresis using GelRed at a concentration of 1:10 000 as a 
nucleic acid dye. The appearance of bands was visualised with a UV transilluminator 
(Gel Doc-II Imaging system). 
Target Primer sequence 
Position of 
primer 
m.3243A>G 
 
Forward: *BIO-TAAGGCCTACTTCACAAAGCG  3142-3353 
Reverse: GCGATTAGAATGGGTACAATGAG 3258-3244 
Sequencing: ATGCGATTACCGGGC  
Table 2.4. Primer sequences for pyrosequencing experiments. BIO – biotinylated. 
Assay set up was created using PyroMark® Q24 Software (QIAGEN). 
Pyrosequencing was completed on PyroMark Q24 (QIAGEN) according to the 
manufacturer instructions. Briefly, 10 μl of the PCR product was added to 40 μl of 
binding buffer, 2 μl streptavidin-coated Sepharose® beads and 28 μl of high purity 
H2O. The samples were agitated at 1400 rpm for 10 minutes to bind the DNA to the 
beads. The PyroMark vacuum workstation was used to wash the DNA with 70% 
ethanol, denaturation solution and wash buffer. The product was eluted in 25 μl 
annealing buffer containing 0.3 μM sequencing primer. The results were analysed 
using PyroMark® Q24 Software. 
2.8 Quantitative PCR 
2.8.1 Quantification of mtDNA copy number and mitochondrial common 
deletion levels 
mtDNA was quantified using CFX96 Touch™ Real-Time PCR Detection System (Bio-
Rad). Reaction volume was 20 µl containing iTaq™ Universal Probes Supermix (Bio-
Rad), 0.3 µM forward and reverse primers and sample DNA. 
Standard curves were used in order to ensure reaction efficiency and accurate 
quantification. Standard PCR reactions were run for each primer set to generate 
templates covering the amplification region of the quantitative PCR (qPCR). PCR 
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reaction conditions were as follows: initial denaturation at 95C for 15 seconds, 
denaturation at 95C for 15 seconds, annealing and extension at 61C for 15 
seconds, elongation at 72C for 10 seconds for 30 cycles. The products were run on 
1% agarose gel using GelRed at a concentration of 1:10 000 as a nucleic acid dye. 
The bands were dissected out under the UV transilluminator (Gel Doc-II Imaging 
system) and the product extracted and purified using QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer’s instructions. The amount of total DNA was 
quantified with NanoDrop 2000 spectrophotometer and mtDNA copy number was 
calculated using the following equation: 
mtDNA copy number = [C ÷ (L x 2 x 330)] x A 
C – total DNA concentration (10-9 nL) 
L – amplicon length (bp) 
A – Avogadro’s number 
Once copy number was calculated, the templates were serially diluted with dH2O to 
generate standard curves with 1  109 to 1  101 copies. qPCR was performed in 
triplicate reactions using iTaq™ Universal Probes Supermix system (Bio-Rad). The 
data were analysed using the Bio-Rad CFX Manager software (Bio-Rad). mtDNA 
was quantified using the 2-∆∆Ct method, where copy number equals 2  (2-∆∆Ct). B2M 
was used as a nuclear reference gene. For the quantification of the common deletion 
levels, the ratio of MTND1 and MTND4 was used. The method for mtDNA copy 
number quantification was modified from a previous publication (Pyle et al., 2007). 
Probe and primer details can be found in Table 2.5, Table 2.6 and Table 2.7. 
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Target Primer sequence 
Product 
size (bp) 
Annealing 
temperature (C) 
B2M Forward: 
CGCAATCTCCAGTGACAGAA 
Reverse: 
GCAGAATAGGCTGCTGTTCC 
1092 61 
MTND1 Forward: 
CAGCCGCTATTAAAGGTTCG 
Reverse: 
AGAGTGCGTCATATGTTGTTC 
1040 61 
MTND4 Forward: 
ATCGCTCACACCTCATATCC 
Reverse: 
TAGGTCTGTTTGTCGTAGGC 
1072 61 
 Table 2.5. Primer sequences for PCR reactions for generation of standards. 
Target Primer sequence Product size (bp) 
B2M Forward: CACTGAAAAAGATGAGTATGCC 
Reverse: AACATTCCCTGACAATCCC 
231 
MTND1 Forward: ACGCCATAAAACTCTTCACCAAAG 
Reverse: GGGTTCATAGTAGAAGAGCGATGG 
111 
MTND4 Forward: ACCTTGGCTATCATCACCCGAT 
Reverse: AGTGCGATGAGTAGGGGAAGG 
107 
Table 2.6. pPCR primer sequences. 
Target Sequence Fluorophore Quencher 
B2M CCGTGTGAACCATGTGACTTTGTC FAM BHQ_1 
MTND1 ACCCGCCACATCTACCATCACCCTC HEX BHQ_1 
MTND4 CAACCAGCCAGAACGCCTGAACGCA Cy5 BHQ_2 
Table 2.7. Sequences for iTaq probes. 
2.8.2 qPCR for the analysis of gene expression 
qPCR was performed in triplicate reactions using GoTaq® qPCR Master Mix reagent 
system (Promega) which uses carboxy-X-rhodamine (CXR) as a reference dye. The 
reaction was run on the Applied Biosystems® QuantStudio™ 7 Flex Real-Time PCR 
System (Life Technologies). The data was analysed using the QuantStudio™ 
software (Life Technologies) and relative gene expression was determined using the 
2-∆∆Ct method using GAPDH as a housekeeping gene. List of primers can be found in 
Table 2.8. 
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Gene Forward primer (5’3’) Reverse primer (5’3’) 
APC2 CTGGACATCGCTTGCTGGAT TGCCTCTCCACTTTGACACC 
CDX2 CTCGGCAGCCAAGTGAAAAC CTCCTTTGCTCTGCGGTTCT 
CRALBP ACCTTTGATGAGATCTTGCAG GAAGCCATTGATTTGAGTTTCC 
CTSB GACGGCTGTAATGGTGGCTA GTACGGTCTGCACCCTACAT 
CTSD TGGACATCGCTTGCTGGAT CCTGCCTCTCCACTTTGACA 
FGF5 ATTTGCTGTGTCTCAGGGGAT CTGTGAACTTGGCACTTGCAT 
FOXA2 GCATTCCCAATCTTGACACGGT
GA 
GCCCTTGCAGCCAGAATACAC
ATT 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
MERTK AGCCTGAGAGCATGAATGTCA
CCA 
TGTTGATCTGCACTCCCTTGGA
CA 
MFN2 ATGCATCCCCACTTAAGCAC ACCTCACTGATGCCTCTCAC 
MITF GCCTCCAAGCCTCCGATAAG CATCTGCTCACGCATGAGTTG 
MIXL GAGACTTGGCACGCCTGT GGTACCCCGACATCCACTT 
N-
CADHERIN 
ACAGTGGCCACCTACAAAGG CCGAGATGGGGTTGATAATG 
NANOG AGAAGGCCTCAGCACCTAC GGCCTGATTGTTCCAGGATT 
NESTIN GAGAGGGAGGACAAAGTCCC GAGAGGGAGGACAAAGTCCC 
OPA1 CGGACCCAAGAACAGTGTGT GGTTCTTCCGGACTGTGGTT 
OTX2 CAAAGTGAGACCTGCCAAAAA
GA 
TGGACAAGGGATCTGACAGTG 
PAX6 GCCTATGCAACCCCCAGT TCACTTCCGGGAACTTGAAC 
PEDF AGATCTCAGCTGCAAGATTGC
CCA 
ATGAATGAACTCGGAGGTGAG
GCT 
RPE65 GCCCAGGAGCAGGACAAAAG GCGCATCTGCAAGTTAAAACC
A 
SILV GGGCCCCCTGCTGGATGGTA CCCGCCTTGGCAGGACACAG 
SOD2 GGAACAACAGGCCTTATTCCA
C 
TGACTAAGCAACATCAAGAAAT
GC 
SOX1 GGAATGGGAGGACAGGATTT ACTTTTATTTCTCGGCCCGT 
T CAGTGGCAGTCTCAGGTTAAG
AAGGA 
CAGTGGCAGTCTCAGGTTAAG
AAGGA 
TYR TAGCGGATGCCTCTCAAAGC CAATGGGTGCATTGGCTTCT 
Table 2.8. List of primers used in the qPCR experiments. 
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2.9 Flow cytometric analysis 
2.9.1 Quantification of the expression of pluripotency markers 
Single cell suspension was made with Versene® (EDTA) 0.02% solution and cells 
were fixed with 2% paraformaldehyde (PFA) for 10 minutes at 37C. Cells were then 
washed with PBS and re-suspended in ice cold methanol. They were then stored at -
20C for at least 30 minutes and for up to 1 month. For the quantification of the 
expression of pluripotency markers cells were washed with PBS, 1  106 cells/ml 
were re-suspended in 100 µl of 2% FBS in PBS with the appropriate concentrations 
of antibodies, Anti-TRA-1-60, FITC conjugate (Merck Millipore; dilution 1:5) and 
Nanog XP® Rabbit mAb Alexa Fluor® 647 Conjugate (New England Biolabs; dilution 
1:50). Cells were then incubated for 40 minutes on a shaker at room temperature. 
Cells were washed using BD FACS™ Lyse Wash Assistant (BD Biosciences) and 
analysed on BD FACSCanto™ II system (BD Biosciences). Data was analysed on 
BD FACSDiva software (BD Biosciences). A minimum of 10 000 events were 
recorded for each sample. 
2.9.2 Apoptosis, DNA damage and cell proliferation 
The assay was set up using the Apoptosis, DNA damage and Cell Proliferation Kit 
(BD Biosciences) according to the manufacturer’s instructions. Briefly, 10 µl of 1 mM 
5-bromo-2'-deoxyuridine (BrdU) solution per 1 ml of growth medium was added 
directly to the cells for 45 minutes. After that, single cell suspension was made with 
Versene® (EDTA) 0.02% solution and cells were fixed and permeabilised with BD 
Cytofix/Cytoperm Fixation/Permeabilisation Solution for 15 minutes. Cells were then 
permeabilised with BD Cytofix/Cytoperm Plus Permeabilization Buffer and incubated 
for 10 minutes on ice. Cells were then re-fixated with BD Cytofix/Cytoperm 
Fixation/Permeabilization Solution for 5 minutes on ice. In order to expose 
incorporated BrdU, cells were treated with 300 µg/ml DNase and incubated for 1 hour 
at 37C. Cells were then re-suspended in BD Perm/Wash Buffer with PerCP-Cy™5.5 
Anti-BrdU, Alexa Fluor® 647 Mouse Anti-H2AX (pS139), PE Anti-Cleaved PARP 
(Asp214) antibodies. Cells were incubated for 20 minutes at room temperature. Total 
DNA was labelled with 1 µg/ml 4',6-diamidino-2-phenylindole (DAPI). Cells were 
analysed straight away on BD FACSCanto™ II system (BD Biosciences) and the 
data was analysed on BD FACSDiva software (BD Biosciences). A minimum of 10 
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000 events were recorded for each sample. Population of cells was gated using 
appropriate single-stained (for each antibody) and unstained controls.  
2.9.3 Measurement of intracellular peroxides 
The following experimental procedure was performed by Dr Gabriele Saretzki 
(ICaMB, CAV, Newcastle University). Cellular peroxide levels were measured by 
using DHR (dihydrorhodamine123) fluorescent probe and DCF (2’,7’-
dichlorofluorescin) (both from Molecular Probes). 2  105 cells were re-suspended in 
serum free DMEM with 30 µM DHR or 80 µM DCF. Cells were incubated for 30 
minutes at 37C in the absence of light, then centrifuged at 800  g for 5 minutes and 
re-suspended in serum free DMEM. Before the analysis, flow cytometer was 
calibrated using 3 µM calibration beads (Polysciences Inc.). The gain for FL-1 (green) 
was set to 100 and FL-3 (red) to 180. Cells were analysed immediately by flow 
cytometry (Partec PAS, Muenster, Germany) using FL-1 and FL-3 channels. The 
median FL-1 and FL-3 fluorescence peak was used to estimate the concentration of 
intracellular peroxides. Background fluorescence was removed by subtracting values 
for unstained cells in the FL-3 channel. All analyses were repeated three times. 
2.9.4 Measurement of mitochondrial reactive oxygen species 
The following experimental procedure was performed by Dr Gabriele Saretzki 
(ICaMB, CAV, Newcastle University). Mitochondrial ROS levels were assessed by 
using DHE (dehydroethidium) (Molecular Probes) and MitoSOX Red (Molecular 
Probes) staining. To measure mitochondrial superoxide levels with DHE, around 2  
105 cells were stained with 10 µM DHE for 30 minutes at 37C protecting the 
samples from light. After incubation, cells were centrifuged and re-suspended in 3 ml 
DMEM without serum. FL-3 (red) median fluorescence was measured by flow 
cytometry (Partec PAS, Muenster, Germany). For the MitoSOX Red staining 
experiments, cells were stained with 5 µM of the solution for 15 minutes at 37 C in 
the dark. Cells were centrifuged and re-suspended in 3 ml of DMEM without serum. 
Samples were analysed by flow cytometry as described in 2.9.3. Unstained cells 
were always analysed alongside in FL-3 and the values subtracted from FL-3 of the 
stained samples. 
 56 
2.9.5 Measurement of mitochondrial mass 
The following experimental procedure was performed by Dr Gabriele Saretzki 
(ICaMB, CAV, Newcastle University). Mitochondrial mass was measured with NAO 
(10-n-nonyl-acridine orange) fluorescent probe (Molecular Probes). Cells were 
prepared as a single cell suspension, centrifuged and re-suspended in 1 ml of DMEM 
without serum with 10 µM NAO and incubated for 10 minutes at 37C in the dark. 
Cells were then centrifuged and re-suspended in 3 ml DMEM with no serum and 
analysed by flow cytometry recording fluorescence in green channel FL-1 by setting 
the FL-1 value to 200 (Partec PAS, Muenster, Germany). 
2.9.6 Measurement of mitochondrial membrane potential 
The following experimental procedure was performed by Dr Gabriele Saretzki 
(ICaMB, CAV, Newcastle University). Mitochondrial membrane potential was 
measured with the JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide) (Molecular Probes) fluorescent probe. 
Single cells were re-suspended in RPMI 1640 medium without phenol red (Life 
Technologies) with 1 µg/ml JC-1. The cells were incubated for 30 minutes at 37C in 
the dark. Cells were centrifuged at 300  g at 4C for 5 minutes, washed with cold 
PBS and re-suspended in 3 ml of PBS at room temperature. Mitochondrial 
permeability transition was quantified by flow cytometry (Partec PAS, Muenster, 
Germany) by measuring fluorescence in FL-1 and FL-3 and then determining the 
ratio of fluorescence in FL-3 (red) and FL-1 (green) corresponding to signals from JC-
1 monomer and aggregate. 
2.9.7 Phagocytosis of photoreceptor outer segments 
Bovine photoreceptor outer segments (POSs) were obtained from InVision 
BioResources. Prior to performing the assay, POSs were fluorescein isothiocyanate 
(FITC) labelled using the following procedure. The POSs were centrifuged at 4500  
g for 4 minutes. They were then re-suspended in AdRPMI, 10% FBS with 0.4 mg/ml 
FITC (Sigma) and incubated for 1 hour at room temperature protected from light. This 
was followed by another centrifugation for 4 minutes at 4500  g. POSs were washed 
three times with PBS and then re-suspended in 2.5% (73 mM) sucrose (Sigma) in 
PBS and stored in -80C until further use. For phagocytosis experiments, normal 
RPE cell medium was changed to the POS medium (AdRPMI, B27, 10% FBS). Once 
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thawed, POSs were re-suspended in POS medium. 1  106 FITC-labelled POSs 
were added per cell culture insert for 4 hours at 37C. In parallel to that, a negative 
control experiment was set up when cells were kept for the same time duration but at 
4C. The incubations were followed by two cell washes with PBS. Cells were then 
dissociated with TrypLE™ Select Enzyme (10X) and washed. They were then re-
suspended in 2% FBS solution in PBS with the addition of DRAQ5 (1:400, 
BioStatus) for 5 minutes. Extracellular fluorescence was quenched with 0.2% Trypan 
Blue Stain (Life Technologies) for 10 minutes. Cells were then washed at least three 
times with PBS and re-suspended in 2% FBS solution in PBS. Cells were analysed 
on BD™ LSR II flow cytometer (BD Biosciences) collecting 10 000 events per 
sample. The data was analysed on BD FACSDiva software (BD Biosciences). 
2.10 Immunofluorescence microscopy 
2.10.1 Pluripotency assessment 
Cells were washed with PBS and then fixed with 4% PFA for 15 minutes at room 
temperature. Cells were then washed three times with PBS and permeabilised with 
0.25% Triton-X-100 (Sigma) for 40 minutes at room temperature. Cells were then 
washed with PBS following by a blocking step with 10% FBS + 1% bovine serum 
albumin (BSA) in PBS for 45 minutes at room temperature. Cells were then stained 
with Alexa Fluor® 555 Mouse anti-SSEA-4 antibody (BD Biosciences) and goat anti-
human Oct-3/4 Affinity Purified Polyclonal primary antibody (R&D Systems) both at a 
concentration of 1:100 in blocking solution at 4C overnight, followed by incubation 
with a secondary antibody anti-goat IgG—FITC secondary antibody (Sigma) at a 
concentration of 1:200 for 1 hour at room temperature. All the antibodies were diluted 
in blocking solution. Nuclei were counterstained with DAPI (CyStain® DNA, 
PARTEC). Images were taken with Zeiss Axiovert 200M – Inverted Widefield 
microscope with Zeiss AxioCam HRm camera (all Carl Zeiss Microscopy GmbH). 
2.10.2 Assessment of retinal differentiation 
Cells or retinal structures were washed with PBS and then fixed with 4% PFA for 15 
minutes at room temperature. Cells were then washed three times with PBS and 
permeabilised with 0.25% Triton-X-100 (Sigma) for 40 minutes at room temperature. 
Cells were then washed with PBS following by a blocking step with 10% normal goat 
serum (Invitrogen) and 1% BSA in PBS for 45 minutes at room temperature. Cells 
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were then stained with primary antibodies at 4C overnight, followed by incubation 
with secondary antibodies for 1 hour at room temperature. All the antibodies were 
diluted in blocking solution. Nuclei were counterstained with DAPI (CyStain® DNA, 
PARTEC) or Hoechst 33342. The list of antibodies can be found in Table 2.9. 
Antibody Company Dilution 
Anti-RPE65 antibody, mouse Abcam, ab13826 1:200 
Anti-ZO1, rabbit Invitrogen, 61-7300 1:200 
Anti-CRX monoclonal antibody, mouse Abnova, H00001406-M02 1:100 
Cy™3 AffiniPure Goat Anti-Rabbit IgG Jackson ImmunoResearch, 
111-165-003 
1:800 
Anti-mouse IgG–FITC antibody Sigma, F2012 1:800 
Table 2.9. List of antibodies. 
2.11 Single-nucleotide polymorphism array 
hiPSCs and fibroblasts that they were derived from were tested for DNA mutations 
and chromosomal abnormalities. The assay and data analysis were performed in 
collaboration with Dr Hussein Sheekh (King Abdulaziz University. Jeddah, Saudi 
Arabia) using Infinium HD Assay Ultra (Illumina). The basic principle of the method is 
as follows; DNA isolation is performed in-house as described previously (Section 2.4) 
and 50 ng of DNA is sent away for the analysis. The assay consists of DNA 
amplification and fragmentation, DNA fragment hybridisation to a probe on the array 
when the probe binds to a complementary sequence on the DNA and stops at the 
site of the variant, the probe is then extended with labelled nucleotides matching the 
target DNA sequence, the nucleotide label is excited by a laser which causes the 
signal to emit detected by the scanner which results in the identification of the allelic 
ratio for a specific locus, the data is then analysed using GenomeStudio® software 
(Illumina). 
2.12 Analysis of RPE pigmentation 
Method of quantification of the pigmentation yield by RPE cells was modified from 
(Lane et al., 2014). Area covered by the emerging pigmented RPE foci was 
measured by taking the images of the 6-well plates with differentiating RPE cells 
using the Epson Perfection V500 Photo scanner (Seiko Epson Corporation). Images 
were acquired at a resolution of at least 300 dots per inch at multiple points during 
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differentiation. The images were analysed with ImageJ (NIH, Bethesda, MD). Images 
were first converted to greyscale and then using threshold tool only isolated 
pigmented foci were made visible. Total pigmented area was quantified by measuring 
grey areas using the software obtaining the total area covered by pigment on a 6-well 
plate. 
2.13 Transmission electron microscopy 
Cells were fixed with 2% glutaraldehyde and kept at 4C. Transmission electron 
microscopy (TEM) including all the cell processing was performed by Ms Tracey 
Davey at Newcastle University Electron Microscopy Research Services. 
2.14 Transepithelial resistance 
Transepithelial resistance (TER) was measured in order to assess barrier properties 
and integrity of the hPSC-RPE cells cultured on hanging cell culture inserts. 
Measurements were carried out with Millicell ERS-2 Voltohmmeter (Millipore). TER of 
the blank insert with PBS was measured first followed by the resistance 
measurements of the cells of interest. An average of two recordings for each sample 
and a blank was taken. In order to calculate the TER values, the recordings for the 
blank were subtracted from the recordings of the samples. The result was multiplied 
by the surface area of the insert and data presented as Ωcm2. 
2.15 Oxygen consumption 
Oxygen consumption rate in control and patient fibroblasts and hiPSCs was 
measured using Seahorse Bioscience XFe96 Extracellular Flux Analyser (Seahorse 
Bioscience). The experiments were performed in a Seahorse 96-well XF Cell Culture 
Microplate. hiPSCs were seeded in the presence of 10 µM Y-27632 (Chemdea) on 
the microplates pre-coated with matrigel at a density of 4  104 cells per well in 200 µl 
of growth medium 48 hours prior to the experiment. Medium was changed 5 hours 
after seeding the cells and then 24 hours later. Fibroblasts were seeded at a density 
of 2.5  104 cells per well in 200 µl of growth medium 24 hours prior to the 
experiment. On the day of the experiment, medium was changed to 175 µl 
bicarbonate-free DMEM with the appropriate concentrations of glucose (Sigma), L-
glutamine (Life Technologies) and sodium pyruvate (Sigma) to maintain the same 
concentration as in the usual growth medium, pH was adjusted to 7.0 - 7.4. Cells 
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were incubated at 37C for 1 hour prior to starting the assay. First the baseline 
oxygen consumption rate (OCR) was measured. Proton leak was measured by the 
addition of 1.5 µM and 1 µM of oligomycin (inhibits ATP synthase) to hiPSCs and 
fibroblasts respectively. Maximal capacity respiration was determined by the 
sequential injection of carbonyl cyanide-ptrifluoromethoxyphenylhydrazone (FCCP) 
(uncouples the electron transport chain and OXPHOS by dissipating the proton 
gradient) (first injection 0.3 µM and 0.5 µM for hiPSCs and fibroblasts, second 
injection 0.5 µM and 1 µM for hiPSCs and fibroblasts respectively). Non-
mitochondrial respiration (NMR) was measured by the addition of 1 µM and 2 µM of 
rotenone (Complex I inhibitor, prevents electron transfer to CoQ) / antimycin 
(Complex III inhibitor, disrupts proton gradient) to the hiPSCs and 1 µM to fibroblasts 
respectively. Data was corrected by the NMR and normalised to the total protein 
concentration measured by Bradford method. Data is presented as pmol of oxygen / 
minute / mg of protein. 
2.16 Protein concentration quantification by Bradford method 
In order to determine protein concentration, cells were lysed with 50 mM Tris-HCl (pH 
7.4), 150 mM NaCl, 1 mM EDTA and 0.1% (vol/vol) Triton-X-100 overnight at 4C. A 
range of standards was made up with BSA (Sigma) and dH2O to the concentrations 
of 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 mg/ml. 10 µl of each standard and the appropriate 
volume of sample cell lysis were added in duplicates to a 96-well plate. BioRad 
Protein Assay Solution (Bio-Rad) was diluted 1:5 with dH2O and 190 µl added to 
each well. The plate was incubated in the dark at room temperature for 10 – 30 
minutes. Absorbance was detected at 595 nm using a UV spectrophotometer. In 
order to determine protein concentration of the samples, standard curve plot of 
absorbance vs. known varying amount of protein of the standards was used. The 
average absorbance taken from the duplicate measurements was used to plot the 
graph. 
2.17 ATP assay 
ATP measurements were performed with the CellTiter-Glo® Luminescence Assay 
(Promega). Cells were seeded on 96-well white microplates (Thermo Scientific) pre-
coated with matrigel at a density of 3  104 cells per well in 200 µl of cell culture 
medium. Cells were expanded for 2 weeks. On the day of the assay, cells were 
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incubated for 1 hour 30 minutes at 37C in 200 µl of the ATP buffer with either 5 mM 
glucose (Sigma) or 5 mM 2-Deoxy-D-glucose (Sigma) or 5 mM glucose with 2.5 
µg/ml oligomycin (Sigma) or 5 mM 2-Deoxy-D-glucose and 2.5 µg/ml oligomycin. 
Following incubation, 90 µl of the buffer was removed and 110 µl of the CellTiter-
Glo® Reagent Buffer was added. The plate was shaken in the dark for 10 minutes to 
induce cell lysis and then left in the dark for further 15 minutes. Luminescence was 
measured with 1000 ms integration time on a Luminoskan Ascent (Thermo 
Scientific). The signal was normalised to mg of protein as determined by Bradford 
assay. 
2.18 Cytosolic calcium measurement 
Cells were seeded on 96-well optical bottom microplates pre-coated with matrigel at 
a density of 3  104 cells per well in 200 µl of cell culture medium and let to expand 
for 2 weeks. On the day of the assay cells were washed two times with PBS. 
Subsequently, cells were loaded with 5 µM Fura-2 Calcium Indicator (Life 
Technologies) for 1 hour at 37C in 100 µl of Hanks' Balanced Salt Solution (HBSS) 
(Life Technologies). Cells were washed with PBS and re-suspended in cell culture 
medium and further incubated for 30 minutes at 37C. Detection of fluorescence was 
achieved with Thermo Scientific™ Varioskan™ LUX Multimode Microplate reader 
(Thermo Scientific) (excitation at 340 nm and 380 nm, emission 510 nm).  
Fluorescence was measured at 340 nm and 380 nm. Rmin 340/380 ratio (under Ca2+ 
free conditions used to calibrate the probe) was measured after loading cells with 2 
µM ionomycin (ThermoFisher) and 10 mM EGTA (Sigma) in HBSS. Rmax 340/380 
ratio was measured after loading cells with 2 µM Ionomycin and 10 mM CaCl2 
(Sigma). The following equation was used for calculating cytosolic Ca2+: 
[Ca2+] = Kd x Q x [(R-Rmin)/Rmax-R] 
R – 340/380 ratio 
Rmin – 340/380 ratio under Ca2+ free conditions  
Rmax – 340/380 ratio under Ca2+ saturating conditions 
Q – ratio of emission intensity at 380 nm for Ca2+ free and Ca2+ saturated  
Fura-2 and Kd was assumed to be 225 nM. The recordings were performed in 
triplicates at 37C.  
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2.19 Statistical analysis 
All data was expressed as mean ± standard error of the mean (SEM) unless 
otherwise stated. One-way analysis of variance (ANOVA) was used to assess 
variation across multiple samples. The test was followed by Tukey’s multiple 
comparisons test. Representation of significance of p value was as follows: p  0.05 
*, p  0.01 **, p  0.001 ***, P  0.0001 ****. All statistical analyses were done using 
GraphPad Prism Software Inc. (San Diego, CA, USA) or IBM SPSS Statistics 22 
(IBM Corporation). 
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Chapter 3. Generation and characterisation of patient-derived 
hiPSCs 
3.1 Overview 
Fibroblasts derived from patients and healthy controls were reprogrammed in feeder-
dependent and feeder-free culture conditions using Sendai-based reprogramming 
systems from Life Technologies. After transfection with the virus, cells were cultured 
for 7 days until they were transferred to plates with matrigel or MEFs for further 
expansion. Emergence of colonies was monitored daily expecting to see the 
appearance of first hESC-like colonies after 21-30 days post transduction. Schematic 
representation of the experimental timeline is shown in Figure 3.1. 
 
Figure 3.1. Experimental timeline for feeder-dependent and feeder-free reprogramming 
of patient fibroblasts [adapted from Chichagova et al. (2015)]. 
Once the hiPSCs are expanded it is important to confirm their pluripotency status in 
order to ensure that the cells are fully as opposed to partially reprogrammed. During 
somatic cells reprogramming it is possible that some cells become partially 
reprogrammed meaning that they can have features of both bona fide hiPSCs and 
differentiated cells. This phenomenon can be associated with cells inducing anti-
proliferative genes, but failing to downregulate lineage-specific transcription genes, 
failing to undergo necessary epigenetic remodelling such as DNA hypomethylation 
and repression or failure to activate the reprogramming factors (Mikkelsen et al., 
2008). For that reason, the field has identified a number of rigorous molecular and 
functional tests in order to validate iPSC status. 
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Firstly, it is confirmed that cells have a typical hESC-like morphology, packed 
in tight colonies with defined borders with cells containing high nuclear to cytoplasm 
ratio. Subsequently, they are tested for the expression of a number of pluripotency-
associated markers including those involved in pluripotency gene regulation network. 
A number of cell-surface antigens and developmentally regulated genes have been 
shown to be associated with the undifferentiated state in hESCs and therefore these 
markers were chosen for pluripotency validation of hiPSCs derived in this study 
(Adewumi et al., 2007). Stage-specific embryonic antigen (SSEA4) has been shown 
to be unique to human embryonic teratocarcinoma cells, which are malignant 
counterparts to hESCs (Kannagi et al., 1983). Keratin sulphate antigen Tra-1-60 has 
been shown to be associated with undifferentiated embryonal carcinoma cells and 
hESCs with cells reducing expression levels upon differentiation (Badcock et al., 
1999; Draper et al., 2002). Another study showed that cells that are to become 
hiPSCs upregulate both SSEA4 and Tra-1-60 (Chan et al., 2009). Transcription 
factor OCT4 was used as it has been previously shown to be important for 
maintenance of undifferentiated state / pluripotency in hESCs (Okamoto et al., 1990; 
Hay et al., 2004; Matin et al., 2004). It is associated with the founder population of 
cells during early embryogenesis and has been shown to be a robust identification 
marker of hESCs (Nichols et al., 1998; Adewumi et al., 2007). Homeodomain protein 
NANOG is associated with undifferentiated state by repressing differentiation into 
primitive endoderm and supporting self-renewal in mouse ESCs (Chambers et al., 
2003; Mitsui et al., 2003). It has been shown that some of these markers expression 
is correlated with each other such as NANOG and TRA-1-60. Additionally, lack of 
SSEA4 expression in TRA-1-60 positive cells and lack of detection of nuclear 
NANOG staining has been shown to be associated with partially reprogrammed cells. 
Therefore it is important to check the expression of a combination of markers (Chan 
et al., 2009). All of the above provides evidence that these markers are robust 
against identification of pluripotent stem cells and they form part of the panel 
identified as being characteristic of hPSCs (Adewumi et al., 2007). 
There are a number of assays that are used to demonstrate the potential of 
pluripotent cells to differentiate into other cell types. One of these assays is induction 
of teratoma in mice which over the years has become a ‘gold standard’ experiment. 
Teratoma induction in mice and other mammals has been carried out for decades 
with earlier studies describing the ability of embryonal cells to form tumours 
containing specialised tissues (Jackson and Brues, 1941; Stevens and Little, 1954). 
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Early studies used teratoma formation assay for investigating the potential of mouse 
and human ESCs and iPSCs to form derivatives of three embryonic germ layers 
(endoderm, ectoderm, mesoderm) after injecting the cells into immunocompromised 
mice (Evans and Kaufman, 1981; Thomson et al., 1998; Gertow et al., 2007; 
Takahashi et al., 2007).  
Alternative methods exist that provide proof of differentiation ability of cells by 
studying differential potential in vitro. The ability of cells to spontaneously differentiate 
in vitro after allowing cells to grow to confluence has been used as a test for many 
years (Evans and Kaufman, 1981; Thomson et al., 1998). For the purpose of this 
project, both the in vitro and in vivo methods were used. 
As a final quality control, the hiPSCs derived for the project together with their 
parental fibroblasts were tested for cytogenetic abnormalities using a single-
nucleotide polymorphism (SNP) array technique (testing against ~300 000 SNPs). 
Various contributors to genomic instability in hPSCs have been described in both 
hESC and hiPSC studies. Variations within the iPSC genome could arise from the 
reprogramming process itself, prolonged cell culture and heterogeneity in the 
parental fibroblast cells (Liang and Zhang, 2013). 
3.2 Results 
3.2.1 Reprogramming patients’ and control fibroblasts with CytoTune 1 kit 
The first round of the reprogramming was performed using CytoTune 1 
reprogramming kit containing four reprogramming vectors each expressing one of the 
four Yamanaka factors hOct3/4, hSox2, hKlf4, and hc-Myc. Three cell lines were 
used in this set of experiments, Patient 1 and Patient 3 cells and Control 1 cells. 
Cells were cultured on MEFs and matrigel with the view of deriving both feeder-
dependent and feeder-free hiPSC clones. Representative images of the appearance 
of cells throughout the experiment are shown in Figure 3.2. The results of the 
experiment showed that as expected 7 days post transfection, all of the cells showed 
some sign of cytotoxicity with some cells rounding up and detaching. However, 28 
days from the start of the reprogramming, cells changed morphology but there was 
no appearance of hESC-like colonies in any of the cells. 
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Figure 3.2. Reprogramming patients’ and control fibroblasts using CytoTune 1 kit 
using both matrigel and MEFs as substrates. Some cytotoxicity was observed by day 7 in 
all cells; however, no hESC-like colonies were noted 28 days after the start of the 
reprogramming. Scale bar, 100 µm. 
3.2.2 Reprogramming patients’ and control fibroblasts with CytoTune 2 kit 
In order to facilitate cell reprogramming, CytoTune 2 – an improved Sendai virus 
reprogramming kit was used. The kit contains three vector preparations: polycistronic 
hKlf4-hOct3/4-hSox2 (KOS), hKlf4, and hc-Myc. This method has been previously 
used in the lab and showed an increased reprogramming efficiency (Dr Tomas Barta, 
personal communication). Introducing reprogramming factors via a polycistronic 
vector increases the likelihood of successful transfection by only requiring one viral 
particle entering the cell in order to deliver multiple transgenes. Once again Control 
1, Patient 1 and Patient 3 cells were transfected. In addition, Control 2 cells and 
Patient 2 cells were obtained and also transfected. Cells were reprogrammed using 
matrigel and /or MEFs as substrates. Representative images from the experiment are 
shown in Figure 3.3. Control 1 cells failed to produce any colonies. Patient 1 cells 
gave rise to hESC-like colonies both on matrigel and MEFs. Patient 2 cells produced 
colonies on MEFs. Patient 3 cells failed to generate any colonies. Control 2 gave rise 
to some colonies however they failed to successfully expand (data not shown). 
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Figure 3.3. Reprogramming patients’ fibroblasts using CytoTune 2 kit using matrigel, 
MEFs or both as substrates. Some cytotoxicity was observed by day 7 in all cells; however, 
no hESC-like colonies were noted 1 month after the start of the reprogramming in Control 1 
and Patient 3 cells. Patient 1 cells produced colonies both on MEFs and matrigel. Patient 2 
cells produced colonies on MEFs. hESC-like colonies are shown with yellow arrows. Scale 
bar, 100 µm. 
Patient 3 cells were originally chosen for the project as they came from the sibling of 
Patient 1. Both of the patients have the same mitochondrial mutation however they 
present with different ocular phenotypes: Patient 1 has a bilateral pigmentary 
retinopathy whilst Patient 3 has normal vision and ocular fundi, making an interesting 
contrast. However, as a result of the reprogramming attempts described above, 
Control 1, Control 2 and Patient 3 cells were excluded from the project. Since the 
attempts to derive hiPSCs from healthy controls failed, already established Control 
hiPSCs reprogrammed and characterised prior to the start of the PhD project by Mrs 
Adriana Buskin (Prof Majlinda Lako’s lab) were used. The results from the 
reprogramming experiments are summarised in Table 3.1. 
  
Fibroblast source 
Mitochondrial 
mutation 
Age / 
Gender 
Ocular phenotype 
Reprogramming 
Kit 
Efficiency (%) 
Patient 1 m.3243A>G 73/F • bilateral pigmentary macular degeneration 
(sparing left fovea) 
• significant visual acuity deterioration over 
the past ten years  
• visual acuities: right eye 6/60, left eye 6/9 
CytoTune 1 0 
CytoTune 2 0.08 (MEFs) 
0.02 (matrigel) 
Patient 2 m.3243A>G 62/M • extensive macular geographic atrophy  
• visual acuities: right eye 6/36, left eye 6/36 
CytoTune 2 0.03 (MEFs) 
Patient 3  
(sibling of Patient 1) 
 
m.3243A>G 61/M • no pigmentary retinopathy or maculopathy 
• normal vision in both eyes  
• visual acuities: right eye 6/6, left eye 6/6 
CytoTune 1 0 
CytoTune 2 0 
Control 1 N/A 57/F Healthy control CytoTune 1 0 
CytoTune 2 0 
Control 2 N/A 74/M Healthy control CytoTune 2 0.002 (MEFs) 
Control hiPSCs ** N/A 51/M Healthy control CytoTune 2 0.29 (MEFs) 
Table 3.1. Summary of the reprogramming experiments outlining patient details, reprogramming kit and efficiency.  Blue shading represents 
successful reprogramming and red shading represents failed attempts to obtain hiPSC clones. ** Cells reprogrammed and characterised by Mrs 
Adriana Buskin prior to the start of the PhD project. 
In the initial stages of cell culture, some of the clones failed to proliferate. As a result, those clones were only partially characterised as 
described below. 
6
8
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3.3 Characterisation of the resulting hiPSC population 
Once the hiPSCs were generated and expanded, they were tested for the presence 
of the Sendai virus genome and transgenes. Subsequently, pluripotency potential of 
the hiPSCs was validated using a number of different molecular and functional 
assays. Prior to all the validation experiments, cells that were cultured on MEFs were 
adapted to matrigel to ensure less batch-to-batch variation and avoid contamination 
with undefined components potentially secreted by MEFs thereby providing more 
reproducibility. 
3.3.1 Sendai clearance 
Although, Sendai virus does not integrate into the host genome, it can take a number 
of passages for it to clear from the cytoplasm. Therefore, prior to carrying out any 
downstream analyses, it is necessary to test whether the transgene and the viral 
genome have cleared from the cells in order to avoid the possibility of its continuous 
expression and mutagenesis. Verification of Sendai clearance is achieved by RT-
PCR once the hiPSC clones are expanded. The absence of transgene and viral 
genome amplicon confirms the absence of Sendai. The results of the experiment 
showed that all clones were clear of the virus by passage 12 (Figure 3.4). 
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Figure 3.4. Verification of Sendai virus genome and transgenes clearance in patient 
hiPSC lines using RT-PCR. No reprogramming factor genes (KOS, hKLF4, hc-Myc) or viral 
vector genome (SeV) was detected in patient clones. hESCs were used as a negative 
control. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a housekeeping 
gene. The expected size of the product is shown next to each gene. P – patient, C – clones 
derived on MEFs, M – clone derived on matrigel. 
Once the absence of the transfection virus was confirmed, cells were ready to be 
used in downstream analyses. 
3.3.2 Pluripotency markers expression 
Patient hiPSCs were assessed for the expression of pluripotency-associated 
markers; surface antigen SSEA4 and nuclear localised transcription factor OCT4 by 
immunocytochemistry. All the clones tested were positive for these markers showing 
their correct localisation. hESCs were used as positive control (Figure 3.5). 
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Figure 3.5. Immunocytochemistry results showing pluripotency markers expression in 
patient hiPSCs. Patient-derived hiPSC clones expressed OCT4 and SSEA4. hESCs were 
used as a positive control. Secondary only antibody was used as a negative control and 
showed no signal (data not shown due to the absence of the image). Scale bar, 100 µm. 
Flow cytometry analysis for TRA-1-60 and NANOG showed that the majority of the 
cells were positive for both of the markers. hESCs were used as a positive control. 
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Figure 3.6. Quantification of the percentage of cell population expressing 
pluripotency-associated markers Tra-1-60 and NANOG by flow cytometry. (A) 
Representative image of the gating strategy for the experiment, including negative cell 
population (dark blue) and isotype control (light blue). Cells are shown in green. (B) Patient 
cells showed similar expression of pluripotency markers when compared to hESCs. The 
majority of cells were positive for both of the makers. 
3.3.3 Assessing the developmental potential of hiPSCs 
There are a number of assays that exist that test the potential of PSCs to generate 
differentiated cell types. Initially, one hiPSC clone from each patient was used to test 
whether the cells are capable of generating germ cell tumours in 
immunocompromised mice. Both of the clones failed to form teratomas after 12 
weeks (data not shown). Subsequently, it was decided to test differentiation potential 
of the cells by inducing spontaneous differentiation in vitro. Cells failed to form EBs 
however they were able to differentiate in monolayer cultures after allowing them to 
proliferate in bFGF-free media for 2 weeks. RT-qPCR showed that at the end of the 
experiment the cells expressed differentiation markers associated with three germ 
layers and extraembryonic tissues (Figure 3.7). The results are shown for Patient 1 
clones. 
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Figure 3.7. Differentiation potential of patient hiPSCs in vitro (day 14 of the 
differentiation). Patient cells showed similar levels of downregulation of pluripotency-
associated marker NANOG when compared to hESCs. Patient cells expressed 
neuroectoderm markers SRY (sex determining region Y)-box 1 (SOX1) and paired box 6 
(PAX6), with Clone 8 having the least and Clone 5 the most potency for neural differentiation 
taken from the expression of PAX6. All cells expressed mesodermal markers mix paired-like 
homeobox (MIXL) and T brachyury transcription factor (T) with less potency comparing to 
hESCs. Cells also showed propensity for endodermal differentiation as assessed by the 
expression of forkhead box A2 (FOXA2). Cells also expressed caudal type homeobox 2 
(CDX2), a trophectoderm marker. Results are shown as relative expression when compared 
to hESCs. GAPDH was used as a housekeeping gene. 
3.3.4 Cytogenetic analysis 
Reprogramming somatic cells can result in accumulation of genetic mutations which 
necessitates tests to eliminate the possibility of de novo changes in the DNA. 
Genomic SNP array was performed on hiPSC clones from both patients as well as on 
parental fibroblasts. Patient 1 fibroblasts had no clinically significant imbalance. 
Clone 4, 5, 7 and 8 had no major changes. Clone M2 had changes on chromosome 
20 resulting in large-scale deletion on 20p and duplication on 20q. Fibroblasts from 
Patient 2 cells showed no major abnormalities. Patient 2 Clone 1 and Clone 2 
showed major changes on chromosome 20 similar to the ones seen in Clone M2. 
Clone 2 did not have changes of known significance. Representative images of the 
results are shown in Figure 3.8. 
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Figure 3.8. Representative images of SNP array results. (A) Karyotype chart showing no 
major DNA abnormalities. (B) Major changes found on chromosome 20 showing deleted 
region on the left-hand side and duplicated region on the right. 
Summary of the hiPSC characterisation is outlined in Table 3.2. Not all cells survived 
in the initial stages of cell culture and therefore only the cells that were viable and 
able to proliferate were investigated. 
 
Sendai 
clearance 
Flow cytometry 
(TRA-1-60, NANOG) 
IHC 
(SSEA4, OCT4) 
In vitro spontaneous 
differentiation 
SNP array 
Patient 1  
Clone 4 ✓    ✓ 
Clone 5 ✓ ✓ ✓ ✓ ✓ 
Clone 6 ✓     
Clone 7 ✓    ✓ 
Clone 8 ✓ ✓ ✓ ✓ ✓ 
Clone M2 ✓ ✓ ✓ ✓ ✓ 
Patient 2  
Clone 1 ✓ ✓ ✓  ✓ 
Clone 2 ✓ ✓ ✓  ✓ 
Clone 3 ✓  ✓  ✓ 
Clone 4 ✓     
Table 3.2. Summary of the hiPSCs characterisation. 
3.4 Discussion 
In the last few years, the use of hiPSCs to model mitochondrial disorders has 
increased and a number of studies reported generation of hiPSCs from patients with 
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the m.3243A>G and other mutations associated with MELAS. The results in this 
chapter described successful derivation and characterisation of hiPSCs from 
patients’ fibroblasts harbouring the m.3243A>G mutation. However, not all patient 
and control cells successfully gave rise to hiPSC clones. There are a number of 
potential reasons that would explain such results and these are discussed below.  
Firstly, reduced reprogramming efficiency could be to do with the 
reprogramming kit itself in the case of the experiments that involved using CytoTune 
1 kit. The same kit was used for the first round of the reprogramming experiments 
which were unsuccessful in both control and patient cells (Figure 3.2). It has been 
previously shown that CytoTune 1 kit shows severe cytotoxicity and lowers 
reprogramming efficiency compared to CytoTune 2 kit. Additionally, CytoTune 1 kit 
could require batch testing in order to ensure its safety, so it is possible that the batch 
used produced cytotoxic effects incompatible with cell survival (Beers et al., 2015). 
In subsequent experiments where CytoTune 2 kit was used, in the case of 
patients’ cells it can be speculated that the presence of the mitochondrial mutation 
could have an effect on their reprogramming efficiency. However, not all cells failed 
to reprogram and in addition, there are a few publications that also described 
successful reprogramming of cells with mtDNA mutations. In 2012, the derivation of 
hiPSC lines from two diabetic patients harbouring the m.3243A>G mutation was 
shown (Fujikura et al., 2012). A year later, another study generated hiPSCs from 
fibroblasts of MELAS patients with the m.13513G>A mutation (Folmes et al., 2013). 
One study showed the potential of hiPSCs obtained from MELAS patients to 
differentiate into neurones (Hamalainen et al., 2013). On the other hand, Yokota et 
al. (2015) demonstrated that high levels of the m.3243A>G over the pathogenic 
threshold (≥ 90%) represent a reprogramming roadblock. Another study looked 
further into the mechanisms of reduced reprogramming efficiency using MEFs from 
mutator mice and showed that mtDNA mutagenesis leads to increased mitochondrial 
H2O2 leading to reprogramming defects (Hamalainen et al., 2015). A recent study 
looked at the effect of homoplasmic mtDNA mutations affecting Complex I and 
causing LHON (m.11778G>C, m.14484T>C, m.4160T>C) and showed a mild but not 
statistically significant reprogramming impairment (Hung et al., 2016). Overall this 
shows that more studies are needed in order to elucidate the effect and the 
mechanism of mtDNA mutations in cellular reprogramming. Some further 
investigations on this matter will be discussed in the next chapter. 
 76 
In addition to the patients’ cells, two of the control cells failed to give rise to 
hiPSCs, cells from a 57 year-old female and a 74 year-old male. It is more difficult to 
speculate what caused the reprogramming failure of these cells without any 
additional experiments. Firstly, reprogramming is a stochastic process which could be 
affected by a number of factors. Chromatin organisation and stochastic epigenetic 
events are some of the factors that could have an effect on reactivation of 
pluripotency circuitry. It has been shown that DNA hypermethylation at pluripotency-
related genes may lead to the failure to achieve a stable reprogrammed state (Polo 
et al., 2012). Treating partially reprogrammed cells with DNA methyltransferase 
inhibitor 5-aza-cytidine has been shown to induce full reprogramming (Mikkelsen et 
al., 2008). Similar to DNA methylation state, remodelling of histone modification is 
also implicated in the success of somatic cell reprogramming. Histone methylation 
was shown to be one of the epigenetic changes during the acquisition of pluripotent 
state (Polo et al., 2012). hiPSC generation can also be affected by epigenetic 
signature of donor cells including miRNA expression and histone modification pattern 
(Li et al., 2013). Other studies suggested that reprogramming could be affected by 
low proliferative capacity of cells (Chan et al., 2009). In the case of the cells that 
came from a 74 year-old donor, it could be speculated that a potential reason for 
poor reprogramming results is the age of the individual the cells came from, which 
could be attributed to upregulation of the cell cycle inhibitory protein p21 (Trokovic et 
al., 2015). Although, other studies claim that the age of donor cells has little effect on 
reprogramming efficiency (reviewed by Mahmoudi and Brunet, 2012). 
According to Cahan and Daley (2013), pluripotency can either be defined as a 
state or as a function. All patient hiPSC clones tested expressed markers that have 
been previously described to be specific to undifferentiated cells, which could be 
attributed to pluripotency as a state. On the other hand, pluripotency as a function is 
related to the ability of cells to differentiate. Patients’ hiPSC clones were all 
pluripotent when it came to pluripotency as a state. Cells were also assessed for their 
functionality using a number of tests. hiPSCs derived from the patients with 
m.3243A>G failed to form teratomas in immunocompromised mice. Previous studies 
showed that even uniform expression of pluripotency genes can lead to variations in 
cells’ propensity to differentiate (Cahan and Daley, 2013). Stewart et al. (2010) used 
clonal tracking with lentiviruses expressing enhanced green fluorescent protein 
(GFP) to show that hESC clones had varying developmental potential when 
subjected to in vitro and in vivo differentiation assays. There was not a single hESC 
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clone that contributed to both assays suggesting that some cells might be self-
renewing but not clonogenic. This type of cells is more likely to differentiate in vitro 
but not in vivo. Therefore, it can be concluded that in vitro and in vivo differentiation 
assays might not be comparable with each other. Studies using mESCs showed that 
low mitochondrial membrane potential results in failed teratoma formation (Schieke et 
al., 2008). Considering that the cells used in the study have a mitochondrial mutation 
it is possible that they might have alterations in the membrane potential leading to 
failed in vivo differentiation. 
In the context of this discussion, it is also important to consider the validity of 
the assays used for assessing differentiation potential of hPSCs. Even though 
teratoma formation assays have been part of stem cell characterisation for many 
years, there are still no standardised procedures or consistency in the way the assay 
is performed, also little is known about host factors guiding cells to differentiate 
(Muller et al., 2010; Buta et al., 2013). Despite the ‘gold standard’ status of the 
teratoma assay, it can be argued that it is a good assay to assess in vivo tumorigenic 
potential of cells which is of paramount importance in clinical safety studies but might 
have little interest for in vitro disease modelling studies as it provides little information 
on the in vitro potential of cells to differentiate or on their potential for normal 
development. Additionally, it has been previously shown that some partially 
reprogrammed cells are able to form teratomas which makes the validity of the assay 
uncertain (Chan et al., 2009). There are a number of alternatives to the teratoma 
formation assays which have been recognised and accepted by the field. EB 
formation or monolayer cultures based on spontaneous or directed differentiation of 
cells with subsequent immunostaining and gene expression analyses is an in vitro 
alternative to teratoma formation. It lacks the physiological cues and oxygen and 
blood supply that are present in teratoma formation assay nevertheless it is an 
acceptable model for assessing the ability of cells to differentiate (Itskovitz-Eldor et 
al., 2010; Buta et al., 2013). Buta et al. (2013) also suggested that the EB formation 
method has several advantages over the teratoma assay by allowing the monitoring 
of differentiation progression over time. Additionally, analysing large numbers of EBs 
gives more powerful statistical measures which is normally not always possible when 
using mice. In the case of the teratoma formation experiments performed with 
patient-derived hiPSCs only one round of injections was performed and it was not 
possible to retest the cells again. However, the cells were able to form derivatives of 
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the three embryonic germ layers demonstrated by the levels of gene expression 
when differentiated as monolayers in vitro. 
As a final quality control component for the hiPSCs, the cells were tested for 
the presence of genomic abnormalities. The results showed that some clones had 
major changes on chromosome 20. Having genomic aberrations in hPSCs is not 
uncommon with cells being prone to acquire small scale mutations as well as major 
abnormalities such as chromosome aneuploidy. Genome defects that are directly 
associated with the reprogramming process are most commonly deletions of tumour-
suppressor genes, whereas at later passages cells tend to duplicate tumour-
promoting genes (Laurent et al., 2011). 
Large duplications of chromosome 20 have been found to be common in 
hiPSCs and it has been suggested to be a mutation hot spot in hESCs (Spits et al., 
2008). Changes on chromosome 20 are common during both early and late 
passaging and 25% of otherwise karyotypically normal cells have gain of 20q. This 
region has a highly repetitive sequence which predisposes it to structural 
rearrangement (Amps et al., 2011). Interestingly, hESCs with amplification of 
20q11.21 acquired during long-term culture have no noticeable difference between 
these and normal cells with regards to morphology, pluripotency marker expression 
and growth (Lefort et al., 2008). It has been reported that several genes involved in 
cell survival and cell growth are contained on the amplified region, including BCL2L1, 
PDRG1, ID1, TPX2, HM13 and KIF3B. Additionally, DNMT3B gene is located on the 
chromosome and codes for de novo DNA methyltransferase. However, it does not 
always mean that those genes are getting overexpressed (Lefort et al., 2008; Amps 
et al., 2011). Recurrent abnormalities in hiPSCs on chromosomes 12 and 20 are 
independent of the reprogramming method chosen for stem cell generation (Taapken 
et al., 2011). In addition to chromosome 20 abnormalities, hPSCs have a number of 
other hot spots associated with the increased risk of genomic aberrations. Early 
reports showed that prolonged culture of hESCs may lead to karyotypic changes, 
such as trisomy of chromosomes 12 and 17 giving the cells a proliferative advantage, 
reduced doubling time and inhibiting apoptosis (Cowan et al., 2004; Draper et al., 
2004). In some cases, despite this adaptation, cells still retained their ability to 
differentiate, however they sometimes also showed increased expression of 
pluripotency genes and expression of early differentiation genes (Enver et al., 2005; 
Mitalipova et al., 2005). Interestingly, NANOG is located on the 12p region which is 
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often duplicated. Similarly, SNP array copy number analysis of multiple hiPSC lines 
showed that some cell lines acquire chromosome 12 abnormalities early on. In some 
cases changes only start to occur at later passages when the cell population 
becomes mosaic with both normal and adapted cells present (Mayshar et al., 2010). 
MELAS hiPSC clone with changes on chromosome 20 (Clone M2) did not show a 
difference in its ability to silence NANOG or upregulate genes associated with three 
embryonic germ layers when subjected to spontaneous differentiation. 
The mechanisms that are involved in genomic instability in hPSCs have been 
investigated by a number of research groups. The process of reprogramming is 
associated with downregulation of the p53 pathway which could affect DNA integrity 
leading to an increase in copy number variation (CNV) in hiPSCs. CNVs result in 
mosaicism with the increase in cell numbers with abnormal copy number state with 
increased passaging (Hussein et al., 2011). Overall, 20% of all hiPSCs are abnormal. 
However, the method by which the cells are analysed may affect the results and it 
has also been shown that SNP array is more sensitive than other types of analysis 
such as karyotyping (Mayshar et al., 2010). 
In conclusion, hiPSCs derived from patients’ fibroblast cells harbouring 
m.3243A>G mutation were successfully generated and characterised to be further 
used in the project. 
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Chapter 4. Derivation of patient hiPSCs with m.3243A>G mutation 
4.1 Overview 
Somatic cells obtained from patients with mutations in the mtDNA give rise to hiPSC 
clones with varying levels of heteroplasmy (Prigione et al., 2011) (Figure 4.1). 
Multiple studies that reprogrammed patient cells obtained homoplasmic, 
heteroplasmic (mutation level range in different studies: 51-87%; ~7-85%; 3.6-99.4%; 
33-100%; ~5-100%) and mutation free clones, which could be used as isogenic 
controls (Fujikura et al., 2012; Hamalainen et al., 2013; Kodaira et al., 2015; Ma et 
al., 2015; Yokota et al., 2015). 
 
Figure 4.1. Schematic representation of healthy and mutant mitochondria segregation 
during the process of reprogramming. 
The mechanism of mitochondrial segregation is not completely understood. Some 
suggest that it could be a result of a mitochondrial genetic bottleneck where mtDNA 
copy number is reduced during the process of reprogramming followed by selective 
amplification of mtDNA (Hamalainen et al., 2013). Another hypothesis is that the 
hiPSC clones retain similar heteroplasmy levels to the individual fibroblast cells each 
clone was derived from suggesting that there is no change in the m.3243A>G 
proportions during the reprogramming potentially allowing the selection of hiPSC 
clones with desired levels of the mutation (Yokota et al., 2015). Ma et al. (2015) saw 
mosaic distribution of the mutation in fibroblasts. 
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The effects of the m.3243A>G on the efficiency of somatic cell reprogramming 
are not fully understood. The results from Chapter 3 showed that cells from Patient 3 
failed to give rise to hiPSC clones. This could be due to the initial levels of mutated 
mtDNA being over the pathogenic threshold or the general inability of the cells to 
support the process of the reprogramming. 
The aim of this chapter was to investigate the levels of mutant mtDNA in patient 
hiPSC clones and to explore the reasons for the failed reprogramming attempts of 
Patient 3 fibroblasts. 
4.2 Results 
4.2.1 Level of m.3243A>G in patient-derived hiPSCs 
Once the hiPSC clones from both patients were derived, the levels of the 
m.3243A>G mutation were checked. The results are summarised in Figure 4.2. 
 
Figure 4.2. Mutant mtDNA amount in patient fibroblasts and hiPSC clones. The parental 
fibroblast cells had similar levels of the m.3243A>G mutation. Upon cellular reprogramming 
hiPSC clones with various levels of mutated mtDNA were derived from Patient 1 cells. 
Patient 2 hiPSC clones all had low levels of the mutation. 
The parental population of fibroblast cells had similar levels of the mutation in both 
patients (69.67% ± 0.48 in Patient 1; 66.3% ± 0.57 in Patient 2). Patient 3 fibroblasts 
had 82% ± 0.00 heteroplasmy and they failed to give rise to hiPSCs. Once the hiPSC 
clones were isolated and sequenced, a wide range of heteroplasmy levels was found 
in Patient 1 hiPSCs with the lowest level being 1.11% ± 1.09 and the highest level 
85.05% ± 0.98. Patient 2 hiPSC clones however had low mutation levels (ranging 
between 0.67% ± 1.15 and 2% ± 1). Patient 2 hiPSC clones were again tested for 
mutant mtDNA at later passages (passage 13, 16 and 24, data not shown) 
confirming that they were all wild-type.  
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4.2.2 Derivation of Patient 2 hiPSCs with high level of m.3243A>G 
In order to isolate Patient 2 hiPSCs with mutant mtDNA, fibroblast cells were serially 
diluted and clones with high (>90%, ~4-30 cells per clone) or mid-level m.3243A>G 
(55-65%, ~125 cells per clone), were isolated. Figure 4.3 (A) shows the clonal 
dilution experiment set up and Figure 4.3 (B) shows the sequencing results for the 
parental fibroblast population and the isolated clones. Patient 1 clones were also 
isolated in the same way in order to assess the range of the mutation levels across 
different fibroblast clones to see whether the level of mosaicism in parental cells 
corresponds to the hiPSCs’ sequencing results. 
 
Figure 4.3. Isolation of fibroblast clones with various levels of m.3243A>G. (A) 
Experimental set up of clonal dilution on a 96 well plate. (B) Pyrosequencing results for the 
levels of mutant mtDNA in individual fibroblast clones from both patients. 
Fibroblast clones from Patient 1 cells that were tested had a range of m.3243A>G 
heteroplasmy complementing the results obtained for hiPSC clones. This potentially 
shows that each individual hiPSC clone had the levels of the mutation of the parental 
fibroblast cell. Interestingly, the original fibroblast population had lower level of 
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mutated mtDNA 38.3% ± 1.5 comparing to the parental fibroblast cell population in 
the first reprogramming experiment (Figure 4.2). This finding demonstrates the 
heterogeneous nature of heteroplasmy levels across populations of cells. 
Parental fibroblast cells from Patient 2 had 69.0% ± 1.0 of mutant mtDNA. For 
the reprogramming experiments, 2 clones with high level mutant mtDNA and 2 
clones with mid-level of the mutation were chosen. Cells were reprogrammed with 
the same reprogramming kit as in the previous experiments (CytoTune 2, Life 
Technologies). Representative images of the reprogramming results are shown in 
Figure 4.4. 
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Figure 4.4. Reprogramming Patient 2 fibroblast clones with different levels of 
m.3243A>G. Neither of the clones with high or mid-level mutated mtDNA gave rise to 
hiPSCs after 37 days in culture. Scale bar, 100 µm. 
Patient 2 cells failed to give rise to hiPSCs when only fibroblasts with high or mid-
level of the m.3243A>G were used as a starting cell population. As can be seen from 
the images in Figure 4.4, cells started to change morphology by day 7, however by 
day 37 no hiPSC colonies were found.  
In order to explain these results, fibroblast cells were tested for a number of 
parameters in order to elucidate the differences between them. 
 85 
4.2.3 Investigating patients’ fibroblasts 
Patient 2 cells failed to give rise to hiPSC clones with mutant mtDNA and Patient 3 
cells failed to reprogram altogether. For this reason, these cells were further 
investigated with the attempt to uncover potential explanation.  
Heteroplasmy levels across different passages varied depending on which 
patient the cells came from. The level of heteroplasmy slightly reduced with 
passaging for Patient 1 and 3 cells. Interestingly, Patient 2 cells had increased levels 
of the mutation reaching 95% ± 1.7 by passage 24 [Figure 4.5 (A)]. Next, total mtDNA 
amount and mtDNA common deletion levels were checked in all cells. Patient 1 cells 
had significantly higher levels of mtDNA copy number comparing to other patients 
and control, which could potentially indicate that there is a mechanism attempting to 
compensate pathogenic m.3243A>G mtDNA mutation. No mtDNA common deletions 
were found in any of the cells [Figure 4.5 (B, C)]. 
 
Figure 4.5. Mutational profiling of patients’ fibroblasts. (A) Pyrosequencing results for 
heteroplasmy level change in patient fibroblast cells over passaging. (B) qPCR results for 
total mtDNA copy number. (C) qPCR results for mtDNA common deletion levels. N=3. Data 
presented as Mean ± SEM. Significance was established with one-way ANOVA followed by 
Tukey’s post hoc test. 
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Oxygen consumption experiments for Patient 1 and Patient 2 cells showed that 
Patient 2 cells had significantly lower levels of basal and maximal respiration. These 
results are consistent with the reduced mtDNA copy number and potentially lower 
protein levels when compared to Patient 1 and control [Figure 4.6 (A, B)]. Patient 3 
cells were not included in the experiments due to timing issues. 
 
Figure 4.6. Mitochondrial respiration in patients’ fibroblasts. (A) Seahorse results for 
basal respiration. (B) Seahorse results for maximal respiration. N=3. Data presented as 
Mean ± SEM. Significance was established with one-way ANOVA followed by Tukey’s post 
hoc test. 
4.3 Discussion 
Reprogramming experiments resulted in the derivation of hiPSC clones with varying 
levels of the m.3243A>G from Patient 1 cells, Patient 2 cells only gave rise to wild-
type hiPSCs and Patient 3 cells failed to give rise to hiPSCs. Clonal isolation of 
Patient 2 fibroblasts with high and mid-level of heteroplasmy and subsequent 
transfection with the reprogramming factors failed to give rise to any hiPSC clones. 
Somatic cell reprogramming is accompanied by a number of changes within 
the cells, many of which involve remodelling of mitochondria. Firstly, ATP production 
shifts from OXPHOS to glycolysis to allow rapid proliferation and reduced production 
of ROS. In addition, mitochondria undergo a number of morphological changes 
including formation of more globular-shaped immature mitochondria with perinuclear 
localisation [reviewed by Lopes and Rego (2016)]. Furthermore, mtDNA goes 
through a number of changes. Using mouse cells, it has been previously 
demonstrated that mtDNA copy number is tightly controlled during the process of 
reprogramming and differentiation (Kelly et al., 2013). The effects of the m.3243A>G 
on the process of cellular reprogramming have not been fully elucidated. It has been 
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previously shown that initial high level of heteroplasmy in the starting population of 
fibroblasts creates a reprogramming block preventing generation of hiPSCs (Yokota 
et al., 2015). Indeed, Patient 2 high mutation level fibroblast clones and Patient 3 
fibroblasts which had >80% of m.3243A>G failed to give rise to hiPSCs. However, it 
is still not clear why Patient 2 fibroblast clones with 55 – 62% of m.3243A>G did not 
give rise to hiPSCs and why in general only wild-type clones were derived from cells 
from this patient. For this reason, further investigations were conducted on fibroblast 
cells to provide additional insight into the reprogramming process. 
The potential variations in mutated mtDNA levels were tested over a number 
of passages in fibroblast cells of all patients. Interestingly, unlike the other two 
patients, Patient 2 cells had an increase in the levels of m.3243A>G over passaging 
reaching ~95% by passage 24. These same cells failed to give rise to hiPSC clones 
with mutated mtDNA. It could be speculated, that due to high proliferative capacity of 
mutated mtDNA in these cells, over time they selected out the low mutation level 
clones. Consequently, high level clones failed to give rise to hiPSCs as a result of the 
reprogramming block discussed earlier (Yokota et al., 2015). Proliferative advantage 
of mutant mtDNA with m.3243A>G has been previously observed by Yoneda et al. 
(1992). The same group suggested that the cells might still be able to survive when 
the proportion of wild-type mtDNA is below 10% by adapting to glycolytic energy 
production or alternatively there might be enough wild-type mtDNA in individual 
mitochondrion that compensates for the presence of mutated mtDNA. Small amount 
of wild-type mtDNA is able to support respiratory activity of the cells or alternatively, 
residual activity of the mutant mtDNA is sufficient to provide this support (Bentlage 
and Attardi, 1996). Dunbar et al. (1995) showed that some cells shift mtDNA ratios 
towards wild-type and some show proliferative advantage of mutant mtDNA 
depending on the cells’ nuclear background. Therefore, in this study, we can 
postulate the differences in heteroplasmy levels change over time by the difference in 
the nuclear background of the cells.  
The level of the mutated mtDNA in cells is important, however, it is also 
necessary to consider the total amount of mtDNA in the cells. One study that looked 
at tissues derived from MELAS patients with the m.3243A>G found that mtDNA 
amount was increased in patient samples when compared to controls (Kaufmann et 
al., 1996). It has also been suggested that cells with lower mtDNA copy number 
reach the pathogenic threshold of the mutation earlier than cells with higher mtDNA 
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copy number. Therefore, increased mtDNA copy number could have a compensatory 
effect on high proportion of mutant mtDNA as the amount of mitochondrial DNA could 
be indicative of the cells ability to produce ATP via OXPHOS (Bentlage and Attardi, 
1996). In this study, Patient 2 and Patient 3 cells had similar levels of mtDNA copy 
number to the controls, however, Patient 1 cells had significantly increased levels. It 
could be speculated that Patient 1 cells were compensating for the defects in 
translation by increasing the amount of mtDNA and thereby allowing successful 
cellular reprogramming. On the other hand, Patient 2 and Patient 3 cells did not have 
this compensatory effect which potentially resulted in failed reprogramming attempts 
and failed attempts to derive clones with m.3243A>G. It is also plausible that Patient 
2 cells were unable to undergo a switch between OXPHOS and glycolysis to reach 
successful reprogramming. 
Increased mtDNA copy number might not necessarily predict mitochondrial 
protein synthesis and function. In order to test mitochondrial function, oxygen 
consumption was assayed using Seahorse XF analyser. The results showed that 
Patient 2 cells had significantly lower levels of basal and maximal respiration which 
could possibly account for the results of the reprogramming experiments.  
Chin et al. (2014) previously reported that ~12% of patients with m.3243A>G 
also have mtDNA deletions which lead to additional clinical features, including 
retinitis pigmentosa and migraine. After testing patients’ fibroblasts for mtDNA 
common deletions, none of the MELAS patients in this study were found to have the 
deletions. Therefore, this is not the feature that can be associated with failed 
reprogramming. 
One study showed that the bioenergetic profile of parent cells affects their 
ability to generate hiPSCs and cells with higher propensity for glycolytic metabolism 
reprogram with higher efficiency (Panopoulos et al., 2012). Therefore, extracellular 
acidification rate (ECAR) could be used as a pre-screen to estimate the likelihood of 
successful reprogramming. ECAR is a powerful tool for measuring the levels of 
glycolysis in the medium surrounding the cells from excretion of lactic acid per time 
unit. It is performed by supplying the cells with glucose and inhibiting ATP synthase 
with oligomycin stimulating glycolysis (TeSlaa and Teitell, 2014). Mitochondrial 
membrane potential, assessed by the tetramethyl rhodamine methyl ester (TMRM) 
dye, has also been shown to be elevated in hPSCs compared to fibroblasts which 
again could mean that Patient 2 fibroblasts with high m.3243A>G were unable to 
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undergo this change resulting in failed reprogramming attempts (Schieke et al., 
2008). These parameters could be used in future studies as a pre-screen of cells to 
be reprogrammed. 
Based on the findings in this and the previous chapter, three Patient 1 hiPSC 
clones were chosen to be used in further experiments. 
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Chapter 5. Functional characterisation of patient hiPSCs 
5.1 Overview 
The main aim of this chapter was to elucidate potential differences that hiPSCs with 
different levels of the m.3243A>G might have. Not all patient clones were able to 
survive at the initial stages of cell culture and some of them had decreased 
expansion rate when compared to controls. A large number of factors can affect cell 
cycle kinetics and survival and some of those were investigated in the experiments 
discussed below. 
Eukaryotic cells undergoing division go through a number of stages during 
proliferation. Typical cell cycle includes G1 (gap 1), S (synthesis), G2 (gap 2) and M 
(mitosis) phases under control of a series of cyclin-dependent kinases. G1 and G2 
phases allow cell growth and include multiple checkpoints ensuring the cell is ready 
for replication and ensuring DNA integrity, whilst DNA synthesis occurs during the S-
phase (Pardee, 1974; Sanchez et al., 1997). hESCs have an average cell cycle of 
~16 hours (as opposed to ~24-32 hours in somatic cells). On average 52-65% of the 
total population of hESCs reside in the S-phase, 20-24% in G1 and 10-20% in G2 
phases. The shortening of the division time in hESCs is attributed to truncated G1 
phase and has been shown to be linked to the maintenance of an undifferentiated 
state (Becker et al., 2006; Filipczyk et al., 2007; Neganova et al., 2009). Ghule et al. 
(2011) used hiPSCs to show that they have similar distribution of the proportions of 
cells at different stages of the cell cycle when compared to hESCs. They found 
that >50% of cells were in S-phase and that cells had a reduced G1 phase. One of 
the most common methods to study cells synthesising DNA is by BrdU, which is a 
synthetic analogue of thymidine and is actively incorporated into newly synthesised 
DNA during the S-phase (Gratzner, 1982). DAPI can be used to quantify the number 
of cells in G1 and G2 phases. Cells in G2 will have double the amount of DNA 
compared to G1 which can be quantified by flow cytometry using appropriate gating 
technique outlined by Pozarowski and Darzynkiewicz (2004). 
In order to ensure genomic integrity, cells employ a number of check points to 
allow transmission of only healthy DNA during proliferation. Abnormalities in DNA can 
cause cell cycle arrest (in G1, S and G2), DNA repair or apoptosis (Bartek and 
Lukas, 2007). Therefore, in the context of cell cycle kinetics it is of value to also test 
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for the presence of apoptosis and DNA damage markers. DNA damage might be 
induced internally (e.g. ROS) or externally (e.g. UV radiation). It has been suggested 
that in most cases, DNA damage is caused by endogenous factors (Momcilovic et al., 
2011). A range of proteins is deployed to chromatin regions that are damaged, which 
in turn initiates a cascade of events including propagation of damage signals. A key 
cellular response to DNA double strand breaks and apoptosis is the histone H2A 
variant H2AX which is phosphorylated at serine 139 as a result of DNA damage 
(forming γH2AX) (Rogakou et al., 1998). Such modification leads to chromatin 
modification providing recruiting sites for repair protein complexes (Rogakou et al., 
1999). Mouse ESCs deficient in H2AX display elevated levels of genomic instability 
as a result of ionising radiation (Bassing et al., 2002). Additionally, MEFs derived 
from H2AX-/- embryos have been shown to have growth abnormalities, premature 
senescence and impaired DNA repair (Celeste et al., 2002). Therefore, assessing 
levels of γH2AX was chosen as a way to test for possible DNA damage in patient-
derived hiPSCs. 
The process of cell death can be classified into two main types. Programmed 
cell death occurs as part of development and morphogenesis and is genetically pre-
determined. The second type is apoptosis, the principal form of cell death. Initially, it 
was associated with the changes in the morphology of cells undergoing cell death, 
including disintegration of plasma membrane, condensation of nuclear chromatin and 
cytoplasmic organelles and loss of mitochondrial membrane potential. The process is 
accompanied by the activation of caspases which leads to protein degradation and 
death [reviewed by Chipuk and Green (2005)]. In this chapter, cell death was studied 
in the context of apoptosis. The field of apoptosis research has been greatly 
advanced by studies using Caenorhabditis elegans. Early studies identified a gene 
called ced-3 as the key regulator of cell death (Ellis and Horvitz, 1986). Later on it 
was shown that CED-3 bears similarities with the human analogue interleukin-1β (IL-
1β)-converting enzyme (ICE) which is a cysteine-aspartate protease (Yuan et al., 
1993). Altogether, there are nine ICE-like proteases and as a group they have been 
denoted as caspases (‘c’ – cysteine protease, ‘aspase’ – cleaving of aspartic residue) 
(Cohen, 1997). Caspase-3 is one of the key executioners of apoptosis. It 
proteolytically cleaves a number of key proteins including poly(ADP-ribose) 
polymerase (PARP) which is a nuclear protein largely involved in DNA repair as has 
been demonstrated in an early study by Benjamin and Gill (1980). Cleavage of PARP 
results in formation of 89 kDa (catalytic) and 24 kDa (DNA binding domain) fragments 
 92 
and is recognised to be a hallmark of apoptosis (Lazebnik et al., 1994; Chaitanya et 
al., 2010). The 89 kDa domain is translocated to the cytosol whereas 24 kDa domain 
binds to DNA preventing DNA repair enzymes binding to the sites of damage 
(Chaitanya et al., 2010). The 89 kDa-cleaved domain is therefore an acceptable 
indicator of apoptosis and it was used in the current study. 
Mitochondria generate ROS primarily as part of OXPHOS resulting in redox 
signalling. ROS are highly reactive oxygen metabolites that are able to react with 
cellular macromolecules. If ROS homeostasis is unbalanced and the cells are not 
able to cope with it, it can lead to oxidative stress resulting in damage to nucleic 
acids, lipids and proteins which might influence cell survival and proliferation 
[reviewed by Ray et al. (2012)]. Superoxide radical is the primary ROS species and it 
is formed when molecular oxygen is reduced [O2 + e-  O2-], a process which can be 
affected by the mitochondrial membrane potential (ΔΨm). Oxygen can be reduced 
further to produce hydrogen peroxide [2O2- + 2H  H2O2 + O2] (Hancock et al., 
2001). There are a number of markers that are used for the direct and indirect 
detection of ROS. DHE and mitochondrial-targeted DHE (mitoSOX) are small 
molecule fluorescent probes which specifically target superoxide (Wang et al., 2013). 
When they react with superoxide they generate 2-hydroxyethidium (2-OH-E+), which 
emits fluorescence (Zhao et al., 2005). Dihydrorhodamine123 (DHR) is another 
probe used for ROS detection. It is converted to fluorescent rhodamine when it reacts 
with H2O2 by-product OH (Wang et al., 2013). Mitochondrial mass was measured by 
looking at the levels of NAO, a probe for mitochondrial membrane. It binds to 
cardiolipin, a phospholipid found in the inner mitochondrial membrane (Petit et al., 
1992). Cardiolipin binds respiratory chain complexes and it has been suggested that 
without it, Complex I and III are inactive (Fry and Green, 1981). It is involved in 
mitophagy by redistribution to the outer mitochondrial membrane (Chu et al., 2014)  
Additionally, some studies suggested that cytochrome c binds cardiolipin as part of a 
pro-apoptotic signalling cascade [reviewed by Jacobson et al. (2002)]. Another dye 
which is widely used is JC-1, which provides assessment of mitochondrial ΔΨm and 
serves as a marker of apoptosis. JC-1 exists as a monomer (green fluorescent peak 
representative of cytoplasmic JC-1) and as an aggregate (red fluorescent peak 
representative of mitochondrial aggregates); mitochondria uptake the monomer into 
the matrix and when it reaches a certain level in energised mitochondria, it is 
converted into aggregates and the ratio of the two provides information about ΔΨm 
(Reers et al., 1991). Measurement of ΔΨm is important because it reflects the ability 
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of mitochondria to force proton flow into mitochondrial cytoplasm and JC-1 has been 
suggested to be an ideal probe for this kind of assessment (Perry et al., 2011). 
A range of other assessments were based on previous work undertaken using 
hiPSCs derived from patients with mitochondrial diseases. As part of this chapter, 
patient-derived hiPSCs were studied for mtDNA copy number, oxygen consumption 
and heteroplasmy levels. 
5.2 Results 
As discussed in the previous chapter, three Patient 1 hiPSC clones were selected for 
further work. Clone 5 had ~50% m.3243A>G, Clone M2 ~70% m.3243A>G, and 
Clone 8 was an isogenic control. These values correspond to average levels of 
mutated mtDNA at the time when the experiments were conducted (Figure 5.1). 
 
Figure 5.1. Patient 1 hiPSC clones selected for further work, including clone 
designations and the percentage of mutated mtDNA. 
5.2.1 Cell cycle, apoptosis and DNA damage assessment 
Initially, ten hiPSC clones were derived from Patient 1 fibroblasts. In the early stages 
of cell culture, most of the clones failed to propagate. Additionally, there were marked 
differences in the ability of these cells to expand. Cells with higher levels of the 
mutation grew more slowly with minimal requirements for passaging. In the initial 
stages, it was noted that Clone 5 (~50% m.3243A>G) in particular did not expand 
well. The differential levels of expansion observed could be explained by either 
reduced cell proliferation or increased levels of cell death. Cell cycle, apoptosis and 
DNA damage assays were carried out in order to investigate whether there were 
differences in these parameters across different clones. Results in Figure 5.2 show 
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that there was no significant difference between control hiPSCs and patient-derived 
hiPSCs in terms of the percentage of cells residing in different stages of the cell cycle 
[Figure 5.2 (A)]. On average, there were ~50% of cells in the S-phase, ~38% in G1 
phase and 13% in G2 phase. The percentage of cells in G1 phase was higher than 
what is expected for this cell type. There was no difference between hiPSCs with 
regards to the levels of the apoptosis marker 89 kDa-cleaved fragment of PARP or 
DNA damage marker γH2AX [Figure 5.2 (B)]. Overall, there was no clear indication 
that patient-derived hiPSCs differed across any of these parameters. 
 
Figure 5.2. Measurement of cell proliferation, apoptosis and DNA damage in hiPSCs by 
flow cytometry. (A) Cells showed similar proliferation capacity as determined by 
incorporated BrdU (S-phase) and DAPI (G1, G2 phases). (B) Cells showed similar levels of 
apoptosis (cleaved PARP) and response to DNA double strand breaks (analysis for 
phosphorylated γH2AX). N=3. Data presented as Mean ± SEM. Significance was established 
with one-way ANOVA followed by Tukey’s post hoc test. 
5.2.2 mtDNA levels and cellular respiration in hiPSCs 
Previous study has showed that hiPSCs with a high mutation load have increased 
levels of mtDNA copy number (Hamalainen et al., 2013). Similarly, in this study 
patient hiPSC clone with the highest level of mutated mtDNA (Clone M2) had 
significantly increased levels of mtDNA copy number compared to the other two 
clones and hESCs. The mtDNA deletions in the major arc of the mtDNA, historically 
referred to as ‘common deletion’, were also checked and it was confirmed that, just 
like in the original fibroblasts, no common deletions were detected. The results are 
shown in Figure 5.3 (A, B). Interestingly, the overall mtDNA copy number significantly 
decreased in all hiPSC clones compared to their parental fibroblasts which could be 
explained by their low energy demands and reliance on OXPHOS compared to 
fibroblasts [Figure 5.3 (C)]. 
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Figure 5.3. Analysis of mtDNA copy number and common deletion levels by qPCR. (A) 
Patient 1 Clone M2 (heteroplasmy ~70%) had significantly higher level of mtDNA compared 
to hESCs, Clone 5 (heteroplasmy ~50%) and Clone 8 (isogenic control). (B) None of the cells 
had mtDNA common deletions. (C) All hiPSC clones had significantly lower levels of mtDNA 
compared to parental fibroblasts. N=3. Data presented as Mean ± SEM. Significance was 
established with one-way ANOVA followed by Tukey’s post hoc test. 
In order to test whether cells had different levels of oxygen consumption, analysis 
using the Seahorse platform was performed. No significant difference was found 
between control and patient hiPSC clones in terms of basal and maximal capacity 
respiration (Figure 5.4). 
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Figure 5.4. Analysis of oxygen consumption by Seahorse. Seahorse analysis showed no 
difference in basal respiration (A) or maximal capacity respiration (B) in different cells. N=3. 
Data presented as Mean ± SEM. Significance was established with one-way ANOVA 
followed by Tukey’s post hoc test. 
5.2.3 Assessment of ROS production, mitochondrial mass and mitochondrial 
membrane potential 
In order to further investigate potential differences between hiPSCs, additional 
parameters of mitochondrial function were investigated. As determined by NAO stain, 
there was no trend towards cells having differences in mitochondrial mass, and no 
difference in ΔΨm as determined by JC-1 [Figure 5.5 (A, B)]. Clone M2 (~70% 
m.3243A>G) seemed to have lowered levels of H2O2 and superoxide when 
compared to the other hiPSCs [Figure 5.5 (C, D)]. 
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Figure 5.5. Measurement of mitochondrial mass, mitochondrial membrane potential, 
intracellular superoxide and peroxides by flow cytometry. (A) Cells showed comparable 
levels of mitochondrial mass, (B) the levels of ΔΨm, (C) peroxides, and (D) superoxide. Error 
bars represent Mean ± SD between 3 technical repeats. Where no error bars are shown, 
only one repeat was possible due to low cell numbers. 
5.2.4 Heteroplasmy level change in patient hiPSC clones over passaging 
Two of the hiPSC clones were monitored for changes in the levels of mutated mtDNA 
over passaging. As can be seen in Figure 5.6, in Clone 5, although initially having 
~32% m.3243A>G, once the mutation load was established in the early passages, it 
remained around ~50% throughout the rest of the study. It should be noted that for all 
the experiments described here and later on, cells were used within the passages 
where the level of the mutation was around 50%. Clone M2 cells were derived with 
high level of mutated mtDNA of 75%. Over passaging the levels of the mutation 
remained at ~70%. Interestingly, by passage 20 the mutation level went down to 
53%. Due to the fact that the cells were tested at passage 15 and 20 and not at 
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passages in-between, it is difficult to speculate at what point the mutation level went 
down. Passage 19 was the latest passage at which these cells were used in any of 
the analyses in the experiments described in this chapter or in any further work. 
 
Figure 5.6. Heteroplasmy level change in patient hiPSCs over passaging. Clone 5 cells 
had similar levels of m.3243A>G over passaging. Clone M2 retained the levels of mutated 
mtDNA over the first 15 passages. Mutation level went down by passage 22 from ~70% to 
53%. 
5.3 Discussion 
The main aim of this chapter was to investigate potential differences in patient-
derived hiPSC clones with different levels of the m.3243A>G mutation. 
One of the first observations made was that cells with mutated mtDNA 
displayed reduced expansion capacity. This finding was also presented by Cherry et 
al. (2013) and Wahlestedt et al. (2014), however, they investigated cells with other 
mutations; the Pearson marrow-pancreas syndrome (caused by single large-scale 
deletions in mtDNA leading to bone marrow failure) and the “mutator” mouse (which 
carry amino acid substitution of the nuclear-encoded Polg gene) respectively. Other 
studies did not comment on whether there was a difference in cell growth therefore it 
is difficult to draw conclusions whether it is a common trait in these cells. 
In order to elucidate whether patient and control hiPSCs had differences in cell 
proliferation, apoptosis and DNA damage they were analysed using BrdU 
incorporation, DAPI, cleaved PARP and γH2AX. No difference was found in cell 
proliferation between control and patient hiPSCs. As discussed earlier in this chapter, 
hPSCs normally have 50-65% of cells residing in S-phase and the results in this 
chapter showed that on average there were ~50% of cells in this phase of the cell 
cycle (Neganova et al., 2009; Ghule et al., 2011). Additionally, it would be expected 
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to see 20-24% and 10-20% in G1 and G2 phases respectively. It was found that 
~38% of cells were in G1 phase and ~13% in G2 phase. There could be a number of 
explanations as to why there is such discrepancy between results associated with G1 
phase. There is some evidence that a shortened G1 phase is associated with the 
pluripotency state in hPSCs and is required for successful reprogramming (Ruiz et 
al., 2011). It was shown that hESCs undergoing cell cycle arrest are subject to 
irreversible differentiation as assessed by expression of pluripotency-related markers 
Tra-1-60 and Tra-1-81. Cells used in this project were checked daily for 
morphological changes associated with differentiation and no such changes were 
observed. Although, it was not feasible to regularly test the cells for the expression of 
pluripotency markers, they were differentiated into RPE at a later stage strongly 
suggesting that the cells remained pluripotent. 
Since no difference in cell proliferation was found between patient and control 
cells, it was next determined whether patient cells had higher levels of apoptosis and 
DNA damage. As shown in Figure 5.2 (B), there was no significant difference 
between patient and control cells. This experiment could be improved by testing the 
cells under stress conditions because it is possible that they have similar base levels 
of these markers, but under adverse conditions they might be more susceptible to 
DNA damage and cell death. 
It is important to keep in mind that Clone M2 had changes on chromosome 20 
which could mean that several genes involved in cell growth and survival were 
amplified masking the effect of the mutation in mtDNA. Moreover, it was Clone 5 that 
grew at a slower rate and this clone did not have DNA abnormalities. However, it is 
not guaranteed that having duplication on chromosome 20 means overexpression of 
the genes located on it as discussed in Chapter 1 (Amps et al., 2011). More work 
would be required to verify whether chromosomal abnormalities had an effect on the 
behaviour of these cells and assessments such as RNA-seq or ChIP-sequencing 
could be performed. 
A number of studies have emerged in the last four years where hiPSCs have 
been derived from patient cells with mitochondrial abnormalities. This provides an 
opportunity to draw some comparisons between the results from this study and 
published work particularly where there are divergent findings in the literature. A 
summary has been provided in Table 5.1.
  
Study Mutation 
hiPSCs 
growth rate 
Total 
mtDNA 
Heteroplasmy change 
over passaging 
Basal 
respiration 
Maximal 
respiration 
ΔΨm (*) ROS (*) 
Cell 
cycle 
Apoptosis DNA 
damage 
Mitochondrial 
mass (*) 
This chapter m.3243A>G ↓ expansion ↑ Clonal variation ND ND ↓ ↓ ND ND ND ↓ 
Fujikura et al. 
(2012) 
m.3243A>G  ND No change         
Hamalainen et 
al. (2013) 
m.3243A>G  ↑ No change         
Folmes et al. 
(2013) 
G13513A    ND        
Cherry et al. 
(2013) 
PS ↓ expansion  Clonal variation ↓  ↓      
Wahlestedt et 
al. (2014) 
Polg (-/-) 
mouse 
↓ expansion      ↓     
Yokota et al. 
(2015) 
m.3243A>G  ↑ Clonal variation         
Kodaira et al. 
(2015) 
m.3243A>G  ND Clonal variation         
Ma et al. (2015) m.3243A>G    ↓        
Hatakeyama et 
al. (2015) 
m.5541C>T 
(myoblasts) 
     ↓ ↑     
Table 5.1. Comparison of studies that use iPSCs to study mitochondrial mutations (compared to controls). ND – no difference; PS - Pearson 
marrow-pancreas syndrome; m.5541C>T, mutation in tRNAtrp in MT-TW gene. Green shading – similar findings to current study; red shading – 
opposing results; grey shading – no data. (*) more repeats needed for definitive conclusions.
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In this chapter, hiPSC clone with the highest level of the mutation was found to have 
significantly higher total mtDNA copy number compared with hESCs and hiPSCs with 
lower levels of the m.3243A>G mutation. All clones had significantly lower mtDNA 
copy number compared with the parental fibroblasts. Two other studies that 
described derivation of hiPSCs with m.3243A>G had similar results (Hamalainen et 
al., 2013; Yokota et al., 2015). However, some studies saw no correlation between 
heteroplasmy level and mtDNA copy number (Fujikura et al., 2012; Yokota et al., 
2015). As discussed in the previous chapter, patients with m.3243A>G have 
increased levels of mtDNA and inability to upregulate the copy number can lead to 
development of a pathological phenotype. Therefore, increase in mtDNA copy 
number was attributed to compensatory mechanisms to account for translational 
defects (Bentlage and Attardi, 1996; Kaufmann et al., 1996). This compensatory 
effect was also observed in a patient with Kearns-Sayre syndrome, which is 
characterised by the diagnostic triad of pigmentary retinal degeneration and CPEO 
developing before the age of 20 years old. This particular patient harboured 3 kb 
mtDNA deletion at a level of 92% in their muscle, nevertheless they had a relatively 
mild clinical phenotype (Wong et al., 2003). It is not clear why there are 
discrepancies in studies discussed in this chapter. Fujikura et al. (2012) suggested 
that low metabolic demand of hiPSCs means that there is no requirement for 
amplification of mtDNA, but this was not observed in this and another study that 
looked into it (Kodaira et al., 2015). Given these inconsistencies, further work is 
required to elucidate the mechanism of mtDNA copy number regulation in hPSCs 
carrying pathogenic mitochondrial mutations. It is also possible that the failure to 
increase mtDNA copy number is the result of increased mitophagy, which allows the 
removal of damaged mtDNA in diseased cells [reviewed by Clay Montier et al. 
(2009)]. 
No difference in oxygen consumption was found between patient and control 
cells, similar to what has been reported by Folmes et al. (2013). This observation 
could be due to the fact that hiPSCs do not rely primarily on mitochondrial respiration 
or possibly because our patient cells had increased number of mtDNA copies. 
However, Cherry et al. (2013) and Ma et al. (2015) saw a decrease in basal 
respiration rate in their cells. Additionally, they saw a decrease in ΔΨm which could 
mean that there were abnormalities in the electron transport chain function (Cherry et 
al., 2013). 
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Cells were also tested for mitochondrial mass, ΔΨm and the presence of ROS. 
Decrease in ΔΨm has been previously described as an early marker of apoptosis 
leading to uncoupling of electron transport from ATP production. The same study 
showed that a drop in ΔΨm is possibly followed by alternations of mitochondrial 
membrane structure as assessed by NAO fluorescence (Petit et al., 1995). With the 
use of the NAO stain, we found no trend towards cells having differences in 
mitochondrial mass between the different clones tested [Figure 5.5 (A)]. There was a 
trend towards Clone M2 (~70% m.3243A>G) having lowered ΔΨm as determined by 
JC-1 [Figure 5.5 (B)]. The same clone seemed to have lowered levels of H2O2 and 
superoxide when compared to other hiPSCs, which could imply that the electron 
transport chain is not active due to reduced ΔΨm and therefore there is less ROS 
production [Figure 5.5 (C, D)]. Future work would require testing for these parameters 
using a pharmacologic control such as FCCP which acts by depolarising 
mitochondrial membrane potential [as first described by Heytler and Prichard (1962)]. 
Furthermore, adding a stress stimulus could give an idea of whether these cells differ 
in their ability to react to adverse conditions. Other studies that used hiPSCs derived 
from patients with mitochondrial diseases also showed a decrease in ΔΨm in their cell 
models (Cherry et al., 2013; Hatakeyama et al., 2015). 
Wahlestedt et al. (2014), Hatakeyama et al. (2015) and results described 
herein showed conflicting data with regards to ROS production. Only Hatakeyama et 
al. (2015) showed an increase in ROS in their cells and this discrepancy could be 
explained by the different mitochondrial mutations that were studied in all three 
projects; m.3243A>G, mouse model of Polg-/- and m.5541C>T. Additionally, 
m.5541C>T was studied in myoblasts which probably have higher energy 
requirements than PSCs and therefore might utilise OXPHOS more resulting in 
higher ROS production. Since, it is not expected that hiPSCs heavily rely on 
OXPHOS, this biochemical feature could explain our observation of no difference in 
ROS production. 
Most of the studies outlined in Table 5.1 also looked at the dynamics of 
heteroplasmy levels over passaging. Isogenic control derived from patient hiPSCs 
did not induce mutation over passaging (data not shown), and similar results were 
obtained in a study by Fujikura et al. (2012). Most previously published studies 
(including this chapter) were in agreement that there is clonal variation when it comes 
to the levels of mutated mtDNA. Some clones retained constant levels whereas 
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others eliminated the mutation or saw an increase (Cherry et al., 2013; Wahlestedt et 
al., 2014; Kodaira et al., 2015). Folmes et al. (2013) observed that the mutation 
purged over passaging (by passage 44) and all the original clones had less than 50% 
m.3243A>G. Fujikura et al. (2012) and Hamalainen et al. (2013) on the other hand 
did not see variability in the levels of m.3243A>G over passaging. As discussed in 
the previous chapter, Dunbar et al. (1995) suggested that the dynamics of the 
mutated mtDNA levels depend on nuclear background. Although, this hypothesis 
might explain the difference between the results in different studies, it is still not clear 
why in this chapter it was shown that hiPSCs clones derived from the same MELAS 
patient showed either stable levels of the mutated mtDNA or reduced levels over 
passaging. 
More work is required to elucidate the effect of m.3243A>G on hiPSCs. It is not 
clear what causes these cells to have lowered cellular proliferation. More efficient 
ways to derive hiPSCs from mitochondrial patients would provide more isogenic 
hiPSCs to draw more rigorous conclusions. At the moment, it is difficult to directly 
compare results between different studies because the hiPSCs used in them are 
derived from different patients with different nuclear backgrounds and disease 
severity, which is a characteristic feature of mitochondrial disease. 
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Chapter 6. Derivation and characterisation of hPSC-derived RPE 
cells 
6.1 Overview 
The main aim of this chapter was to optimise differentiation and propagation 
conditions of RPE cells and compare patient hiPSC-derived RPE cells to controls. At 
present, it is not yet known whether retinal defects seen in patients with the 
m.3243A>G mutation originate in neural retina or RPE cells. Even though the main 
aim of the chapter was to investigate RPE cells, some preliminary conclusions on 
neural retina development were also drawn. 
6.2 Results  
6.2.1 Optimising RPE differentiation protocol using hESCs 
Prior to starting the differentiation experiments with patient hiPSCs, optimal 
conditions for obtaining RPE cells were first identified using hESCs. Initially, a total of 
30 different differentiation conditions were tested, including variations in base 
medium, supplementation and initial seeding density (some of these were previously 
tested by Dr Joseph Collin, Prof Majlinda Lako’s group). All cells were differentiated 
as a monolayer with two different starting plating densities:  
 “Normal initial density”, where medium was changed to differentiation medium 
when cells reached passaging density.  
 “High initial density”, where cells were left to overgrow forming a confluent 
monolayer with all cells being in contact with each other.  
Three different base media were tested: DMEM/F12, RPMI and AdRPMI. DMEM/F12 
is a widely used medium and RPMI has been successfully used for maintenance of 
primary RPE cells (Sonoda et al., 2009). AdRPMI is a more defined version of RPMI. 
In addition, it was supplemented with varying combinations of B27, N2 and IGF1. 
After 3-4 months of differentiation, pigmented areas were manually isolated and re-
plated on 24-well plate transwell inserts where they were left to mature for further ~ 3 
months. Experimental set up with timeline, medium combinations and examples of 
cell seeding is summarised in Figure 6.1. 
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Figure 6.1. Summary of the experimental set up for RPE differentiation experiments. 
(A) Differentiation timeline, including representative images of cells at various time points; (B) 
Differentiation medium combinations. d – day. 
Optimal RPE differentiation medium 
In the first round of experiments, the time was noted when the first pigmented cells 
appeared. There was some variation between the conditions where pigment could be 
observed, however, in all but one condition pigment appeared by day 40 of 
differentiation (37.4 ± 2.4 days from the start of differentiation). Only one combination 
of supplementation of RPMI, where all B27, N2 and IGF1 were added, resulted in 
pigment production but not until after 83 days of differentiation (Figure 6.2). For this 
reason, RPMI base medium was not used in further experiments. Overall, it 
appeared that in most conditions, only normal initial cell density supported pigment 
production. In most of the conditions with AdRPMI as base medium, initial seeding 
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density did not seem important. These conclusions were drawn from the initial pilot 
experiment (N=1). 
 
Figure 6.2. First pigment appearance in a pilot RPE differentiation experiment. In most 
conditions, pigment appeared within 40 days of differentiation, RPMI base medium was the 
least favourable for differentiation. N=1. 
The next set of experiments aimed to further narrow down favourable differentiation 
conditions. DMEM/F12 and AdRPMI were further investigated as base media with all 
different supplementation combinations. In order to measure differentiation outcome, 
the number of isolated pigmented patches was quantified. After repeating the 
experiment three times, it became clear that there was a trend towards a better 
differentiation outcome with AdRPMI supplemented with B27 with high density 
starting population of cells. Additional supplementation with N2 and IGF1 did not 
appear to improve the results. DMEM/F12 media consistently produced less pigment. 
The results are presented in Figure 6.3. 
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Figure 6.3. Assessing different media combinations for their support of pigment 
formation. In conditions with AdRPMI, there were consistently more pigmented patches 
formed. Although, there was no statistical significance, there was a trend towards a better 
differentiation outcome when using AdRPMI and B27 with high density starting cell 
population. The results represent the number of pigmented patches per well of a 6-well plate 
(9.5 cm2) N=3. Data presented as Mean ± SEM. Significance was established with one-way 
ANOVA followed by Tukey’s post hoc test. 
RPE differentiation medium supported the formation of pigmented cells as well as 3D 
structures resembling optic vesicles and optic cups. Some examples of the structures 
formed are shown in Figure 6.4 (A). Monolayer outgrowths of pigmented cells were 
positive for the expression of RPE65 [Figure 6.4 (B)]. 3D structures were randomly 
isolated, cryosectioned and stained for RPE and early neural retina markers, RPE65 
and cone-rod homeobox (CRX). They were also tested for the expression of a RPE 
tight junction marker ZO1 (Stevenson et al., 1986). The 3D structures showed 
presence of RPE65, ZO1 and CRX positive cells [Figure 6.4 (C)]. In addition, the 
number of optic vesicle- and optic cup-like structures was quantified and the results 
are presented in Figure 6.4 (D-F). There was considerable variation in the 
differentiation experiments and it was not possible to conclude which media 
supported neural retinal structures formation; however, in general it seemed that 
AdRPMI was a more favourable base medium. 
 108 
 
Figure 6.4. Retinal structures formation. (A) Examples of different neural retina-like 
structures and pigmented cells; (B) Immunofluorescence of RPE cells showing that they 
express RPE65; (C) Immunofluorescence of optic vesicles showing expression of RPE65, 
ZO1 and CRX; (D) Representative images of optic vesicle-like structures; (E) Representative 
images of optic cup-like structures; Scale bar, 100 µm. (F) Quantification of neural retina-like 
structures in cell cultures is presented as average number of structures per well. No 
statistically significant differences were found between the different conditions. N=3. Scale 
bar, 100 µm (unless otherwise stated). Data presented as Mean ± SEM. Significance was 
established with one-way ANOVA followed by Tukey’s post hoc test. OV – optic vesicle, OC 
– optic cup. 
Investigating RPE propagation methods 
As well as testing differentiation media, a number of pilot experiments were 
performed to test various ECM substrates and expansion methods. Collagen IV, 
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laminin and fibronectin were compared as potential substrates for RPE propagation 
and maturation. Fibronectin did not allow the cells to form a monolayer resulting in 
the formation of areas of cell detachment [Figure 6.5 (A)]. Collagen IV and laminin 
appeared to be more supportive of RPE growth however neither of the substrates 
allowed increase of TER values over time or continuous growth of cells without 
detachment (data not shown). As a result, it was decided to use matrigel as a 
substrate as it contains a mix of ECM proteins, including both laminin and collagen. 
RPE enrichment was performed by either manual dissection of pigmented patches 
with their further re-plating or by subsequent dissociation of the cells into single cell 
suspension prior to re-plating. Direct re-plating resulted in a mixed population of cells 
in cultures however dissociation with a further use of cell strainer ( 40 µm, Millipore) 
resulted in more homogenous populations of cells [Figure 6.5 (B)]. 
 
Figure 6.5. Testing different RPE propagation methods. (A) Testing different ECM 
substrates. Fibronectin did not promote good cell attachment 1 month after plating. (B) 
Testing expansion methods. Direct plating of pigmented patches resulted in a mixed cell 
population, whereas initial dissociation supported expansion of a more pure population of 
pigmented cells. Scale bar, 100 µm. 
Summary 
To conclude, as a result of the experiments described above, RPE differentiation 
conditions were selected to be used in further work with patient hiPSCs. Cells would 
be overgrown to a confluent monolayer with subsequent change of medium to 
AdRPMI supplemented with B27. Pigmented patches of cells would then be manually 
dissected out, dissociated, strained and re-plated on matrigel coated transwell inserts 
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for further maturation and characterisation. For RT-qPCR experiments cells were 
expanded on 24-well plates rather than on transwell inserts. 
6.2.2 Derivation and investigation of RPE cells from hiPSCs with the 
m.3243A>G mutation 
Patient 1 Clone 5, Clone M2 and Clone 8 hiPSCs were differentiated along with 
Control hiPSCs and hESCs. Based on published literature (described in Table 1.2), 
additional expeirments were performed with media supplementation with KOSR. 
Addition of 10% KOSR resulted in better cell survival; therefore, it was added to all 
subsequent hiPSC differentiation cultures.  
Initial characterisation of RPE cells 
hESCs, Control hiPSCs, Clone 5 and Clone M2 all formed pigmented cells with 
typical cobblestone RPE morphology. Interstingly, numerous attempts to differentiate 
Clone 8 hiPSCs to RPE cells failed (at least three attepmts were made). It formed 
cystic bodies and did not produce any neural or retinal-like cells after multiple 
differentiation attempts. Therefore, this clone was not used in subsequent 
differentiation experiments. Representative images are shown in Figure 6.6 (A). No 
notable difference was seen between Control hiPSCs, hESCs, Clone 5 and Clone 
M2 derived RPE cells in the amount of time it took them to produce fist pigment 
patches (30.3 ± 5.6 days, mean ± SD). All cells expressed genes associated with 
differentiating and mature RPE cells assessed by RT-qPCR using RPE cell line 
ARPE19 as a control [Figure 6.6 (B)]. (Note: in all RT-qPCR experiments, statistical 
analyses were performed including all samples and difference between ARPE19 and 
other cells is presented on the graphs. However, the significance of these findings 
will not be discussed as it does not form part of the main objective of this chapter). 
Immunofluorescence was performed for detecing mature RPE marker RPE65 and 
tight junction marker ZO1 in hiPSC-derived RPE cells [Figure 6.6 (C)]. 
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Figure 6.6. Initial characterisation of RPE cells. (A) Representative images of hPSC-
derived RPE cells after 4 months of differentiation. Clone 8 failed to produce RPE cells. 
Scale bar, 100 µm. (B) RPE differentiation markers expression relative to ARPE19 cells 
assessed by RT-qPCR. N=3. Data presented as Mean ± SEM. Significance was established 
with one-way ANOVA followed by Tukey’s post hoc test. (C) Immunofluorescence for RPE 
marker RPE65 (expected to be expressed either in the membranes or in the cytoplasm) and 
tight junction marker ZO1, nuclei counterstained with DAPI. Secondary only antibody was 
used as a control. Scale bar, 100 µm. The figure legend states the cell populations RPE cells 
were derived from herein and in subsequent figures. 
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Reduced differentiation propensity of cells harbouring the m.3243A>G 
mutation 
There was an immediate observation that Clone M2 produced the least pigmented 
cells. To quantify differentiation outcome, plates with differentiating RPE cells were 
scanned and proccessed with ImageJ software. First the images were converted to 
grayscale and then the threshold was adjusted ensuring that only pigmented areas 
were visible. The software was then used to calculate the percentage of the total 
area occupied by pigment [image processing example is illustrated in Figure 6.7 (A)]. 
There was a continuous trend that, Clone M2 had the least percentage of surface 
area occupied by pigmented cells [Figure 6.7 (B)].  
 
Figure 6.7. Pigment appearance over time in hPSC-derived RPE cells. (A) 
Representative example of image processing. Original plate scans were converted to 
grayscale and threshold was changed to make only pigmented areas visible. ImageJ 
software was used to calculate pigmented areas within the wells. (B) Percentage of total 
growth area covered by pigmented cells. There was a trend towards Clone M2-RPE cells 
repeatedly producing the least amount of pigment. N=3. Data presented as Mean ± SEM. 
Significance was established with one-way ANOVA followed by Tukey’s post hoc test. 
Along with RPE cells, neural retina-like structures were developing at the same time. 
In order to make an initial assessment of the ability of the cells to make optic vesicle- 
and optic cup-like structures, these were quantified within 6-8 weeks of the start of 
the differentiation. Interestingly, patient cells produced less optic vesicle-like 
strucutres and no optic cup-like strucutres. Results are presented in Figure 6.8. 
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Figure 6.8. Neural retina formation from patient hiPSCs. Quantification of optic vesicle- 
and optic cup-like structures. Patient-derived RPE cells produced less optic vesicle- and no 
optic cup-like structures. N=3. Data presented as Mean ± SEM. Significance was established 
with one-way ANOVA followed by Tukey’s post hoc test. 
Subsequent experiments focused on investigating RPE cells. 
Functional assays 
Firstly, cells were assessed for their ability to perform functions that are known to be 
typical for RPE cells in vivo. TER measurements were used as an indirect 
measurement of the ability of the cells to form the outer blood-retinal barrier by 
detecting functional tight junctions. No significant difference was found between the 
cells (Figure 6.9). 
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Figure 6.9. Transepithelial resistance measurement in patient hiPSCs-derived RPE 
cells expanded on transwell inserts. N=3. Data presented as Mean ± SEM. Significance 
was established with one-way ANOVA followed by Tukey’s post hoc test. 
Next, relative expression of genes related to phagocytosis pathway [MER proto-
oncogene tyrosine kinase (MERTK)] and cytokine secretion (PEDF) was assessed by 
RT-qPCR. No difference was found between the cells. Results are shown in Figure 
6.10. 
 
Figure 6.10. Relative expression of functional RPE markers assessed by RT-qPCR. 
N=3. Data presented as Mean ± SEM. Significance was established with one-way ANOVA 
followed by Tukey’s post hoc test. 
The ability to phagocytose POSs is one of the main functions of RPE cells and 
defects in this process could lead to various retinal diseases. Although, gene 
expression analysis is a good initial assessment of the differences between the cells, 
it does not confirm whether the cells perform a certain function or not. Therefore, an 
additional assessment of the ability of the cells to phagocytose was carried out by 
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feeding the RPE cells with FITC-labelled POSs and using flow cytometry to quantify 
the results. Prior to the start of the experiment, an attempt had been made to isolate 
POSs from bovine eyes however it was not possible to have a homogenous 
population of POSs (data not shown), therefore they were acquired commercially. 
POSs were FITC-labelled and the labelling was confirmed with immunofluorescence 
[Figure 6.11 (A)]. A number of control experiments were set up to ensure the 
robustness of the data. Firstly, cells were kept at 4C in order to block their ability to 
phagocytose (Yan et al., 1998). Trypan blue was used to quench any extracellular 
fluorescence produced by POSs bound to the extracellular membrane but not 
ingested, giving false positive results on the cytometer (Westenskow et al., 2012). 
Cells were also fed with unlabelled POSs to assess background fluorescence. 
Representative images of the settings results are shown in Figure 6.11 (B-F). Two 
different types of conclusions were drawn from the results of the experiment. 
Percentage of FITC-positive cells indicates the number of cells within the population 
that ingested POSs. Median fluorescence intensity (MFI) represents the amount of 
POSs ingested by individual cells as an indirect indication of cell-surface receptor 
density involved in phagocytosis (Westenskow et al., 2012). The MFI values were 
obtained by subtracting background fluorescence values in the FITC channel in the 
absence of labelled POSs. The results of the experiment showed that there were 
approximately 1/3 less cells within the population of patient-derived RPE cells that 
were able to phagocytose (hESCs 14.5%; Control hiPSCs 17.8%; Clone 5 9.4%; 
Clone M2 10.9%). On the other hand, patient cells that were able to ingest had 
higher numbers of POSs per cell as indicated by MFI values. Quantifications are 
shown in Figure 6.11 (G). The MFI data is suggestive of the potential of the cells to 
ingest POSs by giving a representation of the amount of POSs inside the cells. This 
parameter is important as it gives another valuable dimension to the data and 
provides information on the whole cell population level about the potential of the cells 
to internalise POSs as opposed to the number of cells that are able to phagocytose. 
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Figure 6.11. Photoreceptor outer segments phagocytosis by hPSC-RPE cells, 
including examples of experimental set up, assessed by flow cytometry. (A) FITC-
labelled POSs. Scale bar, 100 µm; (B) Histogram representation of the control experiments; 
(C) Blocking phagocytosis by incubating the cells at 4C; (D) Feeding cells with POSs 
without FITC-labelling; (E) Performing the experiment without quenching extracellular FITC-
labelled POSs; (F) Example of the results with cells fed with FITC-labelled POSs and 
quenching extracellular POSs with Trypan blue, showing its effect; (G) The phagocytosis 
experiment results showed that hESCs and control hiPSCs had higher number of cells that 
were able to phagocytose. Patient cells that were able to phagocytose had the ability of 
ingesting more POSs per cell, as determined by MFI values. All cells were matched with 
regards to the length of differentiation time and were all ~6.5 months old. N=1. 
Summary of the initial findings of patient-derived RPE cells 
From the experiments described above it can be concluded that RPE cells derived 
from Clone M2 (highest level of m.3243A>G) behaved differently with regards to their 
propensity to differentiate producing cells with lowered pigmentation levels. 
Additionally, RPE cells derived from both of the patient hiPSC clones had reduced 
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ability to perform one of the main RPE functions – phagocytosis of POSs. Therefore, 
it was decided to study the cells further.  
Ultra-structural and molecular assessment of RPE cells 
Cells were imaged with TEM in order to investigate their morphology. There were 
striking differences in the morphology of RPE cells derived from patient Clone M2 
hiPSCs, which had ~ 70% of the mutation. As can be observed in Figure 6.12 (A), 
cells did not display the baso-apical distribution of organelles normally seen in RPE 
cells where melanosomes are located apically. They also had underdeveloped 
microvilli. However, most importantly, they contained melanosomes which were 
hollow inside potentially indicating their state of degradation. Clone M2-RPE had 
similar numbers of mature melanosomes and melanosomes associated with 
lysosomes. However, there were significantly more hollow melanosomes with 
atypical morphology. This finding was important as it is in line with clinical 
observations that showed that MELAS patients have areas of RPE depigmentation. 
RT-qPCR results of genes related to pigment synthesis did not reveal differences 
between patient and control RPE cells [Figure 6.12 (C)].  
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Figure 6.12. TEM of patient hiPSC-RPE cells with further quantifications. (A) 
Representative TEM images of RPE cells (Scale bar, 2 µm). Patient RPE cells with high level 
m.3243A>G have atypical melanosomes with hollow morphology. (B) Quantification of the 
numbers of melanosomes. Clone M2-RPE cells had significantly higher levels of hollow 
melanosomes. No difference was found in the numbers of mature melanosomes and 
melanosomes associated with lysosomes. Quantifications are based on cells from 3-7 
random fields. (C) Relative expression of genes associated with pigment synthesis (RT-
qPCR). No difference was found between patient-derived RPE cells, hESCs and control 
hiPSCs. N=3. Data presented as Mean ± SEM. Significance was established with one-way 
ANOVA followed by Tukey’s post hoc test. TYR (tyrosinase); MITF (microphthalmia-
associated transcription factor); SILV (silver locus protein homolog). 
In addition to quantifying melanosomes with different morphologies, mitochondrial 
morphology was also considered. Although there was no statistical significance in the 
findings, there was a trend towards patient-derived RPE cells having less mature and 
more fragmented / damaged mitochondria, which could be a direct result of the 
m.3243A>G mutation. Ideally, more samples would need to be tested to confirm 
whether this trend could be significant. The results are presented in Figure 6.13. 
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Figure 6.13. Quantification of mitochondria with varying morphology. (A) Examples of 
mitochondrial classification. (B) Quantifications of various types of mitochondria. No 
difference was found between cells. Quantifications are based on cells from 3-7 random 
fields. Data presented as Mean ± SEM. Significance was established with one-way ANOVA 
followed by Tukey’s post hoc test. 
The TEM results indicated that patient RPE cells had defects in mitochondrial 
dynamics and contained what looked like degrading melanosomes. In order to 
elucidate potential mechanism behind these findings, relative expression levels of 
genes that are involved in lysosomal degradation and mitochondrial dynamics were 
compared (Figure 6.14). Additionally, cells were tested for the expression of a marker 
related to oxidative stress. CTSD, CTSB and ACP2 are markers associated with 
lysosomal degradation and ACP2 is assumed to have a specific role in melanosome 
degradation (Hayasaka et al., 1975). Looking at these genes was of particular 
interest as it has been previously suggested that melanosomes are specialised 
lysosomes and hollow melanosomes represent the process of autophagy when they 
start degrading their own melanin (Schraermeyer et al., 1999). OPA1 and MFN2 are 
associated with mitochondrial fusion (Griparic et al., 2004). Additionally, MFN2 has 
been implicated in establishment of physical contacts between mitochondria and 
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melanosomes (Daniele et al., 2014). There was no difference in the expression of 
these markers between hPSC-RPE cells apart from one. Clone M2-RPE had 
significantly higher levels of OPA1 compared to hESCs. There was no difference 
between hPSC-RPE cells in the expression of SOD2 (superoxide dismutase 2, an 
enzyme that clears mitochondrial ROS) (Flynn and Melov, 2013). 
 
Figure 6.14. Relative expression levels of lysosomal and oxidative stress genes by RT-
qPCR. No difference was found in the expression levels of lysosomal and melanosomal 
degradation genes CTSD, CTSB and ACP2. No difference was found in the fusion gene 
MFN2. OPA1 was significantly upregulated in RPE cells derived from Clone M2 compared to 
hESC-RPE. No difference was found in the expression of SOD2. Data presented as Mean ± 
SEM. N=3. Significance was established with one-way ANOVA followed by Tukey’s post hoc 
test. 
Although, Figure 6.14 showed no difference in the expression of the selected 
lysosomal genes, in order to confirm that there is no difference between the RPE 
cells it would be necessary to perform lysosomal enzyme activity assay. This would 
be particularly interesting as previous studies have shown an association between 
lysosomal activity and disturbed homeostasis in RPE cells (Chen et al., 2009). 
Three months after the first TEM images were taken, another set of RPE cells 
that were grown in parallel to the first set of cells were imaged in order to confirm 
whether the cells retained their pathological morphology over time. As seen in Figure 
6.15, hESC-RPE cells looked similar to the previous batch of cells in Figure 6.12 (A). 
Control hiPSC-RPE cells had baso-apical distribution of organelles with less signs of 
developing microvilli. Interestingly, Clone 5-RPE cells contained some swollen 
fragmented mitochondria and lipid droplets. Clone M2-RPE cells looked apoptotic 
across all images. Additionally, the cells had disturbed membranes, dysmorphic 
mitochondria, underdeveloped microvilli, vacuoles and a mix of melanosomes with 
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various morphologies. Due to the difficulty of distinguishing between organelles it 
was not possible to replicate the quantifications performed for the first set of TEM 
images. However, from the images in Figure 6.15 it can be seen that patient cells 
looked diseased indicating potential effect of the mutation on their ability to support 
survival. 
 
Figure 6.15. Representative TEM images of hPSC-RPE cells three months after the 
original images were taken [Figure 6.12 (A)]. hESC-RPE continued their development and 
showed more mature microvilli. Control hiPSC-RPE had apical melanosomal distribution and 
less developed microvilli. Clone 5-RPE had very large fragmented mitochondria and lipid 
droplets. Clone M2-RPE had apoptotic nuclei, disturbed membranes, disorganised cytoplasm 
and dysmorphic mitochondria. Scale bar, 2 µm. Note: black vertical lines seen in hESCs and 
Clone M2 are a processing artefact. 
From the TEM images it could be seen that there were signs of a loss of membrane 
integrity in RPE cells harbouring the m.3243A>G mutation. One of the functions of 
melanosomes is to reduce oxidative stress produced by ROS and lipid peroxidation 
(Holliday et al., 2013). Additionally, melanosomes sequester calcium thereby 
protecting the cells. Therefore, morphological changes in these organelles could 
affect the fate of the cells. A pilot experiment was performed to see whether there 
were differences in cytosolic calcium between different RPE cells. The results are 
shown in Figure 6.16. No difference was found between different RPE cells. This 
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experiment would need to be repeated with further optimisations and more biological 
repeats which was not possible to do due to low cell numbers. 
 
Figure 6.16. Cytosolic calcium levels in RPE cells. No significant difference was found 
between different cells. N=2. Data presented as Mean ± SD. 
Mitochondrial assessment of RPE cells 
In order to investigate how the dynamics of the mitochondrial mutation of the cells 
changed throughout the differentiation process, they were checked for heteroplasmy 
level, mtDNA copy number and ATP levels. Figure 6.17 (A) shows the levels of 
m.3243A>G in the RPE cells; on the X-axis, the approximate levels of the mutation of 
the parental hiPSCs they were derived from are indicated. Overall RPE cells derived 
from Clone 5 had slightly increased levels of heteroplasmy comparing to the original 
hiPSCs. Clone M2 had differing results from two different differentiation experiments. 
There did not appear to be a notable difference in heteroplasmy level of RPE cells 
comparing to the original hiPSCs in one differentiation experiment resulting in the 
derivation of RPE cells with ~ 70% of the mutation. Another experiment resulted in 
the derivation of cells with ~ 57% m.3243A>G. The trend in the levels of the mtDNA 
in patient hiPSC-RPE cells mimicked the results obtained for hiPSC clones.  
Clone M2 had significantly higher number of mtDNA copies compared to RPE 
cells derived from Clone 5 and hESCs [Figure 6.17 (B)]. None of the cells had 
mtDNA common deletions (data not shown). There was no notable difference in the 
levels of ATP produced by OXPHOS and glycolysis [Figure 6.17 (C)]. However, it 
should be taken into account that there were only enough cells to perform this 
experiment once and further optimisation could potentially show a different result. 
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It should be pointed out that although Clone M2-RPE cells from different 
experiments had varying levels of the m.3243A>G mutation, cells performed similarly 
in different assays, potentially indicating that pathological phenotype in these cells 
stems from an early time point during development when they were derived from 
hiPSCs with a high level of heteroplasmy. 
 
Figure 6.17. Heteroplasmy levels in patient hiPSC-RPE, mtDNA copy number and level 
of ATP produced by OXPHOS and glycolysis. (A) Percentage of m.3243A>G in patient 
hiPSC-RPE cells, including approximate heteroplasmy levels of the parental hiPSCs (X-axis); 
(B) mtDNA copy number of patient hiPSC-RPE. Clone M2-RPE cells had significantly higher 
levels of mtDNA copy number comparing to hESCs and Clone 5-RPE cells. N=2. (C) ATP 
produced by OXPHOS and glycolysis. No observable difference between the cells, additional 
experiments required. N=2. Data presented as Mean ± SD. RLU – relative light units. 
6.3 Discussion  
This chapter describes one of the key elements of this project aimed at investigating 
patient hiPSC-derived RPE cells with the view of elucidating potential differences 
between them. Prior to that, a number of experiments were undertaken in order to 
establish an optimal RPE differentiation protocol using hESCs. 
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6.3.1 Main findings 
RPE differentiation optimisation experiments with hESCs 
Initially, it was established that AdRPMI supplemented with B27 and 10% KOSR was 
the most favourable medium for RPE differentiation. In addition, growth factor 
reduced matrigel was chosen as substrate. This is not surprising as B27, KOSR and 
matrigel have all been successfully used in differentiation experiments by various 
research groups (summarised in Table 1.2). Up until now, there is no published 
evidence of AdRPMI being used for differentiating hPSCs to RPE. It is similar to 
DMEM/F12 however it is more defined, contains insulin, transferrin and trace 
elements which might be more supportive of cell growth. The final medium 
composition supported the development of both RPE and neural retina progenitors 
which was expected. These structures develop together as a result of complex 
interactions as discussed in the overview of this chapter and in the study by Nakano 
et al. (2012), where it was suggested that optic cup formation relies on the formation 
of neural retina and RPE in a balanced fashion. 
Summary of the findings from the experiments with patient-derived RPE cells 
A number of conclusions were drawn from the experiments performed with patient-
derived cells. 
 Patient hiPSCs were able to differentiate to RPE cells, apart from the isogenic 
control hiPSCs (Clone 8), which failed to give rise to RPE cells 
 They were comparable to the controls in terms of the expression of early and 
mature RPE markers, barrier properties (as measured by TER), expression of 
some genes related to their function (MERTK and PEDF), genes associated 
with pigmentation (TYR, MITF and SILV) and in terms of their mitochondrial 
morphology in the initial TEM experiments albeit with a tendency for an 
increased number of fragmented mitochondria 
 Clone M2-RPE had significantly increased levels of OPA1 
 All RPE cells had comparable levels of SOD2 
 Patient RPE cells derived from hiPSCs with high m.3243A>G (Clone M2-RPE) 
differed from controls and RPE cells derived from hiPSCs with lower levels of 
the mutation (Clone 5) across a number of parameters, including: 
 Their propensity to differentiate towards RPE and neural retina was 
reduced 
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 Pigmentation level when examined by light microscopy was lower 
 mtDNA copy number was significantly increased compared with other 
cells 
 Percentage of cells that were able to phagocytose POSs was lower 
(although had slightly higher values for MFI suggesting that 
phagocytosing cells were not compromised) 
 Ultra-structurally cells looked abnormal, less developed with 
significantly increased levels of hollow / degrading melanosomes 
 Ultra-structural examination at a later time point revealed further 
deterioration with apoptotic nuclei, fragmented mitochondria (in both 
patient cell clones), disturbed membranes and vacuoles. Clone 5-RPE 
cells also looked abnormal with large fragmented and dysmorphic 
mitochondria. 
These particular findings are discussed below in more detail. 
6.3.2 Reduced differentiation propensity of patient hiPSCs 
It is not clear why Clone 8-hiPSCs failed to give rise to RPE cells. Previous work has 
shown that there is donor and hiPSC clone-specific variation in the expression of 
RPE-specific genes (Miyagishima et al., 2016). Although, in this case it cannot be 
attributed to donor variation, it is possible that these cells had reduced intrinsic 
propensity to differentiate and probably required additional supplementation of the 
medium to achieve successful differentiation outcome. As discussed in the overview 
section of this chapter, early eye development is under the control of multiple 
transcription factors. Therefore, it is plausible that the inability of Clone 8 hiPSCs to 
produce neuronal and RPE cell types was a result of changes in regulation of crucial 
pathways required for default differentiation. From the spontaneous monolayer 
differentiation experiment described in (Figure 3.7) it can be seen that Clone 8 had 
reduced upregulation of PAX6, which is crucial for RPE differentiation. A recent study 
investigated reactivation of OTX2 expression after reprogramming under the 
regulation of SOX2 and OCT4 (Li et al., 2016). They showed that there is a formation 
of OCT4-SOX2 regulatory axis which establishes the propensity of the cells to 
differentiate into retinal lineages. In turn, PAX6 is a transcriptional target of SOX2 
and therefore it is plausible to speculate that due to the fact that Clone 8 hiPSCs 
expressed SOX2 and not PAX6 upon spontaneous differentiation this resulted in 
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defects in activation of PAX6 which resulted in the inability of the cells to produce 
RPE cells without subjecting them to directed differentiation (Lee et al., 2013).  
The initial finding in patient RPE cells derived from hiPSCs with high initial 
m.3243A>G was their reduced pigmentation levels and reduced differentiation 
propensity as measured by percentage of pigmented cells that occupy growth 
surface area and by the number of neural retina-like structures formed. Defects in 
mitochondria did not seem to affect patient hiPSCs across multiple parameters 
(discussed in Chapter 5); therefore, it was interesting to see that there was an effect 
on their ability to undergo differentiation. There is conflicting evidence for whether 
mutations affecting mitochondria lead to defects in differentiation propensity of 
hiPSCs. Most papers that have been published on this topic claim that the cells 
differentiate in the same manner as controls. However, Wahlestedt et al. (2014) used 
mutator mouse iPSCs (mutation in Polg gene) to show pronounced defects in their 
ability to form EBs and teratomas and complete failure to produce chimeric mice. The 
same study showed that even though there was little difference between wild-type 
and mutator iPSCs, mutator iPSCs had differentiation defects due to impaired ability 
to switch from glycolysis to OXPHOS. Interestingly, characterisation of the mutator 
mouse model lead to the discovery that these animals have respiratory chain 
dysfunction and age prematurely (Trifunovic et al., 2004). Similarly, another study 
showed that maternally transmitted mtDNA mutations lead to premature ageing and 
brain malformation in mice (Ross et al., 2013). Another study showed that mouse 
ESCs with severe respiratory chain deficiencies show defects in neuronal 
differentiation (Kirby et al., 2009). Therefore, it could be speculated that reduced RPE 
and neural retina differentiation was a result of a failed metabolic switch in these 
cells. These results are also in line with the findings that these cells had defects in 
the ability to form teratomas. 
Due to their potential to be used in cell replacement therapies, it has become 
evident that robust methods for RPE characterisation need to be utilised. In the initial 
optimisation differentiation experiments with hESCs described in the first part of this 
chapter, manual counting was used as a method for identifying the efficiency of the 
protocol. In further experiments with patient hiPSC-RPE, a more reliable method was 
used based on the work by Lane et al. (2014), where scanned images of cell culture 
plates were used to calculate percentage surface area occupied by pigmented cells. 
The disadvantage of this method is that it might miss out on RPE cells with very low 
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level of pigmentation as could be the case with Clone M2-RPE cells. To overcome 
this, Kamao et al. (2014) used Photoshop’s Info Palette (Adobe Systems) which 
gives the user the colour profile of the image based on single cells and produces 
objective quantification of the level of pigmentation of the cells. This method could be 
used to further assess the cells. Another group developed their own method to 
assess the extent of cuboidal cobblestone morphology of RPE cells based on 
computational analysis (Joshi et al., 2016). Automation of evaluation of RPE cell 
maturation status is fast-developing and other parameters have been considered in 
other studies. Based on the notion that RPE cells display spontaneous transient 
increases of Ca2+ mediated by ATP, controlling differentiation and proliferation, 
another group showed that RPE organisation is also connected to Ca2+ and cells with 
uniform morphology have minor calcium waves (Abu Khamidakh et al., 2016). In this 
study the authors developed a semi-automatic method for measuring intracellular 
Ca2+ to assess maturation of cells. For the first time they showed that hESC-RPE 
cells display spontaneous and mechanically induced transient increases in Ca2+. 
Combining multiple observer-independent measurement approaches would be 
a simple and effective assessment of differentiating RPE cells and provide 
quantifiable information for evaluation of differences between patient and healthy 
control cells. Future work would have to take this into account. 
The differences found between patient RPE and control RPE cells are key to 
elucidating the pathogenesis of the retinal disease seen in patients with the 
m.3243A>G mutation. These differences form the basis of the rest of the discussion. 
6.3.3 mtDNA dynamics in RPE cells 
Clone M2-RPE cells had significantly higher mtDNA copy number comparing to other 
cells. The variation in mtDNA copy number has already been discussed in the 
previous two chapters and these results are consistent with the findings in Clone M2-
hiPSCs suggesting the persistence of the phenotype across different cell types with 
high level of m.3243A>G. Interestingly, control RPE cells had five times more mtDNA 
comparing to fibroblasts (739.9 ± 17.4 compared to 147.1 ± 11.2; Mean ± SD). 
Whereas Clone M2 RPE cells had the same number of mtDNA copies (~ 890 
copies). Furthermore, Clone 5 RPE cells had reduced number of mtDNA compared 
to fibroblasts (529.6 ± 14.7 compared to 891.0 ± 34.1; Mean ± SD). This is interesting 
and could potentially imply that the cells did not manage to increase their mtDNA 
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population in order to fulfil the energy demands of RPE cells which potentially 
resulted in them expressing deleterious functional defects. As suggested in the 
previous chapter, there is yet no clear explanation to the differences in the 
heteroplasmy dynamics in patient clones. 
6.3.4 Patient hiPSC-derived RPE cells show functional defects 
Photoreceptor outer segments are continually renewed in a balanced fashion being 
replaced by newly formed outer segment discs. The daily renewal of POSs is 
approximately 10% of their total length and RPE cells are responsible for the removal 
of POSs from 30-40 photoreceptors by the process of heterophagy (Kaarniranta et 
al., 2013). Clearance of shed POSs is one of the most important functions of RPE 
cells and consists of multiple steps and pathways, summarised in Figure 6.18. 
Photoreceptors have high exposure to light and high oxygen concentration 
environment which subjects them to chronic oxidative stress. By eliminating them, 
RPE protects photoreceptors from oxidative damage and accumulation of lipid-
protein aggregates called lipofuscin thereby maintaining healthy sub-retinal 
environment (Sparrow et al., 2010). Clone M2-RPE cells had ~1/3 less cells that 
were able to phagocytose and MFI values suggested that the cells that were able to 
ingest POSs were potentially more efficient at it than controls and Clone 5-RPE cells. 
MFI data showed that Clone M2-RPE cells that were phagocytosing did not show 
deficit in the ability to recognise and engulf POSs and the values were comparable to 
findings by another research group that used the same technique (Westenskow et 
al., 2012). From this finding, a possible conclusion is that there was a smaller number 
of functional RPE cells within the total population of Clone M2-RPE. The potential 
reasons for this observation are discussed in more detail below. 
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Figure 6.18. Components of phagocytosis of POSs [adapted from Kevany and 
Palczewski (2010)]. 
At a population level, there was no difference in the expression of MERTK 
(transmembrane receptor that triggers POSs ingestion) between the RPE cells 
(Figure 6.10). Although it is not the only component of the “engulfment” step and it 
does not give an indication of protein levels, it provides an indication that the cells 
might have been able to perform this step. Therefore, it could be speculated that the 
cells were not able to degrade the POSs in phago-lysosomes. When checked for the 
gene expression level of lysosomal proteases CTSB and CTSD, no difference was 
found between the samples (Figure 6.14). Although gene expression levels were 
comparable, defects in lysosomal function cannot be ruled out and ideally lysosomal 
activity would have to be tested additionally. This is especially important because 
lysosomal overload has been shown to be associated with lipofuscin accumulation, 
vacuolation and phagocytosis disruption in RPE cells (Sundelin et al., 1998; Chen et 
al., 2011b). Interestingly, the effect of lipofuscin accumulation on the ability of cells to 
perform phagocytosis is exacerbated by the presence of mtDNA mutations by not 
providing the cells with enough ATP energy to perform the function (Vives-Bauza et 
al., 2008). It is possible that the cells were not metabolically active enough to perform 
the entire phagocytosis cascade, which could be explained by the TEM results that 
showed that there were a lot of apoptosing cells in those samples with what looked 
like disturbed membranes. Disturbances in the ability of RPE to phagocytose could 
have major impact on retinal health. Early studies using Royal College of Surgeons 
rat (a widely used animal model of retinal degeneration) showed that due to a genetic 
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defect (mutation in MERTK gene), their RPE cells were unable to phagocytose POSs 
resulting in the accumulation of a layer of debris and consequently photoreceptor 
death (Bok and Hall, 1971; Mullen and LaVail, 1976). In humans, defects in RPE 
phagocytosis lead to development of retinitis pigmentosa, Usher syndrome and AMD 
by a variety of different mechanisms (Gal et al., 2000; Gibbs et al., 2003; Kevany and 
Palczewski, 2010). Disturbances to phagocytosis in these diseases were described 
to be a result of mutations in the MERTK gene, myosin VIIa gene leading to 
perturbed transport of ingested discs, or by the accumulation of toxic by-products 
from RPE phagosomes in the form of lipofuscin. One study looked at the eyes of 
donors with AMD with the view of linking the disease-associated pathology to 
mitochondria (Terluk et al., 2015). They mapped mtDNA into nine regions and 
showed that RPE cells had an increase in mtDNA damage. There were a number of 
hot spots where the mutations were most common and strikingly one of them was in 
the same mtDNA region as the m.3243A>G mutation. Interestingly, clinical 
observations showed that MELAS patients with m.3243A>G accumulate lipofuscin 
that are often localised in the areas surrounding the optic disc, and tend to spare the 
areas in the foveal region (de Laat et al., 2013). The same study suggested that the 
phenomenon of foveal sparing could be explained by slower regeneration of cones 
and their lesser dependence on RPE comparing to rods. On the other hand, the 
macular area outside the fovea is densely packed with photoreceptors especially 
rods and therefore this area is primarily affected in mitochondrial retinopathies. 
Histopathological studies on post mortem eyes of MELAS patients have also 
indicated an increased presence of lipofuscin in RPE (Chang et al., 1993; Rummelt 
et al., 1993). Due to the fact that RPE atrophy is localised to only some areas, it 
could explain why patient hiPSC-RPE had comparable MFI values. 
To conclude, disturbances in phagocytosis could be one of the possible 
mechanisms of retinal atrophy seen in patients with the m.3243A>G mutation. 
6.3.5 Patient-derived RPE cells have abnormal melanosome and mitochondrial 
ultrastructure 
Another set of major findings was derived from analysing TEM images of hiPSC-RPE 
cells. There were striking differences in the morphology of melanosomes in patient-
derived RPE cells with the highest level of m.3243A>G compared to other RPE cells. 
The cells had comparable numbers of “normal” melanosomes, but they had 
significantly higher levels of hollow melanosomes resembling a process of 
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degradation. Additionally, there was a clear trend that patient RPE cells contained 
more fragmented mitochondria. Overall, cells looked unhealthy and lacked structures 
such as microvilli (also termed as photoreceptor sheaths) which are vital for RPE-
photoreceptors crosstalk, apical transport and visual cycle [reviewed by Bonilha 
(2008)]. Furthermore, when samples were analysed again three months later, patient 
hiPSC-RPE cells looked so unhealthy with such little cytoplasmic organisation, that it 
was impossible to perform any sort of quantifications. Cells contained swollen 
mitochondria, loss of cristae morphology, vacuoles, very little membrane integrity and 
Clone M2-RPE had apoptotic nuclei. There were striking similarities between these 
cells and cells described in studies which looked at post mortem retinas of MELAS 
patients with m.3243A>G, where it was shown that RPE cells were depigmented and 
mitochondria had abnormal morphology (Chang et al., 1993; Rummelt et al., 1993). 
As can be seen from Figure 6.19 (A, B), similar to the RPE cells derived from hiPSCs 
from patients with the m.3243A>G, RPE cells found in post mortem eyes of patients 
with the same mutation show areas of hypopigmentation and vacuolation. There 
were also similarities in the morphology of mitochondria seen in cells described in the 
literature and the cells derived during this project [Figure 6.19 (C, D)]. Mitochondria 
were elongated and swollen, however some mitochondria described in the literature 
contains denser cristae, than what was seen in hiPSC-derived RPE cells (Figure 
6.15). 
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Figure 6.19. Histopathological findings in post mortem tissues from patients with 
m.3243A>G mutation. (A, B) RPE cell layer has areas of hypo and hyperpigmentation (seen 
underneath the photoreceptor outer segments [OS] layer) and some vacuoles can be seen 
(white arrows) [adapted from Rummelt et al. (1993)]; (C, D) RPE mitochondria are elongated 
(asterisks), swollen, and abnormal (arrow) [adapted from Chang et al. (1993)]. 
These findings complement findings on disturbances in phagocytosis. It appears that 
there is a back log of degrading and possibly undigested material inside the cells, 
possibly leading to cell death. 
When melanosomes with defective morphology were first observed, it was not 
clear whether it was to do with them being immature and not forming properly or 
whether they were mature melanosomes undergoing degradation. The first 
hypothesis was ruled out after establishing that the cells had comparable levels of 
expression of genes involved in melanogenesis, such as TYR, MITF and SILV 
(Figure 6.12). TYR regulates synthesis of tyrosinase which is located in melanocytes 
and is involved in the first step of melanin production. Tyrosinase catalyses the 
conversion of tyrosine to dopaquinone which is a precursor to two types of melanin: 
eumelanin (dark coloured, photoprotective, antioxidant, located on the surface) and 
pheomelanin (yellow, reddish-brown, phototoxic, pro-oxidant, core location) (Ito and 
Wakamatsu, 2008). SILV encodes a protein involved in biogenesis and maturation of 
melanosomes and is a structural protein (Kobayashi et al., 1994). SILV expression is 
regulated by MITF which is pivotal for RPE maturation as discussed earlier in this 
chapter. Melanogenesis is an energy demanding process. Daniele et al. (2014) 
showed that mitochondria contact melanosomes via the MFN2 protein thereby 
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facilitating the process of melanogenesis by supplying ATP to the organelles. At gene 
expression level, there was no difference found in MFN2 levels between different 
RPE cells as shown in Figure 6.14 providing another indication that the process of 
melanosomal synthesis was not altered in the cells. 
Melanin is mainly synthesised in postnatal RPE and there are studies that 
show that there is general decrease in the number of pigment granules per macular 
RPE with age which is accompanied with the association of melanosomes with 
lysosomes and formation of lipofuscin, as a result of the inability of RPE to cope with 
phagosomal load (Feeney-Burns et al., 1984). Sarna et al. (2003) suggested photo-
oxidation as a possible trigger to decreased melanin content. Also, there is a positive 
correlation between age and the number of RPE cells undergoing apoptosis at a rate 
of about 1.96% per year. They suggested that expression of BCL-2 (anti-apoptotic 
gene) inhibits apoptosis (Del Priore et al., 2002). Some melanin biosynthetic gene 
variants have been shown to be a risk factor for AMD (Holliday et al., 2013). It has 
been shown experimentally that damaged melanosomes could adversely affect 
cellular health. Repopulation of ARPE19 cells with melanosomes from aged donors 
results in decreased mitochondrial activity and increased cell death after exposure to 
blue light (Rozanowski et al., 2008). This is unsurprising, considering their functional 
significance.  
Melanosomes are located near the apical surface of RPE cells where they are 
in close contact with photoreceptors. Their transport inside the cytoplasm is 
facilitated by myosin VIIa along actin filaments – an ATP dependent process. 
[Interestingly, mutations in myosin VIIa leads to Usher syndrome (Sparrow et al., 
2010)]. The main function of melanosomes is to protect the cells from light damage. 
Indeed, it is known that short wavelengths of light are filtered by the cornea and the 
lens (<295 nm and 300-400 nm respectively), whereas vitreous filters the infrared 
light (>1400 nm). Visible light (400-760 nm), which is damaging to the retina, is 
absorbed by various pigments, including melanin, leading to generation of ROS. 
Interestingly, various mitochondrial proteins such as COX and flavins absorb 450-520 
nm light inducing production of H2O2 and singlet oxygen (Lascaratos et al., 2007; 
Osborne et al., 2010). In general, melanosomes prevent light from being absorbed by 
other chromophores, they have an important antioxidant function  as well as 
sequestering free radicals, metal ions and Ca2+ preventing apoptosis (Borovansky 
and Riley, 2011). A literature search showed that the melanosomes observed in 
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Clone M2-RPE had a striking resemblance to degrading melanosomes described by 
others (Insausti and Casas, 2009). It could be hypothesised that these changes lead 
to the inability of the melanosomes to perform one of their key functions namely 
absorption of stray light. It is possible that the changes seen in MELAS RPE cells 
could be an exacerbation of the processes seen in normal ageing. Indeed, RPE cells 
from aged donors have been shown to contain large disrupted mitochondria unable 
to cope with cellular energy demands increasing their susceptibility to oxidative 
stress and a similar trend is seen in AMD patients (He et al., 2010). Melanosomes 
possess lysosomal activity in RPE cells (Schraermeyer et al., 1999). Gouras et al. 
(2011) investigated RPE cells in rhesus monkeys (Macaca mulatta) and described 
hollow melanosomes found in those cells as a new class of organelles that degrade 
their own melanin via lysosomal and autophagic actions. As can be seen from Figure 
6.20, melanosomes in rhesus monkeys described in this study have a remarkable 
resemblance to the melanosomes in the TEM images of RPE cells derived in this 
project (Figure 6.12). Gouras and colleagues suggested that such morphological 
changes were the result of vulnerability to stress and pointed out that melano-
lysosomes accumulated in monkey RPE lead to early maculopathy. Another study 
showed that RPE in the macular area contain a greater content of melano-lysosomes 
due to the higher exposure to stress in that area, which follows the hypothesis of a 
loss of melanin due to an increased amount of stress (Feeney-Burns et al., 1984). 
This is consistent with mitochondrial stress secondary to the m.3243A>G mutation. 
The exact mechanism of maculopathy as a result of accumulation of hollow 
melanosomes is not clear, however it is clear that retinal atrophy in MELAS patients 
might have common pathways with the pathological reduction of pigment seen in 
patients with AMD [reviewed by Bonilha (2008)]. It is also possible that loss of 
melanin in these organelles is an exacerbation of a normal ageing process as a 
result of the cells being under stress (Feeney-Burns et al., 1984). It may be that as a 
result of the m.3243A>G mutation the melanosomes acquire their lysosomal 
characteristics which leads to self-degradation via autophagic actions. 
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Figure 6.20. Examples of degrading melanosomes found in rhesus monkeys (Macaca 
mulatta). Melanosomes described by the authors show resemblance to hollow 
melanosomes seen in RPE cells derived from patients with m.3243A>G. [Adapted from 
Gouras et al. (2011)]. 
TEM images also showed that patient RPE cells had enlarged fragmented 
mitochondria and RT-qPCR results showed that Clone M2-RPE had increased levels 
of OPA1 which is associated with mitochondrial fusion and formation of cristae 
junction. Tondera et al. (2009) introduced a concept of stress-induced mitochondrial 
hyperfusion (SIMH), when enlarged mitochondria accumulate in cells as a result of 
various stress stimuli, including UV irradiation and serum deprivation. Elevated 
mitochondrial fusion, and as a result mitochondrial size, is associated with resistance 
of cells to apoptotic stimuli and autophagy and has been observed in RPE of ageing 
rhesus monkeys (Gouras et al., 2016). Indeed, increase in autophagy has been 
associated with clearance of mtDNA with pathogenic mutations. Dombi et al. (2016) 
showed an increase in autophagy in fibroblasts from patients with pathogenic 
m.13051G>A mutation. Studies looking at impaired autophagy, and specifically 
mitophagy, have gained a lot of popularity in recent years. There has been a report 
suggesting a link between disturbed mitophagy and neurodegeneration associated 
with a nuclear-encoded mutation in OPA1 (Carelli et al., 2015). Degradation of 
enlarged organelles is energy dependent and it is possible that the cells have a limit 
of the volume of the organelle they can process. Senescent mitochondria produce 
more ROS and the inability of the cells to perform autophagy and lysosomal 
degradation can be detrimental. Alternatively, it is possible that damaged 
mitochondria have less respiration and produces less ROS which means they are not 
tagged for removal. Accumulation of partially or non-degraded material leads to cells 
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being unable to perform their function. This is especially crucial in post-mitotic cells 
such as RPE, as there is no dilution of the material as a result of cell division. It is 
possible that if the cells contain too much non-degraded material in their lysosomes, 
the cells start directing lysosomal enzymes to these aggregates which in turn leads to 
not having enough enzymes for the newly formed autophagocytosed material (this 
hypothesis goes in line with the finding that patient RPE cells had comparable levels 
of gene expression for lysosomal enzymes). [Reviewed by Terman et al. (2010)]. 
As can be seen from TEM images in Figure 6.15, the membranes in the cells 
seem to have lost their integrity and there were numerous vacuoles observed inside 
the cells, which could be a sign of RPE stress (Justilien et al., 2007). The 
consequences of damaged melanosomal membranes could be drastic. Firstly, 
melanosomes contain quinones which are involved in melanin synthesis. If they were 
to be released they could have a cytotoxic effect by inhibiting DNA polymerase or 
binding to DNA (interestingly, this is sometimes the reason for isolated RPE DNA 
being pigmented) (Borovansky and Riley, 2011). Cytotoxic effects of damaged 
melanosomes have been previously observed in malignant melanoma (Borovansky 
et al., 1991). Additionally, lost integrity of lysosomes can lead to release of their 
material into the cytosol leading to cell death (Terman et al., 2010). 
In general, the degree of pigmentation of RPE cells is related to their function 
and cells with less pigment have reduced secretion of growth factors, including VEGF 
and PEDF (Kamao et al., 2014). PEDF has a protective effect on mitochondria after 
exposure to ROS by improving mitochondrial function, therefore it could be 
speculated that in the cells, such as RPE harbouring m.3243A>G, where 
mitochondrial function is already compromised having fully functional RPE cells is 
evermore crucial (He et al., 2014). 
6.3.6 Conclusion 
To conclude, two major findings have been made in this chapter. Firstly, patient-
derived RPE cells had striking morphological similarities to cells seen in patients with 
m.3243A>G at post mortem. Interestingly, there were clear morphological 
abnormalities in melanosomes which could explain the areas of RPE 
hypopigmentation seen in patients. Secondly, there were less patient RPE cells that 
were able to perform the most crucial RPE function namely phagocytosis. Defects in 
phagocytosis are associated with a number of other retinal diseases. Accumulation of 
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undigested material in the cells, including melanosomes and enlarged mitochondria, 
could explain their inability to perform their function. These events are typically 
associated with normal ageing however in RPE cells with m.3243A>G they are 
potentially exacerbated and pathological. 
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Chapter 7. Conclusion and future perspectives 
The main aim of my project was to investigate the molecular and cellular basis that 
underpin the characteristic retinal pathology seen in patients with the m.3243A>G 
mutation by making use of hiPSCs obtained from patient somatic cells. It was 
hypothesised that the resulting hiPSC clones would have varying levels of the 
mutated mtDNA, providing an ideal setting to make comparisons between isogenic 
clones. Based on previous clinical findings, it was expected that, when differentiated 
to RPE, the cells would have the phenotype similar to that seen in patients, providing 
a validated model system for current and future work. 
7.1 Major findings 
As shown in Figure 7.1 (A), attempts were made to reprogramme fibroblasts obtained 
from three patients with the m.3243A>G and two healthy control donors. As a result, 
it was possible to obtain hiPSCs from two patients’ cells. Multiple attempts were 
made to isolate hiPSCs from other donors however they were unsuccessful. Control 
hiPSCs previously generated in the lab and hESCs were used for comparisons with 
patient cells. 
Somatic cells from Patient 1 gave rise to 10 hiPSC clones with 3 clones being 
selected for further analyses. The fibroblasts from this patient had ~70% of the 
mutated mtDNA and elevated levels of mtDNA copy number. hiPSC clones that 
harboured the mutation had initial reduced propensity for proliferation (Clone 5 with 
~50% mutation) or increased levels of mtDNA copy number (Clone M2 with ~70% 
mutation). hiPSC clones did not differ from the controls across a number of other 
parameters, including cell cycle kinetics, oxygen consumption, mitochondrial mass, 
mitochondrial membrane potential, intracellular superoxide or levels of peroxide. 
Fibroblasts from Patient 2 gave rise to 4 hiPSC clones that all purged the mutation. 
Subsequent attempts to isolate clones with high levels of the mutated mtDNA have 
failed. Fibroblasts from this patient had ~66% of the mutated mtDNA and had 
reduced basal and maximal respiration. There was no difference in mtDNA copy 
number between these cells and the control. Schematic summary is shown in Figure 
7.1 (B). 
Two Patient 1 hiPSC clones, both with mutant mtDNA, were able to 
differentiate to RPE cells. They were comparable to each other and to control hPSCs 
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across a number of parameters, including gene expression levels, protein expression 
and TER values. RPE cells derived from the hiPSC clone with ~50% m.3243A>G 
were deficient in phagocytosis and had ultra-structural changes associated with the 
disease state, including presence of enlarged and fragmented mitochondria. RPE 
cells from the hiPSC clone with ~70% m.3243A>G had reduced differentiation 
propensity, reduced pigmentation levels, defects in phagocytosis, degrading 
melanosomes, altered mitochondrial morphology, apoptotic nuclei and increased 
levels of OPA1 gene encoding mitochondrial fusion protein, which could indicate that 
cells were under stress. A schematic representation is shown in Figure 7.1 (C). 
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Figure 7.1. Schematic representation of the major findings of this PhD project. 
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7.2 Limitations of the study 
Like any other study, the work described in this thesis has its limitations, some of 
which are described below. 
7.2.1 Patient samples and controls 
Two hiPSC clones from one 73 year-old patient were used to demonstrate retinal 
dysfunction seen in clinical observations. Cells from a 51 year-old donor were used 
as an hiPSC control. A better way to interpret the results would be to have more 
patient samples or more clones from the same patient to compare. In addition, an 
isogenic homoplasmic control or an age matched control would have given a better 
comparison. 
An alternative could be to use the same control, but instead introduce the 
m.3243A>G mutation. A persistent pathological phenotype in the control would make 
a convincing argument for a proposed pathogenesis. Or alternatively, the mutation in 
Patient 1 cells could be corrected. Some preliminary reports have been published in 
recent years that explored the possibility of this approach. Bacman et al. (2013) used 
mitochondria-targeted transcription activator-like effector nucleases (mitoTALENs) in 
order to eliminate mtDNA with common deletion or m.14459G>A mutation in the MT-
ND6 gene, associated with LHON disease, from osteosarcoma cell cybrids. A later 
study also showed the application of mitoTALENs in eliminating mtDNA harbouring 
the same LHON mutation by generating mouse oocytes carrying human mutated 
mtDNA (Reddy et al., 2015). Jo et al. (2015) used clustered regularly interspaced 
short palindromic repeats (CRISPR) / mitoCas9 system in HEK-293T cells to target 
Cox1 and Cox3. Although still in its infancy, a mtDNA manipulation approach holds 
many promises. 
A primary sample of RPE cells from a donor of similar age would have been 
better as a RT-qPCR control rather than ARPE19 cell line. 
7.2.2 Cytogenetic abnormalities 
In an ideal setting, it would be better to compare hiPSCs without acquired nuclear 
DNA changes, such as those seen in Clone M2. One of the suggestions for future 
work would be to test the hiPSCs for cytogenetic abnormalities early in the project in 
order to avoid using cells with nuclear abnormalities in disease modelling studies. 
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7.2.3 Using hiPSCs as a disease model 
Although, hiPSCs hold a great potential for elucidating mechanisms in many 
diseases, including the diseases associated with mitochondria, they have a number 
of limitations that could affect interpretation of the results. Firstly, there is significant 
variation between different hiPSC clones, even if they are derived from the same 
person. Such variation could be in the form of differentiation propensity and 
maturation, and as a result their ability to mimic patient phenotype. Additionally, 
robust differentiation protocols that work across multiple clones and cell lines are still 
lacking, which makes it difficult to assess the effect of the mutation on differentiation 
propensity. Ideally, more patient and control cells should be used to increase 
statistical power of the experiments. However, tissue availability, time and financial 
restrictions could impede on increasing sample size. 
7.3 Suggestions for future work 
Apart from some of the comments that were already made in individual chapter 
discussions, some additional experiments that could be done are outlined below. 
I. Whole-genome sequencing of patient and control cells would give an 
indication of whether there were any additional nuclear DNA and / or mtDNA 
abnormalities that could have influenced the results. 
II. An experiment to confirm tRNALeu(UUR) translational deficiency would be 
required to confirm the mechanism of the mitochondrial involvement in the 
pathology seen in RPE cells. 
III. Lysosomal activity assay and assays assessing autophagy would confirm 
aberrant clearance of degraded melanosomes, abnormal mitochondria and 
photoreceptor outer segments in RPE cells. 
IV. Analysis of mitochondrial network disturbances in RPE cells to elucidate its 
potential involvement in apoptosis and mitophagy. 
V. ROS levels and mitochondrial mass would be another way to assess RPE 
cellular health. 
VI. The nuclei of some RPE cells were apoptotic as seen in the TEM images. 
Molecular analysis of apoptosis would be useful as an additional confirmation. 
VII. Testing additional RPE functions, such as growth factor secretion, would show 
whether there are additional effects of the mutation on cellular health. 
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VIII. Differentiation of the hiPSCs towards neural retinal subtypes, especially 
photoreceptors and RGCs, would further elucidate the effect of the 
m.3243A<G on retina. Alternatively, having a fully laminated retina with an 
integrated RPE layer would allow a better model of the disease. 
IX. Test more ECM proteins to enhance RPE propagation. 
7.4 Significance of the findings 
The RPE cells derived from patient hiPSCs had remarkable similarities to the cells 
found in post mortem retinal tissues of patients harbouring the same mutation. This is 
the first time retinal manifestations associated with m.3243A>G have been 
recapitulated in vitro. Up to 25% of patients with the mutation have ophthalmological 
complications, including pigmentary retinopathy (El-Hattab et al., 2015). The ability to 
mimic these manifestations would allow elucidating potential pathological 
mechanisms of the disease and allow testing novel therapeutic agents aimed at 
alleviating or treating the symptoms. Crucially, what the results in this thesis have 
shown is that retinal pathology could be a result of the inability of RPE cells to 
perform at least two of their major functions: phagocytosis of photoreceptor outer 
segments, and stray light absorption due to dysfunctional melanosomes. 
Furthermore, understanding the mechanisms of RPE abnormalities associated with 
the m.3243A>G mutation could uncover pathological mechanisms in similar 
conditions, including AMD. 
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